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ABSTRACT This aim of this study was to assess patients' expected therapeutic alliance and symptomatology before beginning psychotherapy, and comparing these baseline assessments with measures of alliance and symptomatology obtained on a continuous basis across a minimum of 10 weeks of therapy. Assessments of alliance and symptomatology, were made every half-week for a range of seven to fourteen times during the baseline period and a range of twenty-two to forty-four times during the treatment phase. Seven female patients and one male patient participated in the study. Three questions were the focus of this study: (I) Does the introduction of therapy have an impact on the initial formation of alliance? (2) Does the alliance change over time or does it stabilize? (3) Is there a time-contingent relationship or a simultaneous relationship between alliance and outcome, and if it is time-contingent, does a1liance predict outcome or does outcome predict alJiance? The results indicated that for a majority of subjects the introduction of therapy reduced totals on the Confident Collaboration scale, the Confident Collaboration 2 scale, and the Goal and Task Agreement scale. There was no significant impact on the Bond scale, the Patient Dedication scale, and the Idealized Relationship scale. The results also supported the hypothesis that therapeutic alliance remained stable over time. Small effect sizes (ranging from absolute values of .109 to .157) indicated one instance of alliance predicting symptomatology, three instances of a simultaneous relationship between symptomatology and alliance, and five instances of symptomatology predicting alliance. 
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CHAPTER I 
INTRODUCTION 
The Concept of Alliance in Therapy The concept of alliance has its roots in the writings of the father of psychoanalysis, Sigmund Freud who, as early as 19 12, wrote of the need for the therapist to maintain "sympathetic understanding" so that the healthy component of the client's ego could develop a positive attachment towards the therapist and thus engage more fu1ly in the work of therapy (Freud, [ 19 13] 1958, pp.139- 140). Although Freud initially conceived of this process as the result of positive transference, he later contrasted the difference between transferential aspects and the positive, reality-based aspects of the client's attachment to the therapist. These positive components of the therapeutic relationship allowed the client and therapist "basing themselves on the external world ... to band themselves together ... This pact constitutes the analytic situation" (Freud, 1940, p.173). Sterba ( 1934) further developed this idea by introducing the term ego alliance to describe the process by which the healthy, reality-based aspect of the client's self collaborated with the therapist to overcome the client's neurosis. Subsequently, Zetzel ( 1956) wrote of the difference between transference and alliance and she conceived of the alliance as the non-neurotic aspect of the therapeutic relationship that enabled the client to distinguish between transference and reality in relation to the therapist. She coined the term 
l 
therapeutic alliance and she suggested that successful therapy is marked by varying 
periods when either transference or the al liance dominates the relationship. Greenson 
( 1965) in a landmark paper on alliance and transference neurosis, introduced the term working alliance to describe this reality-based collaboration and proposed that it was one 
of three components of the therapeutic relationship, the other two being the transference 
relationship and the real relationship. 
Psychodynamic theorists writing on alliance from an object relations perspective (e .g., 
Gitleson, 1962; Horwitz, 1974; Bowlby, 1988) stressed how the client is capable of 
forming a positive, need-gratifying relationship with the therapist that is grounded in 
reality. Other psychodynamic theorists maintain that alliance is not merely affected by 
transference, but that a11 aspects of the therapeutic relationship are manifestations of 
transference neurosis (Gelso & Carter, 1985). Gelso & Carter (1985) contend that the 
alliance is an unreal relationship founded on displaced emotions and thoughts originating 
from an earlier conflictual relationship. Similarily, Hatcher (1990) conceptualized the 
alliance as an alternative perspective on positive transference, with inherent intra­
personal and inter-personal components, in contrast to Greenson ( 1965) who saw alliance 
as a separate and distinct process. 
In an attempt to reconcile psycho-dynamic perspectives on the alliance, Horvath, Gaston 
& Luborsky (1993) stated that a definition of the alliance "needs to take account of the 
influence of prior experiences (that is, positive and negative transference) and, at the 
same time, to delineate the alliance as a distinct aspect of the relationship" (p.250). In an 
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attempt to provide such a comprehensive definition, Frieswyk et al. ( 1986) adapted Greenson 's concept of alliance and they stressed the "patient's collaboration with the therapist in the task of observing and evaluating the patient's experience" (p. 33) as the central focus of alliance. However, they acknowledged that "the patient's capacity to collaborate is affected by the state of the transference" (p. 33) and they argued that therapist activity should not be considered a component of the therapeutic alliance. 
Empirical Research on Therapeutic Alliance Impetus for empirical study of necessary components of the therapeutic relationship also came from the work of Carl Rogers. Rogers (195 1) in his book Client-Centered Therapy put forward the view that the therapist 's communication of empathy, congruence and unconditional acceptance were necessary and sufficient features of successful therapy. As Horvath (2000) .. noted in his recent paper on the therapeutic relationship, Rogers' theory was unique in .that it posited these factors to be responsible for change in all therapeutic endeavors and it stressed that it was the therapist who was responsible for the provision of these conditions. More importantly, though, Rogers also subjected his claims to empirical investigation, thus paving the way for future research into the process of therapy. Surprisingly, reviews of the empirical work done on Rogers' theory, such as Mitchen,  Bozart & Kraft ( 1977), indicate that although a good therapeutic relationship correlates with successful outcome, 
3 
it is actually the client's perception of the therapist's attitudes that is related to outcome rather than ratings of empathy, congruence or unconditional regard as observed by independent raters. In a similar vein, Lacrosse ( 1980) found that the therapist's influence is proportional to the degree to which the client perceives the therapist as expert, attractive and trustworthy (although Horvath (198 1 )  found this to be a modest and inconsistent effect across modalities). Thus it became evident that future research on the alliance would have to account for the client's perception of the therapeutic relationship. A flurry of research on therapy and outcome answered Hans Eysenck's ( 1952) claim that the outcome associated with psychodynamic therapy was no greater than that associated with either routine medical care or no treatment at all . Increasingly rigorous outcome research soon provided evidence that therapy could account for more change than spontaneous remission alone (e.g., Smith, Glass & Miller, 1980). However, it simultaneously called into question the specificity of various techniques as the evidence failed to show that any one approach to therapy was superior to another (see Luborsky et al., 1975 ; Garfield & Bergin, 1 986; Lambert, 1991). This provoked a move among researchers to begin developing a pan-theoretical understanding of the aspects of therapy that might be responsible for change. Edward Bordin offered such a pan-theoretical conceptualization of the therapeutic alliance in his presidential address to the 1975 Annual Conference of the Society for Psychotherapy Research (Bordin, 1975 - as cited in Horvath, 2000). Bordin described the alliance as a predominantly conscious "here-and-now" relationship, although he noted 
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that in the early phases of therapy it cou]d be influenced by past relations and unresolved attachments. He agreed with Rogers' (1951) claim that the alliance was a factor in all therapeutic relationships but in contrast to Rogers, Bordin conceptualized the alliance as a bi-directional process that involved collaboration between the therapist and client. He saw the alliance between the client and therapist as composed of three elements: bonds (interpersonal attachments, trust, liking); tasks (agreement on what needs to be done in therapy and how the activities in therapy will contribute to a successful outcome); and goals (consensus on outcome expectations). As Horvath (2000) describes, Bordin conceived the alliance as "both a facilitative condition that provided the ambiance to implement a variety of therapeutic tasks effectively and a beneficial therapeutic agent in its own right" (p. 167). As a result of Bordin' s presentation, there was a resurge of interest in research on the topic of therapeutic alliance. By 1991, Horvath and Symonds were able to publish a meta-analytic review of research on alliance and its relation to therapeutic outcome. Horvath & Symonds analyzed the results of twenty studies that assessed working alliance and outcome, and using the product-moment correlation coefficient r as an index of effect size (ES), they found that the overall weighted ES was 0.26 (p<0.001). Individual ES values for each study ranged from -0.04 to 0.64 suggesting that the "heterogeneity of ESs may be the result of differences in alliance measurement methods, differences in alliance­outcome relations across outcome variables, treatment differences among the studies, variations in the client factors, or a combination of these or other factors" (p.143). Results from the Horvath and Symonds (1991) meta-analysis also indicated that neither the 
5 
number of sessions nor the type of treatment received (psychodynamic, eclectic/mixed, or cognitive therapies) appeared to have a reliable influence on the relationship between alliance and outcome. Martin, Garske and Davis (2000) completed a more recent meta-analytic review of the relation of therapeutic alliance with outcome, citing the number of new studies since Horvath & Symond's (199 1) review as justification for an updated review. Fifty-eight published studies and 21 unpublished studies were used in their more recent review. The authors calculated the overall weighted alliance-outcome correlation to be 0.22. An exploratory analysis of possible moderator variables affecting the alliance-outcome correlation suggested that the "type of outcome measure, type of alliance rater (patient, therapist, or observer), type of outcome rater (patient, therapist, or observer), time of alliance rating (early, middle, late, or averaged across sessions), methodological quality or type of psychotherapy failed to account for additional variance" (p. 445). The authors concluded that the "overall alliance-outcome correlation represents a single population of effects that cannot be reduced by a moderator variable into a more explanatory model" and that their study was "supportive of the hypothesis that the alliance may be therapeutic in and of itself' (p. 446). However, although it was clear from their results that strength of alliance was predictive of outcome, they acknowledged that alternative explanations for the relationship were possible. Hatcher and Barends ( 1996) describe their research looking at what specific factors of alliance were related to patients' perception of improvement. The authors found that two 
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factors, Confid�nt Collaboration and Idealized Relationship were significantly related to improvement (r = 0.37 and r = -0.24 respectively). Confident Collaboration was summarized by the author with the statement "the patient is confident in and committed to a process that feels promising and helpful" (Hatcher & Barends, 1996, p. 1329). Idealized Relationship, according to Hatcher and Barends ( 1996) was comprised of two types of items: those reflecting helpful collaboration with the therapist and those reflecting more or less serious disagreement with the therapist. The items on this scale are reverse- scored so high scores indicate "not disagreeing." However, the negative correlation (-0.27) led the authors to conclude that "patients who are the most reluctant to disagree with their therapist, relative to their reported overall alliance, actually report less progress in therapy" (Hatcher & Barends, 1996, p. 1329). Other factors that assessed goal and task agreement with the therapist, the sense of bond with the therapist, and patient dedication to the process of therapy, did not significantly correlate with patient improvement. ·:·�· . In a more recent study, Clemence et al. (2003), again found a significant relationship between the Confident Collaboration subscale on the Combined Alliance Short Form -Patient Version (CAS-F) and the patient 's estimate of improvement (r = .66, p<.001). They noted that this finding was similar to results from two other independent research groups (Stiles et al., 1998; Hatcher, 1999). Using a step-wise regression, the authors found that a model including Confident Collaboration, Idealized Relationship and time in therapy best predicted improvement. 
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Limitations of Current Research on Therapeutic Alliance 
There is an important limitation to the use of meta-analytic techniques and the research 
designs described in the last section, as a means to understanding the relationship 
between alliance and outcome. The limitation is that these studies are correlational and/or 
quasi-experimental in nature. There is an underlying, but unproven, assumption that 
changes in alliance precede symptom change. However, without continuous measurement 
of both alliance and symptoms it is impossible to ascertain if, for example, alliance 
measured early in treatment is predictive of final outcome because it "causes" change in 
symptomatology, or rather that early alliance is reflective of symptom improvement 
occurring after pre-treatment assessment of symptomatology. For example, patients who 
feel that they are improving may then begin to experience the therapy and the therapist in 
a more positive light It is impossible to tell which comes first. A more continuous 
measure of change in alliance and symptomatology is required if we are to achieve a · 
more detailed understanding of the correlation between alliance and outcome. 
The importance of continuous measures across time is evident when one considers the 
results of two separate studies by Martin et al . (2000) and Clemence et al . (2003). Martin 
et al . (2000), in their meta-analytic review, found that patients rated the alliance across 
sessions more reliably than therapists or observers (in terms of test-retest correlations). 
They interpreted this finding to suggest that patients viewed the alliance as more stable 
over time and as a result they were "more likely to view the alliance as positive at 
tennination if their initial assessment was positive
,, 
(p.447). On the basis of this result, 
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the authors stressed the importance for the therapist to establish a positive alliance early in therapy - however, they also admitted that this finding should be considered tentative due to the small sample size used for this specific comparison (N = 16 reliability indices). Although this finding is supportive of the current study' s reliance on client rated measures of alliance, it must be interpreted cautiously as such a low number of point estimates of alliance do not allow us to infer that patients' views of alliance are actually "stable over time." To accurately assess for stability, a greater number of measures are required across time. Clemence et al. (2003) found a positive correlation between patients' rating of alliance and session number, indicating that alliance is not stable over time. However, this study had a cross-sectional design, that is, ratings of alliance were taken at one time only - after the patient's most recent psychotherapy session fo1lowing the start date of the study. Thus for some patients alJiance was being rated in the early stages of treatment and at a later stage for others. The differing results of these two studies can be -accounted by limitations in their methodology - I will argue that the most appropriate way to study the progress of alliance is to continuously assess it across time. Another problem in alliance research is to be found in the supportive evidence that Horvath and Symonds (1991) provide from their meta-analysis that the relationship between alliance and outcome is more than simply the result of a "halo" effect. A further analysis of the 20 studies used in their meta-analysis indicated that client rated outcome was better predicted by alliance (ES = 0.2 1) than therapist rated outcome (ES = 0.17), which in tum was better predicted than observer rated outcome (ES = 0.10). However, 9 
interpretation of these differences is compromised by the variability in the ES' s  found 
throughout the studies, as noted by the authors. Furthermore, the higher correlation 
between client-rated measures of alliance and client-rated measures of outcome in 
comparison with therapist- and observer-rated measures of outcome may simply be the 
result of a source effect, whereby the use of similar sources for measurement inflates the 
correlation. 
Orlinsky and Howard ( 1 986) cautioned that there is a potential method bias associated 
with studies that use measures of outcome and process obtained from the same source. A 
potential problem in the area of alliance research is that a client who is satisfied with the 
process of therapy is more likely to rate the outcome more favorably. Alternatively, a 
positive outcome may influence how a client later construes the process that brought 
about the change, e.g., idealization of the therapist. Both possibilities would imply that 
alliance might not be causative in regard to outcome but simply correlational and efforts 
to improve alliance may potentially be a misapplication of the therapist' s efforts. 
Thus, as part of their meta-analytic review, Horvath and Symonds ( 199 1 )  investigated the 
hypothesis that process-outcome relations are inflated by a "halo" effect whereby a 
possible bias is produced in studies that use measures of process and outcome variables 
from the same source. In order to investigate the hypothesis that the relation between 
alliance and outcome is no more than the result of an artifactual "halo" effect, Horvath 
and Symonds (199 1 )  contrasted ES 's  of studies in which outcome and alli ance measures 
were obtained from both homogeneous sources and heterogeneous sources. The mean 10 
homogeneous ��urce ES was 0.21  and the mean heterogeneous ES was 0.18. A further analysis of studies in which results were based on both homogeneous and heterogeneous designs failed to yield significant differences. The authors concluded that differences between ES's for studies using homogeneous and heterogeneous designs was "probably not systematically related to the 'source' factor" (p.144). As described above, the evidence that Horvath and Symonds ( 1991) provided to support their rejection of the "halo" hypothesis relied on the fact that the association between alliance and outcome was unaffected by whether or not the alliance and/or outcome measures were obtained from heterogeneous or homogeneous sources. However, the correlational nature of the evidence provided by the authors does not allow us to reach a definitive conclusion - variance in an outside observer's rating of alliance could still be due to preceding changes in symptomatology. Any significant relationship between this rating of alliance and later or concurrent measures of outcome may be better explained by a strong correla�on between the early and late measures of symptomatology. Once again we are left to wrestle with the question of which came first - changes in alliance or changes in outcome? Clemence et al. (2003) noted that it is unclear, from both their own study and previous studies, whether patients' confidence in therapy later led to therapy gains or whether they got better and then became more confident with the therapist and therapeutic process. An alternative hypothesis to the proposal that alliance plays a causative role in therapeutic outcome is that indications of good alliance may simply be epiphenomena associated 
1 1  
with improvement. This hypothesis can be expressed as a question: does alliance predict 
outcome or does outcome predict alliance? 
If this alternative hypothesis (of symptom change driving alliance change) holds, then the 
alliance should not "account for a significant proportion of final outcome after the 
variance associated with therapeutic gains measured at the same time as the alliance has 
been statistically removed" (Horvath, Luborsky, & Gaston, 1993, p. 260). Furthennore, it 
has been argued that if outcome predicts or leads alliance then "early, particularly first 
session measures of the alliance ought to be clearly less efficient predictors of outcome 
than measures obtained later in therapy" and the development of alliance "ought to 
follow therapeutic progress in a parallel fashion", i .e., the alliance ought to go from poor 
to better as symptoms are reduced (Horvath, Luborsky, & Gaston, 1993, p. 260). 
To date, evidence from research has seemingly supported the hypothesis that alli ance 
predicts outcome. Gaston et al . (1991)  calculated partial correlations between alliance 
and outcome that controlled for initial symptomatology and in-treatment symptomatic 
change and she found that alliance predicted 36%-57% of the variance in final outcome 
over and above short-term improvements. Both Horvath and Symonds ( 1991)  and Martin 
et al . (2000) in their separate meta-analytic reviews of the relation between alliance and 
outcome found early and late measures of alliance to be equally predictive of outcome, 
while middle-phase or averaged measures of alliance were less predictive. Finally, Safran 
et al . (1990) found that a positive outcome was associated with successful repairs of 
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alliance ruptures rather than with a linearly-increasing, non-responsive development of 
alliance throughout therapy. 
Yet again, however, the studies used to test this hypothesis simply evaluate the degree of 
association between alliance and outcome. No attempt is made to assess continuous 
changes in both variables across time and thus to assess which variable is the lead, or 
predictor, variable. Research has clearly determined that there is a relationship between 
alliance and outcome but some important questions remain to be asked about the nature 
of this relationship and therapeutic alliance. First, does the introduction of therapy make a 
difference to a patient perception of al1iance? The assumption in the literature is that 
alliance forms in response to actual therapy and this makes intuitive sense. A patient' s  
expectations about a therapist and the therapeutic process may be formed prior to starting 
therapy and continue to affect his/her perception of the therapy to such a degree that it 
over-clouds any reactions developed in response to the actual therapy. This question 
harkens back to the original psychodynamic literature on alliance - is there a distinction 
between alliance as a positive transference and alliance conceived as a reality-based 
collaboration (Freud, [ 19 13] ,  1958; Zetzel, 1956; Greenson, 1965)? 
Second, does alliance change over time or does it stabilize? Clemence et al . (2003) 
present data to suggest that it does change, while Martin et al . (2000) argued that it is 
stable. An answer to this question could help determine if continuous measures of 
alliance are required in studying alliance, or if a few single-point estimates would suffice, 
e.g., immediately prior to therapy and at the third session. Third, is there a time-
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contingent relationship or a simultaneous relationship between alliance and outcome? If 
there is a time-contingent relationship, then do changes in alliance influence changes in 
symptoms or do changes in symptoms influence changes in alliance? This is a pivotal 
question in alliance research, as Barber et al . (2000) noted when arguing for the need to 
control for early symptom improvement if trying to determine the direction of the 
alliance-outcome relationship. 
Time Series Designs in the Study of Therapeutic Alliance 
These questions require a different methodology than has been used to date in the alliance 
literature, if they are to be answered with confidence. Recognition of this problem is 
evidenced by a paper by Kokotovic and Tracey ( 1990) in which they failed to find a 
relationship between working alliance and premature termination. They suggested that a 
more detailed assessment of how the al liance changes and develops over the initial 
sessions might be necessary if this relationship is to be further explicated. Specifically, 
they stated that "repeated measures of the alliance need to be made . . .  one-point 
assessments, regardless of when made, do not appear to provide a complete picture of the 
process of working alliance establishment" (Kokotovic & Tracey, 1990, p. 2 1 ). 
One approach to addressing this problem in alliance-outcome research is to apply a time­
series design to the problem. Time series analysis in psychology is most commonly 
associated with single subject research designs. Detailed analyses of individual cases 
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have provided the impetus for much of current psychological theory and "clinical 
psychology has been defined as the application of psychological principles and 
techniques to the problems of the individual" (Kazdin, 1992, p. 1 52). However, 
researchers in psychology have typically employed a nomothetic approach to the study of 
behavior that allows an understanding of variables through an analysis of group 
differences. Such analyses allow general statements to be made that are applicable to 
"average" individuals. 
Though utterly indispensable, random assignment, controlled group studies are not the 
only types of designs that can further the understanding of if and how an intervention 
works. The small n, time-series design can, if used properly, enable researchers to make 
perfectly viable and useful contributions to the literature (Barlow & Hersen, 1 984; 
Chambless et al . ,  1996). A time series design is capable of answering all of the three 
questions posed above, and it can offer additional information on the efficacy of 
treatment by e:valuating change in symptomatology relative to baseline levels as 
treatment is introduced. The purpose of the current study is to apply a time-series design 
to the questions posed above regarding therapeutic alliance, as well as evaluating the 
utility of such a design when applied to clinical research and outcome studies. 
Kazdin (1992) outlines several reasons why single subject case studies are of value to 
researchers. First, case studies serve as a source of ideas and hypotheses, that is, they 
generate promising hypotheses that can be further tested in larger group designs. Second, 
case studies have often been a source for developing therapy techniques. Third, case 
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studies enable us to study rare phenomena. Fourth, case studies can provide a counter­
instance for laws that are considered to be universally applicable. Finally, case studies 
can have persuasive and motivational value. However, it is notable that Kazdin fails to 
emphasize the direct empirical contribution that case studies can make, and there are 
clear reasons why this is so . Case studies have historically failed to incorporate 
systematic observation and controlled conditions and so many alternate explanations for 
any observed changes are possible. There is also a difficulty in assessing how the results 
of a single case study can be generalized to other individuals. 
Improvements have been made to the design of single-subject studies so that more valid 
inferences can be drawn from their results (Whitley, 1995). These include specification of 
criteria by which the internal validity of single-case designs can be evaluated 
(KratochwiH, 1992; Kratochwill, Mott , & Dodson, 1984; Yin, 1984). These criteria can 
be classified into five general categories: measurement criteria , replication criteria, 
control criteria, impact criteria and treatment criteria (Kratochwill et al., 1984). These · 
criteria serve to uemphasize the impact and breadth of the effect of an intervention as 
means of ruling out chance effects and confounds as explanations for changes in the 
dependent variables" (Whitley, 1995, p. 323). 
While a group design assesses the effect of an intervention by comparing group 
differences, a single subject design compares different conditions applied to the same 
individual over time. Essentially, a single subject experimental design re1ies on 
continuous assessment of the variable of interest across phase A (e.g. ,  pre-treatment or 16 
baseline) and phase B (e.g., treatment). Baseline assessment provides information about the initial level of the variable of interest and, more importantly, enables prediction of its level should the intervention not occur. This predicted level can be contrasted with the level obtained in the treatment phase to evaluate if the introduction of the intervention resulted in a significant change in the level of the variable. Unfortunately, evaluating the significance of the change can be complicated by the presence of autocorrelation in the data. Autocorrelation signifies the inherent relationship between observations taken at one point in time and observations taken on the same subject at a different time. The autocorrelation coefficient is the Pearson-Product­Moment correlation for two vectors of the same data. As Robey, Schultz, Crawford & Sinner (1999, p.451) explain: For a first order autocorrelation coefficient, the first vector contains the observations as they were collected in series. The first element of the second vector is set empty; the second element is the first observation, the third element is the second observation, and so forth. The second vector is said to be lag- 1 variate. A correlation coefficient is calculated for the two vectors of data. So, for example, a lag-1 autocorrelation coefficient indexes the association between all values that are one time interval apart, i.e. , the correlation between the values of the variable at time I and time 2, the values at time 2 and time 3, the values at time 3 and time 4, etc. A key problem with time series data is that the presence of autocorrelation can bias the analysis decisions and lead to Type I errors because the observations are not independent, i.e., the data predicts itself. A positive autocorrelation produces liberally 
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biased errors and a negative autocorrelation produces conservatively biased errors 
(Crosbie, 1987). 
Fortunately, statistical programs have been developed to correct for the presence of 
autocorrelation in time series data. Box and Jenkins (1970) proposed a parsimonious 
class of models called the autoregressive, integrated, moving average (ARIMA) models 
to represent time series data . However, although this procedure has been found useful by 
researchers, it is complex and requires a good deal of experience and judgement to use 
effectively (Gottman, 1981). Gottman (1981) developed the interrupted time-series 
analysis (ITSA) for serially dependent time-series observation . Fundamentally, ITSA 
produces three statistical tests : (i) an F test of the null hypothesis that no general change 
occurred in the progression from phase A to phase B; (i i) a t-test for the null hypothesis 
that no change in slope occurred between phases A and B; and (iii) a t-test for the null 
hypothesis that no change in level occurred between phases A and B. 
Both the ARIMA and ITSA procedures require a large number of observations in each 
phase (Robey et al. ,  1999). Crosbie (1993) found that ITSA algorithms underestimate 
positive autocorrelation with short series of data and so he improved upon Gottman' s 
ITSA algorithm for assessing time series data. The improved algorithm, named 
ITSACORR, produces output that includes a test of overall change, a test of change of 
s]ope , and a test of change in level between phases. Robey et al . ( 1999) found that 
ITSACORR maintained Type I error ''at or below the nominal level with satisfactory 
statistical power in the analysis of short-series data (i .e. ,  fewer than 50 observations per 
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period)" (Robey et al . ,  1999, p.460). The algorithm only appeared to falter when the autocorrelation was greater than 0.60 and sample sizes were less than 20, and thus Crosbie (1993) recommended a typical minimum of 10 observations per period. The advantage of ITSACORR ,  therefore, is that allows for an analysis of serially dependent data using a number of observations that are more clinically realis tic. However , there are some problems associated with Crosbie 's ( 1993) ITSA CORR analysis. With increasing autocorrelation present in the data and effect sizes Jess than 5, ITSA CORR's power can become significantly lowered (as a careful reading of Crosbie 's 1993 paper reveals). Also the collection of ten data-points for each phase may be prohibitive in a clinical setting , as patients are typically unwil 1ing to delay treatment for the purpose of obtaining a baseline. For increased power with smal1 -n data streams, McKean , Naranjo , and Huitema (2001) recommend the use of a bootstrapped version of Spearman' s rho for examining between-phase change in time-series data sets . Spearman 's rho was chosen due to its excellent small-sample properties. However , even the bootstrapped rho does not properly adjust for the increased Type-I error associated with positive autocorrelation , and it is not recommended for use with auto-correlated data streams (Jeong & Chung, 2001). 19 
Other Time Series Methodologies for Autocorrelated Data Streams 
A more viable approach to lessening the impact of autocorrelation and n-size on Type-I 
error is to conduct Monte-Carlo analyses on simulated data streams with known 
properties. For example, one could generate 10,000 random data streams (no 
programmed effects) with a baseline n-size of 5, a treatment n-size of 10 and a 
programmed autocorrelation of .67. Then we could calculate Spearman ' s rho between a 
phase variable (0, 0, 0, 0, 0, 1 ,  1 ,  1 ,  1 ,  1 ,  1 ,  1 ,  1 ,  1 ,  1 )  and the random data for each of the 
10,000 simulated streams and determine how many times out of 10,000 the value of rho 
was greater than some pre-determined value (for example, .30). This would be the 
number of times that rho is equal to, or greater than; .30 by chance alone when there is 
autocorrelation of .67 present and when phase-n sizes are equal to 5 and 10. 
If, for example, rho was equal to, or greater than, .30 for 532 of the 10,000 of the random 
streams, the ·probability of concluding there is an effect when in fact there is not with rho 
= .30 under conditions of autocorrelation = .67 and n-sizes of 5 and 10 is .0532. 
Therefore, we would expect that any time we have a time-series data stream with auto­
correlation = .67, 5 baseline and 10 treatment data points and the value of rho (between 
our phase variable and our clinical data) is .30, there is a 5 .32% chance that this value 
represents a type-I error. Since this value is greater than the preset alpha in social 
sciences (.05 or 5% ), we fail to reject the null hypothesis  that rho = 0. 20 
In keeping with this logic, an initial test of change in the level of each variable was 
performed using this Simulation Method (manuscript in progress, Borckardt et al ., as 
described above). It was hypothesized that there would be a significant decrease in 
symptom lev�ls (improvement) across the phases, as indicated by significant Spearman 
rho values. The null hypothesis was that there would be no significant change m 
symptom levels across phases, i .e. , the Spearman rho values would be non-significant. 
It was further hypothesized that there would be a significant change in the levels of 
alliance variables across the phases, reflecting the patient's changing attitude to therapy 
once engaged in the therapy proper. A change in alliance, as signified by significant 
Spearman rho values, would be suggestive of a shift from a transference relationship to a 
focus on the real relationship once therapy begins. The null hypothesis, which predicted 
no significant change in therapeutic alliance across phases (as indicated by non­
significant Spearman rho-values), would support Martin et al' s (2000) finding that 
patients report alliance as stable over time, but may also suggest that the therapist's initial 
activity in therapy has little impact on establishing an alliance, as it remains unchanged 
from baseline. In such a case, it could be argued that transference elements of the 
therapeutic relationship take precedence over the real relationship. 
This method, although allowing for an initial assessment of an effect on variable levels 
with the introduction of therapy, is limited in its ability to determine what accounts for 
the change. For example, a trend in baseline that produces a downward slope in 
symptomatology (improvement), and that continues into the treatment phase, will 
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produce a lower mean in the treatment phase and a significant Spearman rho. However, 
the inferred effect for treatment would be a statistical artifact as the lower mean was due 
to the trend that began before treatment was introduced. Thus, an analysis is required that 
allows for modeling and assessment of the various components that describe the data 
stream. 
A popular approach to time-series modeling is the Durbin two-stage procedure (Durbin, 
1960). This method first obtains autoregressive parameter estimates from the residuals of 
an initial fit of a linear model and then refitting the linear model on the basis of the 
estimates obtained in the first stage. For the current study, a two-stage Durbin-type 
approach (Durbin, 1960; Fuller, 1996) was applied to the data, fitting ARIMA models in 
the second stage for those variables in which there was an autoregressive component in 
the initial residuals. Four parameters were contained in the model: the intercept, baseline 
slope, level change and slope-change parameters. A t-statistic was estimated for each 
parameter to determine its significance. 
Huitema and McKean ( 1998) have demonstrated that, ·although ARIMA models are 
typically recommended for the analysis of interrupted time-series data, conventional 
regression models can also fit such data when there is no auto-regression in the residuals. 
They recommend the use of such linear regression models with small sample sizes, as 
ARIMA modeling is generally not recommended for samples sizes less than 50 because 
of reduced power (Box, Jenkins, & Reinsel, 1994). Huitema & McKean (2000) estimated 
the power of the Durbin-Watson Ordinary Least Squares regression method for data 22 
streams of 30 and 50 points with the population parameter p = . 70, .50, and .30 and four parameters in the model (e.g., intercept, baseline slope, level change and slope change). For p = .70, .50, and .30, and an n of 30 data points, power was calculated as .83, .67, and .37 respectively. With p = .70, .50, and .30, and an n of 50 data points, power was calculated as .98, .92, and .6 1 respectively. Therefore, because of expected small samples in the current study, conventional linear models (containing intercept, baseline slope, level change and slope-change parameters) were retained if the first stage of the analysis indicated no autoregressive component in the residuals. 
Cross-Correlational Methodologies and the Study of Therapeutic Alliance In addition to providing an answer to the question of whether alliance changes over time or remains stable and if the introduction of treatment affects the alliance in relation to the baseline, a time series analysis allows researchers to assess the cross-correlation of two time series and thus investigate the degree to which one time series predicts another. In essence, such an analysis tests whether across time the state of the alliance is largely determining therapeutic outcome or whether therapeutic outcome largely determines alliance . Such an approach allows for an evaluation of the degree of association between alliance and outcome while, by nature of the design, also permitting us to assess whether alliance leads outcome or vice versa. 
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There are at least three possible approaches to this question. Bakeman, Adamson and Strisik (1995) describe a method that utilizes loglinear analysis to assess the degree to which one series predicts another. Unfortunately, while their approach is intuitively appealing, it is best suited for discrete behavioral events and it requires that continuous time series data be reduced to categorical data thus reducing variability. An alternative approach is provided by Gottman and Ringland ( 1981)  who employed a procedure that utilized transfer function models to test for a lead-lag relationship between two series. Essentially, they fitted autoregressive models to each series and then attempted to predict the residual from an auto-regression on each series from the past of the other series. If there is no gain in prediction with the added term, then the smaller autoregressive model without the past of the other is sufficient. Due to autocorrelation, they could not derive exact F-ratio statistics to compare the smaller model with the larger models; instead they employed likelihood-ratio tests. In a review of cross-correlation analysis methods, Cook, Dintzer and Mark (1980) argue for the use of the Haugh-Box procedure (Haugh & Box, 1977; Haugh, 1976) as the most appropriate form of analysis. This procedure is a revision of the Box-Jenkins (1976) joint pre-whitening (whereby autoregressive components are partia11ed out of the data streams) and cross-correlation procedure, and requires independent pre-whitening of the data in both series using their own ARIMA models. In essence, this procedure models the time series data for the two variables of interest and then cross-correlates the resulting residuals from these models. The SPSS cross-correlation function can be used to 
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calculate the degree of association between any two variables (or their residua ls) across time . Cook et al .  ( 1980) list several advantages in using this procedure . First , independent pre­whitening minimizes "spurious cross-correlations which may arise because of auto­correlation in Xt and Yt" (p. 123). Second , "feedback effects (in which Xt affects later values of Yt and Yt also affects later values of Xt) should be easier to detect" (p . 123-124). Third , "one need not specify a priori which is the causal series" (p . 124). Fourth , Haugh ( 1976) has shown that when the series X and Y are unrelated , the cross­correlations between the residuals are "normally and independently distributed with a mean of zero and a standard deviation of 1/✓N" (Cook et al . ,  1 980, p . 124), thus allowing cross-correlations to be assessed against a standard error . Fifth , and most importantly , by pre-whitening the two series , "we remove that part of the current observation which could be predicted from past observations . Thus , when the pre-whitened series , aX, is significantly correlated with lagged values of the pre-whitened series , aY, aX is predicting part •of Y that could not be predicted by past values of Y a lone" (p . 124 ). There are , however , limitations to the Haugh-Box approach . Even if there is no autocorrelation between variables in a series Y, if the autoregressive series X causes the variable Y, then observed values of Y may be autocorrelated because of an indirect link through the autocorrelated causal variable X. Pre-whitening would remove this autocorrelation, even though this autocorrelation should be attributed to X, not Y. As a 
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result, the causal parameter may be underestimated using the Haugh-Box procedure 
(Cook et al . ,  1980, p. 126). 
Cook et al . (1980) consider the use of ARIMA models for pre-whitening to be a second 
disadvantage of the Haugh-Box procedure, as it requires the exercise of the researcher' s 
judgment at several decision points. However, they do not consider this to be a serious 
problem as one can conduct several Haugh-Box analyses using different ARIMA models 
if there is a question about the model fit. They also note that "the alternative ARIMA 
models that might be chosen usually lead to similar results because the alternative models 
are mathematically similar" (p. 126). 
Other shortcomings of the Haugh-Box are also discussed by Cook et al . ( 1980, pp. 1 26-
127). First, ARIMA models may also not be the best choice to describe certain time 
series models and so the pre-whitening does not adequately transform the residuals into 
white noise. Second, if a series is completely regular it can be fully predicted on the basis 
·of its own past, and therefore detecting its covariation with another series is impossible. 
Third, the residuals can be assumed to contain a higher proportion of measurement error 
than the original series, thus possibly attenuating the relationship between the residuals .  26 
. Objectives and Hypotheses of the Current Study The central purpose of this study is to address three questions about the relationship between therapeutic alliance and symptom change (or outcome) in therapy. These questions were presented in the preceding introduction: ( 1) Does the introduction of therapy have an impact on the initial formation of alliance, or is alliance primarily a transference phenomenon In other words, is it a here-and­now phenomenon or is it more influenced by prior expectations? (2) Does alliance change continuously over time or does it stabilize? (3) Is there a time-contingent relationship or a simultaneous relationship between alliance and outcome? If there is a time-contingent relationship, then do changes in alliance influence changes in symptoms or do changes in symptoms influence changes in alliance? The first quest!_�n regarding the impact of therapy on the formation of alliance will be addressed by assessing for an intervention effect for therapy on alliance. Results from the Simulation Method and regression modeling or ARIMA modeling will be evaluated to determine the extent to which the introduction of therapy impacts alliance. The null hypothesis is that there will be no significant change in alliance across the two phases. Specifically, it is hypothesized that the Spearman rho values (obtained from the Simulation Method) for changes in the six alliance factors will be non-significant. Non­significant Spearman rho values are sufficient support for the null hypothesis, but the 
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presence of significant Spearman rho values does not necessitate rejection of the null hypothesis. With the occurrence of significant Spearman rho values indicating a change in the treatment phase level of alliance, the null hypothesis can only be rejected if the t­statistic of either the parameter for level change or slope change in the treatment phase is significant. Otherwise, the presence of a significant baseline slope parameter or autoregressive parameter could account for a change in alliance across the phases that is unrelated to the introduction of therapy. The null hypothesis will be rejected if there is a significant level change or slope change parameter indicating a treatment effect in the regression or ARIMA model. In order to provide some estimate of the generalizability of the results bearing on this hypothesis, a count was made across all subjects of the number of significant baseline slope parameters and of the number of significant level change or slope change parameters indicating a treatment effect. A binomial test was then performed to test for a discrepancy in the ratio of non-significant to significant treatment-phase mean and slope parameters. A result indicating a statistically . greater number of significant treatment effect parameters than would be expected by chance, would entail a rejection of the null hypothesis. A summation of effect-size, from all subjects, for change in means across the two phases will also be presented for all six factors. The second question could be addressed by a visual analysis of the data points of each alliance factor, which would indicate stabilization by the presence of a non-varying horizontal line at some point in the series. A complete lack of variance was unlikely, 
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however, and thus relative stability was also assessed through a consideration of slope and level changes across time. The null hypothesis could be stated as the expectation of no change in alliance across time, both before and after the introduction of therapy. The null hypothesis was rejected if and only if there was either a significant slope change parameter for the baseline phase or the treatment phase (estimated from a regression or ARIMA model), indicating ongoing change in alliance across time. As an indication of the generalizability of this hypothesis , a count was made for each alliance factor across all subjects of the number of times there were significant slope parameters. A binomial test was then performed to test for a discrepancy in the ratio of significant baseline and treatment slope parameters versus non-significant baseline and treatment slope parameters . A result indicating a statistically greater number of significant slope parameters than would be expected by chance, would entail a rejection of the null hypothesis of no change in slope. The third question requires testing of the hypothesis that there is a time-contingent relationship between the client's perception of the alliance and outcome. Specifically, the null hypothesis can stated as the expectation that there will be no statistically significant correlation between residuals in the alliance series and residuals in the symptomatology series at lag values other than 0. Using the Haugh-Box procedure described in the introduction, the correlogram of alliance and outcome measures will be assessed for the presence of significant cross-correlational r-values for lags other than zero. The presence of significant cross-correlational r-values for lags other than zero will entail rejection of 
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the null hypothesis, indicating that the relationship is time-contingent. Alpha-levels for significance were set at a =  .10, with a Bonferroni correction requiring p-values <.01 for significance. Only relationships between certain variables were tested. Specifically, it was hypothesized that there would be a significant lead-lag relationship (significant r-values at lags other than zero) between Confident Collaboration (CCOL) on the Combined Alliance Short Form - Patient Version 3 (CAS3) scale and (1) the measure of symptom distress (OQSD) on Lambert & Burlingame's (1996). Outcome Questionnaire (OQ-45), (2) the total score on the OQ-45 (OQ-Total), (3) the total score on the Beck Depression Inventory (BDI), and (4) the total score on the Beck Anxiety Scale (BAI). These specific hypotheses were derived from previous findings in the literature that Confident Collaboration is significantly related to measures of patient improvement/ symptom change (Hatcher, 1999, Stiles et al., 1998, Clemence et al . ,  2003). It was hypothesized that Confident Collaboration scale 2 on the CAS3 (COL2) would be significantly related to the measure of interpersonal functioning on the OQ-45 (OQ-IR), the measure of social functioning on the OQ-45 (OQ-SR), and the BDI and the BAI. No literature exists on this scale 's relationship to outcome, but it was expected to be significantly related to these variables, partly because of it expected similarity to the Confident Collaboration scale. However, the COL2 scale emphasizes the patient's confidence in the therapist, rather than confidence in the therapeutic process in general, and so the hypothesis specifically addressed areas of interpersonal functioning (OQ-IR 
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and OQ-SR), rather than symptomatic change. The expected relationship to the BDI was intended to address the aspect of social withdrawal inherent in depression - it is hoped that a confident relationship with a therapist may engender greater confidence in a patient to re-initiate social contacts . The expected relationship to anxiety reflects the expectation that confidence in the therapist may serve to bind anxiety in the patient and have effects outside the therapy. It was hypothesized that the Idealized Relationship scale on the CAS3 (IDRX) would be significantly cross-correlated with general outcome measures : symptom distress (OQ­SD), total score on the OQ-45 (OQ-Total), depression, (BDI), and anxiety (BAI). Hatcher and Barends ( 1996) found a significant but negative correlation between improvement and the IDRX. Hence, a similar negative correlation was expected to be found between IDRX and outcome measures; which would suggest a relationship between how much a patient disagrees with a therapist and the amount of symptomatic improvement. It was also hypothesized that the Idealized Relationship (IDRX), Patient Dedication (DEDP) and Bond (BOND) subscales on the CAS3 would be related to outcome measures of interpersonal functioning (OQ-IR) and social functioning (OQ-SR). These three alliance factors address the patients perceived relationship to the therapist but only one of them, IDRX, has been found to be significantly related to outcome (Hatcher & Barends, 1996, Clemence et al., 2003). Goal and Task Agreement (GOAL) was also expected to be related to interpersonal functioning (OQ-IR) and social functioning (OQ­SR), as it is expected that the capacity to agree on shared tasks would be reflected in both 3 1  
interpersonal domains and group-oriented settings, such as work. Psychodynamic theories of therapeutic action (e.g., Malan, 1995; Menninger, 1958) emphasize how work on the here-and-now relationship within therapy impacts interpersonal and social functioning outside of therapy. Indeed, Goldfried (1991) found that psychodynamic and cognitive-behavioral therapists provided interpersonal feedback to patients to equal degrees but that such feedback was more strongly related to outcome for the psychodynamic therapists. It is more likely that a relationship between these alliance factors and outcome will be observed if outcome is considered in terms of interpersonal and social functioning, rather than symptom distress. Three alliance factors were expected to be related to anxiety as evaluated by the BAI: Goal and Task Agreement (GOAL), Bond (BOND) and Patient Dedication (DEDP). The assurance inherent in developing a clear set of goals was expected to have a positive effect on presenting anxiety. It is also possible that changes in anxiety would affect a patient's capacity to be assured by a clear therapeutic plan of action. Feeling attached to the therapist is likely to increase comfort in the therapy and act to reduce general anxiety. Likewise, anxiety may impede the development of a close relationship. Patient dedication reflects negative aspects of the patient's participation in therapy; anxiety and inhibited participation are expected to be related, based on psychodynamic literature regarding resistance in therapy (e.g., Malan, 1995). Indeed, Wachtel (1997, p. 86) describes therapy as a general extinction of anxiety as "progressively more anxiety-provoking thoughts are in tum expressed and go unpunished." 32 
Given the limited power of the Haugh-Box procedure to detect a time-contingent relationship (Cook et al., 1980), any of the predicted relationships as described on the last three pages that were significant at the . 1 0  level (with a Bonferroni correction) were further evaluated using a meta-analytic approach. The cross-correlational r-statistics for the relationship would be converted to Fisher's Z and averaged across all subjects for that particular lag-value. The obtained Z-value was then re-converted to an effect-size as per Rosenthal and Rosnow (1991). Using Cohen's ( 1992) classification system, r-values between . 1 0  and .29 were classified as small effects ; r-values between .30 and .49 as medium effects; and r-values equal to, or greater than, .50 as large effects. The null hypothesis, that there is no time-contingent relationship between alliance and outcome, can be expressed as the expectation that there will be no significant effect size (i.e., the absolute value of the estimated effect size across an subjects will be <. 10) for the cross-correlationally derived r-values . Also, for each posited relationship (e.g., CCOL with OQ-SD, OQ-Total, BDI and BAI) the significant lag-values will be evaluated to determine whether alliance leads outcome or vice versa. Negative lags would indicate that outcome drives alliance, while positive lags would indicate that alliance drives outcome. Zero lags will indicate simultaneous covariance. Lag-values associated with significant cross-correlational r-statistics in a single subject, without replication in other subjects, will only be considered suggestive of a possible causal direction . The presence of a significant effect size, summed across all subjects, for that particular relationship at that specific lag-value will be required if the null hypothesis of no time-contingent relationship between alliance and outcome is to be confidently rejected. 
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CHAPTER II 
METHOD 
Design The design of this study was primarily an AB type within-subject bivariate time domain design, where A refers to a pre-treatment baseline phase and B refers to a treatment phase. Multiple measures were taken at each time point in both the A and B phases of the study and these measures were repeated across all time points, allowing for an evaluation of treatment effects. Furthermore, the application of multiple measures at each time point allowed assessment of the degree to which one series of measurements (alliance) increases prediction of a second series of measurements (outcome/ symptomatology) over the second series' own past. 
Subjects Subjects were clients at the University of Tennessee Psychological Clinic. All clients who presented for their initial intake interview were asked to provide answers to four measures - a modified CAS-3, the OQ-45.2, the BDI-11 and the BAI - before beginning the interview. At the end of the intake interview, the interviewer decided if the client was suitable for inclusion in the study. Inclusion criteria were that ( 1 )  the client has a 
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circumscribed presenting problem with depression or anxiety as a symptom; and (2) the 
interviewer judged the client to be adequately psychologically minded to benefit from 
short-term psychotherapy. Exclusion criteria included ( 1 )  evidence of an organic 
disorder; (2) evidence of a current manic episode; (3) current suicidality; (4) psychosis; 
(5) age less than 18 years old; and (6) any evidence of a condition requiring immediate 
hospitalization. 
Originally ten female subjects and two male subjects participated in the study. However, 
only seven female subjects and one male subject completed the study with an adequate 
amount of data-points to be used in an analysis. Four subjects were excluded because 
they dropped out of treatment prematurely; three prior to the treatment phase, and one 
after her seventh week of therapy. The average age of the subjects was 22 years (SD = 
10. 16) with a range from 21  to 43. There was a bimodal distribution of ages, with four 
subjects aged between 21  and 23, one subject aged 27 and three subjects aged between 40 
and 43. Seven subjects, including the male subject, were Caucasian and one subject was 
African American. 
Seven subjects presented with a depressive disorder or were seeking help for depressive 
symptoms. Only one subject presented with primary diagnosis of panic disorder, although 
even she was simultaneously treated for depressive symptoms. The following sections 
present brief sketches of each subject including their presenting problem and diagnosis. 
Certain details have been changed to protect the identity of the subject, including their 
. name and profession. DSM-IV diagnoses are presented for each subject. 
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Subject 1: Aili sh 
Ailish was a 22-year-old single, Caucasian female who worked in financial services. She 
presented at the clinic with concerns about her chronic moodiness, which had long been a 
part of her life. She also complained of a general anxiety. Summary findings of a 
psychological evaluation indicated that she had superior intellectual abilities, and used 
this strength to cope with her persistent feelings of anger, low self-worth, and generally 
Dysthymic disposition. She was considered to be psychologically-minded by her 
evaluator and motivated to change how she felt. However, she was prone to 
intellectualizing the process of change, which served to estrange her from the feelings 
that might need expression in therapy. It was recommended that she begin once-weekly 
psycho-dynamic psychotherapy that addressed her morbid mood states, unmet 
dependency needs, and feelings of loss and separation that had been exacerbated by the 
untimely death of her mother. Her therapist was a female clinical psychology graduate 
student in her third month of clinical practice. 
Her DSM-IV (American Psychiatric Association, 1994) diagnosis was: 
Axis I - 300.4 Dysthymic Disorder 
Axis II -
Axis III 
Axis IV 
Axis V -
Rule out, Generalized Anxiety Disorder 
799.9 Diagnosis deferred, Dependent & Melancholic Features 
None reported 
None reported 
GAF = 65 (at intake) 36 
Subject 2: Brianna Brianna was a 23-year-old African-American female , who worked as an administrative assistant. She presented at the clinic for help with depressive and anxiety symptoms. She also sought help for figuring out the direction of her l ife. She stated that she had previously been diagnosed with manic depression and an anxiety disorder . Her mother had passed away five months prior to her presentation at the clinic. She was trying to start anew but was encountering resistance from her relatives .  Her prior therapy experience was at a university counseling center , but health problems with her mother prevented her from staying in therapy . Her presenting symptoms included middle insomnia , daily fatigue, and decreased appetite . She was recommended for weekly insight-oriented therapy at the clinic , and she appeared to be quite clear about what she wanted from therapy . Her therapist was a female clin ical psychology graduate student in her second month of clinical practice . Her DSM-IV diagnosis at time of intake was: Axis I - 311 Depressive Disorder , NOS Axis II -Axis III -Axis IV -Axis V - 799 .9 Diagnosis deferred None reported None reported GAF = 55 (at intake) 
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Subject 3: Ciara 
Ciara was a 40-year-old divorced, Caucasian woman. She had worked as a systems 
analyst for some years, but was unemployed at the time of presentation to the clinic. She 
presented at the clinic in order to develop more adaptive coping skills and to learn to set 
better boundaries with others. She was sexually abused from age 7 to age 1 5, and she had 
experienced depression (emotional flatness and sense of worthlessness) and disordered 
eating (overeating followed by loss of appetite) since that time. Ciara reported some close 
friendships, but noted that she was careful about maintaining a certain distance in 
relationships. She was also seeking help for her ongoing depressive symptoms and she 
was recommended to begin once-weekly insight-oriented therapy at the clinic. Her only 
prior experience of therapy was stress management for a few months in 1995. Her 
therapist was a male clinical psychology graduate student in his eleventh month of 
clinical practice. 
Her DSM-IV diagnosis at time of intake was 
Axis I - 300.4 Dysthymic Disorder, Early Onset 
307 .50 Eating Disorder, NOS 
Axis II -
Axis III 
Axis IV -
Axis V 
309.8 1  Post-Traumatic Stress Disorder, Chronic 
799.9 Diagnosis deferred 
None reported 
Unemployed 
GAF = 55 (at intake) 
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Subject 4: Deirdre 
Deirdre was a 2 1-year-old, Caucasian female who was a nursing student at the time of 
intake. She presented at the clinic with depressive symptoms, including lack of 
motivation, concentration difficulties, low appetite, and sleep difficulties that varied from 
week to week (insomnia, hypersomnia, early waking). Her mother died from cancer when 
Deirdre was 16 years old. She reported that relationships with others often drained her 
because she felt that she was always listening to other people's problems. Her therapist 
noted that Deirdre had a dysthymic character. Weekly insight-oriented therapy aimed at 
exploring her lack of motivation, emotional constriction, feelings of indifference and 
indecision, with a short-term goal of reducing her depressive symptoms. The therapist 
noted that Deirdre was anxious about therapy and so she decided to initially work on 
establishing a strong alliance and bond in the therapy, whereby the patient would feel 
safer to discuss her feelings in therapy. The patient ended therapy abruptly after 32 
sessions. Session content at the time of termination revolved around school issues, 
increased sleep, others' perception of her, and some dream-work. Her therapist was a 
female clinical psychology graduate student in her sixth month of clinical practice. 
Her DSM-IV diagnosis was: 
Axis I - 300.4 Dysthymic Disorder 
Axis II -
Axis III -
Axis IV 
Axis V 
799. 9 Diagnosis deferred 
None reported 
None reported 
GAF = 55 (at intake) 
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Subject 5 :  Elaine Elaine was a 43-year-old Caucasian, divorced female who presented at the clinic, seeking help to control her bipolar condition and also to develop greater emotional stability. She was also seeking clarification of her central concerns so that she could develop better coping skills. Her central concern at time of presentation was interpersonal difficulties with her daughter. Elaine was also experiencing work difficulties . Elaine had a pattern of involvement with men that was marked by initial idealization, followed by harsh disappointment. She also reported that she had never felt like she fit in with peers, and at the time of presenting to the clinic, she was becoming aware of a greater desire for social isolation. It was recommended that she begin weekly psychodynamic psychotherapy with an initial focus on helping her develop clear goals for the therapy, and reducing her depressive symptoms. Her therapist was a male clinical psychology graduate student in his seventh month of clinical practice. Her DSM-IV diagnosis was: Axis I ­Axis II -Axis III -Axis IV Axis V - 296 .7 Bipolar I Disorder, Most recent episode unspecified Rule out Borderline Personality Disorder Migraines, narcolepsy & high blood pressure (reported by patient) Family tension & work difficulties GAF = 50 (at intake) 
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Subject 6: Fiona Fiona was a 2 1 -year-old single, Caucasian female studying literature as an undergraduate student. She was referred by her psychiatrist for help with recurring panic attacks; the patient believed that the panic were triggered by stress. She was also seeking help with interpersonal issues, and she wished to understand a past abusive relationship with a boyfriend as well as her lack of a relationship with her biological father. Her therapist noted that she was of average intellectual functioning and that she had an obsessive­compulsive personality style. Fiona was recommended to begin once weekly insight­oriented therapy with the goal of improving interpersonal relationships and her style of relating to men, as well as improving her ability to cope with stress and anxiety. The therapist also aimed to improve mood, alleviate depressive symptoms and help improve the patient 's self-image. Her therapist was a female clinical psychology graduate student in her second month of clinical practice. Her diagnosis was Axis I - 300.0 1 Panic Disorder without Agoraphobia Axis II -Axis III Axis IV -Axis V - 799.9 Diagnosis deferred, Obsessive-compulsive features Hypothyroidism, low blood sugar, anemia and history of cervical cancer (all reported by patient) None reported GAF = 55 (at intake) 
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Subject 7: Gerald Gerald was a 43-year-old, married, Caucasian male who presented to the clinic seeking therapy for a long history of social anxiety and depression. He also reported a history of changing jobs and an inabil ity to sustain employment . Data from his psychological evaluation indicate that while he possessed superior intelligence, long-term stressors disordered his thinking and compromised his functioning. Weekly insight-oriented psychotherapy was recommended, with an emphasis on supportive work to help the patient develop new ways of tolerating anxiety and stress. Despite clear intelligence, a tendency towards perfectionism and a strong sense of responsibility, his assessment indicated that these qualities would be severely compromised by paranoid concerns, disordered thinking and over-reliance on repression . It was recommended that the therapy proceed slowly due to Gerald's low self-esteem, shyness, intellectualization and avoidance. A strong therapeutic alliance was expected to take a long time to build. His therapist was a male clinical psychology graduate student in his second month of clinical practice. His diagnosis was: Axis I -Axis II Axis Ill Axis N 296.32 Major Depressive Disorder, Recurrent, Moderate Rule out : 300.04 Dysthymic Disorder 30 1.22 Schizotypal Personality Disorder w/ Narcissistic features Migraine headaches (reported by patient) Social support, occupational problems Axis V GAF = 45 
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Subject 8: Hilda Hilda was a 27-year-old, single, Caucasian female who presented to the clinic with symptoms of depression after the ending of a 3½-year romantic relationship. She reported depressed mood, crying episodes, sleep disturbance, low appetite, weight loss, anhedonia, hopelessness, decreased self-esteem, increased anxiety and irritability at work. Her therapist noted that Hilda was of average intelligence but that her thoughts and feelings were disorganized. She also had little sense of self or capacity for independence. Hilda was recommended to begin weekly insight-oriented psychotherapy. Soon after therapy began, she reconciled with her boyfriend and her depressive symptoms began to lift. The initial focus of therapy was to develop a therapeutic alliance that would allow her to feel secure. However, her irregular attendance was disruptive and, from the therapist 's perspective, a solid alliance was not accomplished. She eventually began exploring issues around food, self-image and control, but she abruptly terminated. Her therapist was a female clinical psychology graduate student who was in her sixth month of clinical practice . Her diagnosis was: Axis I -Axis II Axis III -Axis V - 309.0 Adjustment Disorder with Depressed Mood, Acute 307 .51 Bulimia Nervosa 799.9 Diagnosis deferred, dependent features None reported Axis IV - Primary support group GAF = 55 (at intake) 
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Measures Four scales were used for the purpose of this study: the Beck Depression Inventory - II (BDl-11), the Beck Anxiety Inventory (BAI), the Outcome Questionnaire (OQ-45.2), and the Combined Alliance Short Form - Patient version 3 (CAS3). A modified form of the CAS3 is given to patients during the period before treatment (the baseline phase) that contains the same items, but different instructions. The modified instructions ask patients to "think about your expectations of therapy since the last time you filled out this form, and decide what category best describes how you expect you will experience therapy once it begins." The unmodified instructions ask the patient to "think about your experience in therapy since the last time you filled out this form, and decide which category best describes your own experience." The Beck Depression Inventory - II The BDI-11 is a version of the Beck Depression Inventory (BDI-IA; Beck & Steer, 1993b) that was modified in order to it more consonant with DSM-ill-R & DSM-IV criteria for depression. It was constructed to assess the severity of self-reported depression in adolescents and adults. The BDI-II consists of 21 items, each of which are rated on a 4-point scale ranging from 0 to 3 and total scores can range from 0 to 63 . According to Beck et al. (1996), BDI-11 scores ranging from O to 13 indicate "Minimal" depression; scores ranging from 14 to 19 are "Mild;" scores from 20 to 28 are "Moderate;" and scores greater than 28 are "Severe." Respondents are asked to describe themselves for the "Past Two Weeks, Including Today." 
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With regard to its reliability and validity , Beck, Steer and Brown (1996) reported that the I-week test-retest reliability for 26 outpatients was high (r = 0.93, p<.00 1). In a comparison of the BDI-11 and the BDI-IA (Beck & Steer, 1993b), Beck, Steer , Ball and Ranieri ( 1996) administered both scales to 140 psychiatric outpatients. The correlation between the BDI-11 and the BDI-IA was 0.93 (p<.001) and the coefficient alpha of the BDI-IA for the 140 outpatients was 0.89 and 0.9 1 for the BDI-11. Neither instrument was significantly associated with the characteristics of sex, ethnicity and age and both were positively related to being diagnosed with a mood disorder . The authors concluded that the two measures "displayed a similar pattern of relationships with the same psychological characteristics" and that the "transition from the usage of the BDI-IA to that of the BDI-11 should introduce no meaningful interpretative problems" (Beck, Steer , Ball & Ranieri , 1996, p. 596). Regarding its convergent and discriminant va1idities , Beck et al. ( 1996) also reported that , for 87 outpatients , it was more positively correlated with the revised Hamilton Psychiatric Rating Scale for Depression (Riskind, Beck, Brown, & Steer , 1987; r = 0.7 1) than it was with the revised Hamilton Rating Scale for Anxiety (Riskind et al . ,  r = 0.47). The Beck Anxiety Inventory The Beck Anxiety Inventory (BAI ; Beck & Steer , 1993a) is a 21 item questionnaire that was designed as a measurement of clinical anxiety that could reliably discriminate anxiety from depression while displaying convergent validity (Beck, Epstein, Brown & Steer, 1988). Its 21  items were derived from an initial pool of 86 items that were gleaned 
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from three self-report scales: the Anxiety Checklist (Beck, Steer, & Brown, 1985); the Physician's Desk Reference Checklist (Beck, 1978); and the Situational Anxiety Checklist (Beck, 1982). Each item requires the respondent to rate how much he/she has been bothered by each symptom over the past week on a 4-point scale ranging from 0 (Not at all) to 3 (Severely - I could barely stand it). The items are summed to obtain a total score than can range from O to 63. BAI scores ranging from 8 to 15 indicate mild anxiety, scores from 16 to 25 indicate moderate anxiety and scores from 26 to 63 indicate severe anxiety. Beck, Epstein, Brown & Steer ( 1988) found that the alpha coefficient for the final 21 -item BAI was 0.92 and that the item-total correlations ranged form 0.30 to 0.7 1 with a median of 0.60. The 1 -week test-retest reliability for a subsample of 83 patients was found to be 0.75. A factor analysis indicated two underlying dimensions - the first being somatic symptoms and the second being subjective anxiety and panic symptoms (Beck et al., 1988). The authors reported that the correlation between the BDI and the BAI was 
0.48. However, in a test of its discriminant validity , a combined factorial analysis of the 2 1  BAI and the 21  BDI items was performed and it resulted in three factors made up of BAI items and one factor of BDI items. As the authors noted, "only one BAI item ("terrified") loaded on the Depression factor, and it had a secondary loading" (Beck et al., 1988, p. 895). Furthermore, in the same study one-way analyses of variance followed by Tukey' s tests indicated that the mean BAI score was significantly higher in a group diagnosed as having a primary DSM-III anxiety disorder than in either the depressed or the control groups, which did not differ from each other. 
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The Outcome Questionnaire The Outcome Questionnaire (OQ-45.2; Lambert, Hansen et al., 1996) is a 45 item questionnaire that was produced as a result of the collaboration between two managed care corporations and a university research program. It was designed to measure three areas of client functioning: symptomatic distress, interpersonal problems, and social role adjustment. As well as measuring "symptomatic complaints, poor interpersonal relations, and dysfunction in social roles," it also contains items that assess "positive mental health or quality of life" (Lambert, Okiishi, Finch & Johnson, 1998, p. 64). Clients answer each item on the basis of a 5-point scale ranging from O to 4 (the anchor labels are "Never" and "Almost Always"). Twenty-five items comprise the Symptomatic Distress (SD) subscale, resulting in a possible score ranging from O to 100. A further 1 1  items make up the Interpersonal Relations (IR) subscale, allowing a range of scores between O and 44. The Social Role Adjustment (SR) subscale contains a further 9 unique items, thus providing a score ranging between O and 36. The three individual scores on these subscales are then summed to produce a Total score, which ranges between O and 1 80. A total score of 63 is taken as an indication that the client is outside the functional range on the OQ: most clients enter therapy with a raw score of 75 or higher. The reliable change index was estimated to be 15 (Lambert, Okiishi, Finch, & Johnson, 1998, p. 64). Thus, for example , a client who enters therapy in the dysfunctional range but who moves below 63 on the OQ-45.2 by the end of therapy and who decreases their Total score by at least 15 points is considered "improved." 
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Internal reliability was reported to be in the low 0.90' s and its test-retest coefficients ranged between 0. 70 - 0.80 (Lambert, Okiishi, Finch & Johnson, 1998). Lambert et al . (1998) also detailed the results of several validity studies, which indicated that the OQ-45.2 correlated highly with the Symptom Checklist-90-R, General Severity Index (Derogatis, 1977), r = 0. 72; the Beck Depression Inventory (Beck, Steer, & Garbin, 1 988) r = 0.80; and that it correlated moderately with measures of interpersonal problems and social role adjustment (Inventory of Interpersonal Problems [Horowitz, Rosenberg, Baer, Ureno & Villasenor, 1988), r = 0.60; Social Adjustment Rating Scale [Weissman & Bothwell, 1976] , r = 0.62), (Lambert, Burlingame et al . , 1996; Umphress, Lambert, Smart, Barlow & Clouse, 1997). The OQ-45.2 was also found to be relatively stable in non-treated individuals while being sensitive to change in patients undergoing psychotherapy (Lambert, Thompson, Andrews, Kadera, & Eriksen, 1996). The Combined Alliance Short Form - Patient Version 3 The Combined Alliance Short Form - Patient Version 3 (CAS3, Hatcher & Barends, 1 996) is a 33 item self report measure of therapeutic alliance that was derived from the factor analysis of three separate alliance measures - the Working Alliance Inventory (WAI; Horvath & Greenberg, 1986, 1 989); the Penn Helping Alliance Questionnaire (HAQ; Alexander & Luborsky, 1986); and the California Psychotherapy Alliance Scales (CALPAS; Gaston, 1991 ). Clients rate their experience of therapy on a scale of 1 to 7 (with corresponding labels of "Never" and "Always"). The scale has also been found to have adequate reliability and validity with alpha coefficients ranging from a = 0.84 for 
48 
the Idealized Relationship subscale to a = 0.91  for the Bond subscale (Personal communication from R.L. Hatcher as referenced on p.90 of Ackerman, Hilsenroth, Baity & B lagys, 1999). Scores are obtained for 6 subscales - each subscale is composed of at least five separate items. The individual subscales were obtained from the factor analysis of the original three alliance scales (Hatcher & Barends, 1996). The first subscale, Confident Collaboration, may be summarized as the patient being "confident in and committed to a process that feels promising and helpful" (Hatcher & Barends, 1996, p. 1329). A sample item on the subscale is "Do you feel that even though you might have moments of doubt, confusion, or mistrust, that overall therapy is worthwhile?" A second subscale, termed Confident Collaboration 2, was included in the most recent version of the scale and, in contrast to the first Confident Collaboration subscale, it emphasizes confidence in the therapist, rather than the overall process of therapy. An item from this subscale is "My therapist and I work well together on my problems." The Goals and Tasks subscale consists of 5 items and assesses the client 's perception of having similar goals and tasks as the therapist. One item on that subscale is "My therapist and I agree on what is important for me to work on ." The Bond subscale consists of 5 items and measures the degree to which the client feels he/she is liked and accepted by the therapist . An item on this subscale is "I feel my therapist cares about me even when I do things that he/she does not approve of ." 
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The Idealized Relationship subscale consists of 5 items (all reverse-scored) and reflects 
two types of items: "(a) items reflecting a sense of helpful collaboration with the therapist 
and (b) items reflecting more or less serious disagreement with the therapist" (Hatcher & 
Barends, 1996, p.1329). An example of an item on this subscale is "Do you find your 
therapist 's comments unhelpful, that is, confusing, mistaken, or not really applying to 
you?" The Dedicated Patient subscale contains 5 items (al1 reverse-scored) and focuses 
on the negative aspects of the patient's participation in the therapeutic process and, unlike 
the Idealized Relationship subscale, it does not include items that reflect helpful 
collaboration with the therapist. This subscale focuses on the actions of the patient . An 
item on that subscale is "When important things came to mind, how often did you find 
yourself keeping them to yourself, rather than sharing them with your therapist?" 
Procedure 
Potential clients at the University of Tennessee Psychological Clinic were screened to 
assess their suitability for the current study. The screening occurred when the client came 
to the Clinic for their initial intake interview. Upon presenting to the clinic for the intake 
interview, all clients were presented with four scales (in addition to the standard forms 
that they fill in before the intake) that they were asked to complete before beginning the 
interview. The scales were the modified form of the CAS3, (assessing expectations for 
alliance), the OQ-45.2, the BDI-II and the BAI as described in the measures section 
above. At the end of the interview, the interviewer decided, on the basis of the inc1usion 
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and exclusion c�teria -listed in the Subject section above, if the client was a suitable candidate for this study. If the client was deemed suitable he/she was asked to sign a consent form that explained the nature of the study and what they were required to do. He/she was then given a packet of four questionnaires that were to be completed at home on day four after the interview -the client was informed that a student would contact them on that day to remind them to complete the packet. The three questionnaires in the packet were the modified CAS3, the OQ-45.2, the BDI-11 and the BAI. As per the description in the consent form, the client was again informed that they would have to complete this packet twice a week for at least the following 12 weeks - once at home on the fourth day after each assessment/therapy session and once at the clinic immediately before an assessment/therapy session. The assessment period extended over a minimum of two weeks and involved two separate assessment sessions, with each session one week apart and with the first assessment session occurring exactly one week after the initial interview. This procedure, in conjunction with the pre-intake screening, provided the required minimum of seven separate baseline data-points for each measurement without the need to extend the period between intake and therapy to more than three weeks. At the end of each assessment session the client was given the relevant four questionnaires to complete at home. They sealed their dated and completed 5 1  
questionnaires in a provided envelope, and gave the envelope to the receptionist before 
the next therapy session. Immediately prior to each assessment session, the client 
completed the same packet in the clinic and upon completion, he/she also gave these 
dated questionnaires in a sealed envelope to the receptionist. No names were on the 
forms, in case the patient lost the forms before giving them to the receptionist. Upon 
receipt of the envelopes, the client's  initials were placed on the outside and the envelope 
was collected that day and stored by the either the primary investigator or a research 
assistant. 
During the psychotherapy phase, which began no earlier than one week after the second 
assessment (depending on the wait-list for the clinic), the same procedure was followed 
with the client completing the questionnaires on a twice weekly basis - once immediately 
before a therapy session while at the clinic and once at home on the fourth day after each 
therapy session . The only change to the procedure was that the CAS3 was given in a non­
modified form, as the assessment of a11iance was to be in response to the actual therapy 
rather than the client' s expectations regarding the nature of the therapeutic relationship. 
Again, no names were on these forms. The collection of data during the psychotherapy 
phase continued for at least ten weeks of therapy session . This provided the investigator 
with at least 19 treatment-phase data-points. 
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Data Analysis 
Data for each subject on all outcome measures (OQ-SD, OQ-IR, OQ-SR, BDI & BAI) 
and all alliance subscales (CCOL, COL2, GOAL, BOND, DEDP & IDRX) were graphed 
for an initial visual analysis. Twelve graphs were created for each subject, one for each 
variable, plotting its value at each time point in the baseline phase and the treatment 
phase. Means and standard deviations for all variables across both phases were also 
calculated. 
Spearman's Rho and empirically derived probability values (derived using Borckardt 's 
Simulation Method as described in the Methodology chapter) are presented for each 
variable as an initial check for treatment effects - significant negative Rho-values are 
associated with significant decreases across the treatment phase relative to baseline , while 
significant positive Rho-values are similarly associated with significant increases. Effect 
sizes for changes in the mean level of each variable from the baseline to the treatment 
phase were calculated by dividing the difference in phase means by the standard 
deviation of the baseline (White et al . ,  1989, Busk & Serlin, 1992). 
A regression analysis was then run for each variable of interest, using the following 
equation: 
Y(T) = �O + �LT + �2.X + �3 .XT + e 
where Y(T) is the value of the variable of interest at time T. For each data point in the 
baseline phase , T = n-Nl ,  where n = (1, 2, 3, . . .  , NI )  and NI is the number of points in 
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the baseline phase. For each data point in the treatment phase, T = (1,  2, 3, . . . , N2) where N2 is the number of points in the treatment phase. For example, with a baseline of 
5 points and a treatment phase of 7 points the values for T = (-4, -3, -2, - 1 , 0, 1 ,  2, 3, 4, 5, 6, 7). The value of X is 0 for each point in the baseline and 1 for each point in the treatment phase. XT is an interaction term obtained by multiplying the values of X and T, producing values of 0 for each point in the baseline phase and a sequential range of values for each point in the treatment phase = ( 1 ,  2, 3, . . .  , N2), where N2 is again the number of points in the treatment phase . In the example just given, values for X = (0, 0, 0, 0, 0, 1 ,  1 ,  1 ,  1 ,  1 ,  1 ,  1) and values for XT = (0, 0, 0, 0, 0, 1 ,  2, 3, 4, 5, 6, 7). The unstandardized residuals produced by the regression analysis for each variable was saved in an SPSS data file, and an autocorrelation correlogram and a partial autocorrelation correlogram were created for each set of residuals using the SPSS autocorrelation graphing function. Each set of residuals was analyzed for the presence of autocorrelation using this autocorrelation graphing function. For each variable, the highest lag-value of the significant autocorrelations from the partial autocorrelation function (PACF) was selected as the autocorrelation parameter value for the model to be used in an ARIMA analysis. For example, if the correlogram produced by the partial autocorrelation function indicated significant autocorrelation at lags 1, 2, 4 and 7, then 7 would be chosen as the autocorrelation parameter value. Decisions on which parameters to choose were determined by p-values associated with Box-Jenkins statistics provided by SPSS (these statistics estimate the significance of autocorrelation values associated with particular lag values). 
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The residuals fr�m the initial regression analysis were also evaluated for the presence of stationarity . The test used to detect stationarity was to correlate the residuals with the variable T ;  significant correlations would indicate the absence of stationarity , and an appropriate ARIMA model would be fit to the data . The presence of moving averages was determined by visual inspection of the auto-correlation (ACF) and partial auto­correlation (P ACF) correlograms of the regression residuals . If a moving average was detected , an appropriate differencing parameter was fit to the ARIMA model . No ARIMA analysis was performed on those variables for which there was no significant autocorrelation in the regression residuals . However, an ARIMA analysis was run on those variables whose regression residuals were determined to contain a significant autocorrelational component . The ARIMA analysis was run in SPSS using the same equation as above : Y(T) = po + P l  .T + P2.X + P3.XT + e ,  but with an autocorrelational parameter included in the model . Residuals derived from the ARIMA analysis were saved to an SPSS file . R2 values and F-statistics for the linear regression and ARIMA models were calculated from the SPSS output. Both the simple regression analyses and the ARIMA analyses produced ANOV A tables that indicated which components of the equation (T, X and/or XT) significantly accounted for explained variance . To determine if there was a lead-lag relationship between alliance variables and outcome variables , the analysis followed the steps of the Haugh-Box procedure as described by Cook et al . ( 1980, p.123): "( I) determine the ARIMA(p ,d ,q) model of Xt, using the customary identification-estimation-diagnosis procedures and then prewhiten Xt by its 
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own ARIMA model to obtain · the estimated white noise series, aXt; (2) likewise determine the ARIMA(p,d,q) model of Yt, and prewhiten Yt by its own ARIMA model to obtain the estimated white noise series, aYt; (3) cross-correlate the residual series, aX and aY." The cross-correlational function in SPSS was applied to the residuals of the variables hypothesized to have a lead-lag relationship, using the residuals of the regression analyses or the residuals of the ARIMA analyses (for those variables in which autocorrelation was detected in the original regression residuals). The analysis was run up to lag 5 only (-5 to +5, including zero), which required a total of 11 correlations for each variable. Cross-correlational r-values, and the associated standard error were produced in the SPSS output, with associated lag values to indicate the direction of possible causation or influence. Given that the analysis of each variable required 11 correlational analyzes, a Bonferroni correction was applied to the data. With a present alpha level of .10 for the cross-correlational analysis, r-values were only considered significant at p<.0 1 .  Finally, a meta-analytical procedure as described by Rosenthal and Rosnow (1991) was applied to the cross-correlational results from all subjects, to determine possible effect sizes for positive, negative and zero lags. Only cross-correlational r-statistics for lag­values found to be significant (for at least one subject) were evaluated in the meta­analysis. Thus, for ex.ample, if the cross-correlational analysis that was run up to lag 5 on the hypothesized relationship between OQ-SD and IDRX produced a significant r-56 
statistic at lag = 1 for any particular subject , then the r-statistics from all subjects for this relationship at lag = l would be used to estimate an effect size. All cross-correlational r-values were first converted to Fisher 's z-values and then summed. R-statistics were omitted for those subjects whose graphs indicated a clear lack of var iance for either variable in the hypothesized relationship of interest. The summed Fisher 's z-values were then divided by the number of subjects used to provide the r­statistics , in order to calculate the mean Fisher z-value. The resulting mean z-values were then converted to r-values as estimators of effect size for each particular relationship. 
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CHAPTER III 
RESULTS 
Overview The results chapter contains sections for each subject. Every section contains 12 graphs, one for each variable, plotting its value at each time point in the baseline phase and the treatment phase. Spearman's Rho and empirically derived probability values (derived using Borckardt' s Simulation Method as described in the Methodology chapter) are presented for each variable as an initial check for treatment effects - significant negative Rho-values are associated with significant decreases across the treatment phase relative to baseline, while significant positive Rho-values are similarly associated with significant increases. Linear regression and ARIMA analyses were run on the variables of interest. Both the simple regression analyses and the ARIMA analyses produced ANOV A tables that indicated which components of the equation (T, X and/or XT) significantly accounted for explained variance. A summary of the results from the appropriate ANOVA tables for each variable is presented in each section. Finally, the cross­correlational function in SPSS was applied to the residuals of all the variables, using the residuals of the regression analyses or the residuals of the ARIMA analyses (for those variables in which autocorrelation was detected in the original regression residuals). The Pearson-r statistic, and the associated standard error from the SPSS output are presented in each results section for all statistically significant cross-correlations. The lag value is also included to indicate the direction of possible causation or influence. 
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Subject One - Ailish The first subject, Ailish, provided data across a baseline of 14 time-points and a treatment phase of 22 time-points (7 weeks and 11 weeks respectively). There were no missing data. Figures 1-4 display, respectively, her self-ratings of symptom distress, interpersonal relationship functioning, social functioning and an overall measure of distress as assessed by the OQ-45. Figures 5 and 6 display, respectively, her self-ratings of depression as assessed by the BDI and her self-ratings of anxiety as assessed by the BAI. Figures 7-12 display her self-ratings of components of therapeutic alliance; namely , confident collaboration, confident collaboration scale 2, goal & task agreement, bond, dedication as a patient, and idealization of the therapeutic relationship, respectively . The subject 's mean symptom scores (with standard deviations in brackets) at baseline were OQ-SD= 31.71 (7 .99), OQ-IR= 13.36 (1.29), OQ-SR= 10 .86 (2.26), OQ-TOT= 55.93 (9.42), BDI= 15.71 (3.97), and BAI= 5.36 (1.99). Mean symptom scores in the treatment phase were OQ-SD= 25.59 (3.27), OQ-IR= 12.77 (1 .24), OQ-SR= 9 (1.62), OQ-TOT= 47.36 (4.52), BDI= 14.41 (1.97), and BAI= 4 .14 (1.32). The subject's mean expected alliance scores at baseline were CCOL= 28.21  (1.57), COL2= 40.86 (3.91), GOAL= 21 (1.96), BOND= 15 .64 (1 .72), DEDP= 31.93 (2.58), and 
IDRX= 32.43 (1.40). Mean alliance scores in the treatment phase were CCOL= 26.32 (2.18), COL2= 39.77 (1 .28), GOAL= 21.82 (1.37), BOND= 13.86 (1.87), DEDP= 31.82 (0.83), and IDRX=33.86 (1.14). 59 
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Figure 1 :  Self-ratings of Symptoms Distress as assessed by the OQ-45 for baseline and treatment conditions for subject 1. 
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Figure 2: Self-ratings of Interpersonal Relationships as assessed by the OQ-45 for baseline and treatment conditions for subject 1. 
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Time Figure 3: Self-ratings of Social Roles as assessed by the OQ-45 for baseline and treatment conditions for subject 1. 
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Figure 7: Self-ratings of Confident Collaboration as assessed by the CAS3 for baseline and treatment conditions for subject 1. 
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Figure 8 :  Self-ratings of Confident Collaboration 2 as assessed by the CAS3 for baseline and treatment conditions for subject 1 .  63 
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Figure 9: Self-ratings of Goal and Task Agreement as assessed by the CAS3 for baseline 
and treatment conditions for subject 1. 
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FigurelO: Self-ratings of Bond as assessed by the CAS3 for baseline and treatment 
conditions for subject 1 .  
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Time Figure 11 :  Self-ratings of Patient Dedication as assessed by the CAS3 for baseline and treatment conditions for subject 1. 
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An initial analysis of treatment effects was conducted using Borckardt 's Simulation Method. The autocorrelation parameter, Spearman Rho-values, associated probabilities and effect sizes are presented in Table 1 .  All probability values were obtained by running 10,000 iterations. There were 14 points in the baseline phase and 22 points in the treatment phase for each variable. The following equation was used for a regression analysis of each variable of interest : Y rn = f3o + � 1 .T + �2.X + �3.XT + e where Yen is the value of the variable of interest at time T. For this subject, Anna, the sequential range of 36 values for T were (- 13, - 12, ... , - 1, 0, 1, . .. , 2 1, 22) with -13 corresponding to the first data point, - 12 corresponding to the second data point, etc. The corresponding first 14 values of X were all 0, i.e., 0 for all baseline points, and 1 for each of the remaining 22 points in the treatment phase. The corresponding first 14 values of XT were also all 0, while the sequential range of values for the 22 points in the treatment phase were ( 1 ,  2, . .. , 21 ,  22). The autocorrelation correlogram and partial autocorrelation correlogram created for each set of regression residuals using the SPSS autocorrelation graphing function indicated the presence of significant autocorrelation for several variables. Table 2 displays the ARIMA model parameters for those variables that were found to have significant autocorrelation in the regression residuals .  The parameter value given in these models represents the lag­value of the highest-lagged significant autocorrelation. Model parameters were omitted for those variables in which no autocorrelation was found present. An R2 statistic, F 
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Table 1: Rho-values , associated probabilities and parameters from Simulation Method analysis for Subject 1. Auto- Spearman Probability Effect-Size correlation Rho OQ-SD 0.54 -0.48 0.040 -0.766 OQ-IR 0.40 -0.21 0.203 -0.454 OQ-SR 0.49 -0.42 0.059 -0.821 OQ-TOTAL 0.48 -0.54 0.0 16 -0.909 BDI-TOTAL 0.42 -0. 1 5  0.275 -0.329 BAI-TOT 0.18 -0.29 0.074 -0.615 CAS3-CCOL 0.45 (4)8 -0.55 0.003 -1.2 10  CAS3-C COL2 0.30 (9)8 -0.24 0.059 -0.278 CAS3-GOALS 0.27 0.2 1 0. 144 0.417  CAS3-BOND 0.38 -0.49 0.0 16 - 1.037 CAS3-DEDPT 0.05 -0.41 0.005 -0.043 CAS3-IDRX 0.48 0.49 0.027 1.025 Note (a): Number in brackets indicates if a lag-value higher than 1 was used in analysis. In such cases, the autocorrelation value is derived from the higher lag. 67 
Table 2: Statistics derived from linear regression and ARIMA analyses for subject 1. 
ARIMA R2 F-statistic ( dt) Probability 
model8 OQ-SD .610 16.67 (3,32) .000 OQ-IR 1 .21 1  2.07 (4,31) .100 OQ-SR 8 .691  4.88 ( 11,24) .0()1 OQ-TOTAL 4 .625 6.66 (7,28) .001 BDI-TOTAL 2 .44 1 4.73 (5 ,30) .005 BAI-TOT .269 3.92 (3,32) .017 CAS3-CCOL .383 6.62 (3,32) .001 CAS3-CCOL2 9 .785 6.98 (12,23) .001 CAS3-GOALS 14  .710 2.60 ( 17, 18) .050 CAS3-BOND .388 6.77 (3,32) .001 CAS3-DEDPT 8 .38 1 1.34 ( 1 1,24) >. 10 CAS3-IDRX 6 .684 6.25 (9,26) .001 Note (a): ARIMA model parameters are given only for those variables for which an ARIMA analysis was performed. The R2 statistics, F statistics and associated probabi lity values were calculated using the sums of squares and degrees of freedom from the regression analysis. For those variables for which an ARIMA analysis was used, the residual sum of squares and the degrees of freedom were derived from the ARIMA model. 
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statistic and an associated probability value , derived from the linear regression analysis , were given for each variable without significant autocorrelation in the regression residuals. For those variables with significant autocorrelation in the regression residuals, these statistics were calculated from the ARIMA analysis. The presence of stationarity in the data was ascertained by correlating the regression residuals for each variable with the time variable t. No significant r-values were obtained, indicating the presence of stationarity. Table 3 displays the probabilities associated with the t-ratio statistics obtained for �­coefficients in either the ARIMA equations or the regression equations. For variables on which only a regression analysis was performed, no probability value is given for the ARIMA component. A cross-correlational analysis was performed on the residuals produced from either the regression analysis or the ARIMA analysis. Symptom measures - the three factors and total score of the Q045, the BDI and BAI - were cross-correlated with the six factors of the CAS3. Correlational values were included in the following tables if their absolute value was 2 standard errors greater than zero. Tables 4 and 5 display the lag-value and associated r-statistic in parentheses of these correlational values. In both tables , significant predicted correlations are marked in bold. For N = 36 data-points, a = .10, and with a Bonferroni correction made for 1 1  correlations, to reach significance the r-value must be >0.425. Significant, but unpredicted, correlations are in italics. 
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Table 3: P-values from t-tests of autoregressive (AR) coefficients, time (T) coefficients, level (X) coefficients and interaction (XT) coefficients for subject 1. Autoregressive Time Level Interaction Component° T X XT OQ-SD .000 . 190 .000 OQ-IR .033 .409 .820 .599 OQ-SR .005 . 184 .706 .000 OQ-TOTAL .018 .000 . 178 .000 BDI-TOTAL .047 .000 .029 .002 BAI-TOT .017 .802 .022 CAS3-CCOL .019 .06 1 .004 CAS3-CCOL2 .000 .000 .000 .000 CAS3-GOALS .020 .000 .000 .000 CAS3-BOND .420 .760 .039 CAS3-DEDPT .024 .287 .743 . 156 CAS3-IDRX .037 .242 .740 .000 
Note (a): Probability values are only given for those variables for which an ARIMA analysis was performed. 
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Table 4: Cross-correlation lags and r-values for symptom measures and the first three factors of the CAS3 for subject 1 .  OQ-SD OQ-IR OQ-SR OQ-TOTAL BDI-TOTAL BAI-TOT Confident Collaboration Lag = 2 (- .383) Lag = 4 ( .397) Confident Collaboration 2 Lag = -2 (.505) Lag = 2 (-.397) Lag = 3 (-.358) Lag = -2 (.364) Lag = l (- .36 1) Lag = -1 (-.380) Goal and Task Agreement Lag = -4 (.393) Table 5: Cross-correlation lags and r-values for symptom measures and the last three factors of the CAS3 for subject l .  Bond OQ-SD Lag = -1 (.443) OQ-IR Lag = 3 (-.336) OQ-SR Lag = -2 (-.356) OQ-TOTAL BDI-TOTAL BAI-TOT Dedicated Patient Lag = 4 (-.483) Lag = 0 (.4 15) Lag = 4 (-.454) Lag = 1 (-.444) 
7 1  
Idealized Relationship Lag = 2 (-.349) Lag = -1 (-.384) 
Subject Two - Brianna 
The second subject, Brianna, provided data across a baseline of 9 time-points and a 
treatment phase of 28 time-points (4½ weeks and 14 weeks respectively). There were 
missing data for times 18, 24, 34 and 36 - data for these times were calculated as the 
average of the data from the preceding and succeeding time points. Figures 13-16 
display, respectively, her self-ratings of symptom distress, interpersonal relationship 
functioning, social functioning and an overall measure of distress as assessed by the OQ-
45. Figures 17 and 18 display, respectively, her self-ratings of depression as assessed by 
the BDI and her self-ratings of anxiety as assessed by the BAI. Figures 19-24 display her 
self-ratings of components of therapeutic alliance ; namely, confident collaboration, 
confident co11aboration scale 2, goal & task agreement, bond, dedication as a patient, and 
idealization of the therapeutic relationship, respectively. 
The subject 's mean symptom scores (with standard deviations in brackets) at baseline 
were OQ-SD= 31.67 (7.16), OQ-IR= 14.33 (4.16), OQ-SR= 12.44 (1.34), OQ-TOT= 
58.44 ( 10.35), BDI= 7 .11 (2.23), and BAI= 6.11 (3.81). Mean symptom scores in the 
treatment phase were OQ-SD= 21.64 (5.62), OQ-IR= 11.96 (2.89), OQ-SR= 8.30 (2.66), 
OQ-TOT= 41.91 (9.55), BDI= 1.70 (1.97), and BAI= 2.39 (2.00). The subject's mean 
expected alliance scores at baseline were CCOL= 28.22 (2.53), COL2= 36.78 (4.02), 
GOAL= 22 (2.26), BOND= 21.55 (1.16), DEDP= 17.11 (3.75), and IDRX= 25.67 (1.56). 
Mean alliance scores in the treatment phase were CCOL= 28.34 (3.66), COL2= 40.875 
(6.20), GOAL= 23.87(3.85), BOND= 26.86 (3.33), DEDP= 15.41 (3.15), and IDRX= 
32.43 (3.37). 
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Figure 17: Se lf-ratings of Depression as assessed by the BDI for baseline and treatment conditions for subject 2. 
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Figure 18: Se lf-ratings of Anxiety as assessed by the BAI for baseline and treatment conditions for subject 2. 
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Figure 19: Se]f-ratings of Confident Collaboration as assessed by the CAS3 for baseline 
and treatment conditions for subject 2. 
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Figure 20: Self-ratings of Confident Collaboration 2 as assessed by the CAS3 for 
baseline and treatment conditions for subject 2. 76 
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Figure 21 : Self-ratings of Goal and Task Agreement as assessed by the CAS3 for baseline and treatment conditions for subject 2. 
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Figure 22: Self-ratings of Bond as assessed by the CAS3 for baseline and treatment conditions for subject 2. 
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An initial analysis of treatment effects was conducted using Borckardt 's Simulation Method . The autocorrelation parameter , Spearman Rho-values , associated probabilities and effect sizes are presented in table 6. All probability values were obtained by running 10,000 iterations. There were 9 points in the baseline phase and 28 points in the treatment phase for each variable . The following equation , as described at the beginning of this chapter , was used for a regression analysis of each variable of interest : Yen = po + P t .T + P2.X + P3.XT + E where T is the value of the variable of interest at time T. For this patient , the sequential range of 37 values for T were (-8, -7, . . , -1, 0, 1 ,  . . , 27, 28) with -8 corresponding to the first data point , -7 corresponding to the second data point , etc. The corresponding first 9 values of X were all 0, i.e . ,  0 for all baseline points , and 1 for each of the remaining 28 points in the treatment phase . The corresponding first 9 values of XT were also all 0, while the sequential range of values for the 28 points in the treatment phase were ( 1 ,  2, ... , 27, 28). The autocorrelation correlogram and partial autocorrelation correlogram created for each set of regression residuals using the SPSS autocorrelation graphing function indicated the presence of significant autocorrelation for several variables . Table 7 displays the ARIMA model parameters for those variables that were found to have significant autocorrelation in the regression residuals . The parameter value given in these models represents the lag­value of the highest-lagged significant autocorrelation . Model parameters were omitted 79 
Table 6: Rho-values , associated probabilities and parameters from Simulation Method analysis for Subject 2. 
Auto- Spearman Probability Effect-Size 
correlation Rho OQ-SD 0.49 -0.58 0.005 -1.40 OQ-IR 0.37 (3t -0.31 0.058 -0.57 OQ-SR 0.78 -0.59 0.029 -3.08 OQ-TOTAL 0.59 -0.53 0.021 -1.60 BDI-TOTAL 0.63 -0.69 0.001 -2.42 BAI-TOT 0.40 (6t -0.46 0.002 -0.98 CAS3-CCOL 0.56 0.06 0.409 0.05 CAS3-CCOL2 0.73 0.29 0.200 1 .02 CAS3-GOALS 0.56 0.23 0.204 0.83 CAS3-BOND 0.72 0.55 0.029 4.55 CAS3-DEDPT 0.21 -0.19 0.163 -0.45 CAS3-IDRX 0.7 1 0.66 0.004 4.32 
Note (a): Number in brackets indicates if a lag-value higher than l was used in analysis. In such cases, the 
autocorrelation value is derived from the higher lag. 
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Table 7: Statisti�s derived from linear regression and ARIMA analyses for subject 2 .  
ARIMA R2 F-statistic (dtj Probability 
models OQ-SD .573 14.78 (3,33) .000 OQ-IR .327 5.33 (3,33) .004 OQ-SR 7 .807 10 .89 ( 10,26) .00 1  OQ-TOTAL 5 .736 9.76 (8,28) .00 1 BDI-TOTAL 8 .747 6.7 1  ( 11,25) .00 1  BAI-TOT .350 5 .92 (3,33) .002 CAS3-CCOL 12 .805 5.79 ( 15,2 1) .00 1  CAS3-CCOL2 1 .646 14.59 ( 4 ,32) .001 CAS3-GOALS 1 .398 5.29 (4,32) .005 CAS3-BOND 3 .746 14 .68 (6,30) .001 CAS3-DEDPT 10 .5 13 1.87 ( 13,23) .100 CAS3-IDRX 5 .770 1 1.73 (8,28) .00 1  
Note (a): ARIMA model parameters are given only for those variables for which an ARIMA analysis was performed. 
The R2 statistics, F statistics and associated probability values were calculated using the sums of squares and degrees of 
freedom from the regression analysis. For those variables for which an ARIMA analysis was used, the residual sum of 
squares and the degrees of freedom were derived from the ARIMA model. 
8 1  
for those variables in which no autocorrelation was found present. An R2 statistic, F 
statistic and an associated probability value, derived from the linear regression analysis, 
were given for each variable without significant autocorrelation in the regression 
residuals. For those variables with significant autocorrelation in the regression residuals, 
these statistics were calculated from the ARIMA analysis. The presence of stationarity in 
the data was ascertained by correlating the regression residuals for each variable with the 
time variable t. No significant r-values were obtained, indicating the presence of 
stationarity. 
Table 8 displays the probabilities associated with the t-ratio statistics obtained for �­
coefficients in either the ARIMA equations or the regression equations. For variables on 
which only a regression analysis was performed, no probabi lity value is given for the 
ARIMA component. 
A cross-correlational analysis was performed on the residuals produced from either the 
regression analysis or the ARIMA analysis. Symptom measures - the three factors and 
total score of the Q045 , the BDI and BAI - were cross-correlated with the six factors of 
the CAS3. Correlational values were included in the fo1Iowing tables if their absolute 
value was 2 standard errors greater than zero. Tables 9 and 10 display the lag-value and 
associated r-statistic in parentheses of these correlational values. In both tables, 
significant predicted correlations are marked in bold. For N = 37 data-points, a =  . 10, and 
with a Bonferroni correction made for 1 1  correlations, to reach significance the r-value 
must be >0.4 18. Significant, but unpredicted, correlations are in italics. 
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Table 8: P-values from t-tests of autoregressive (AR) coefficients , time (T) coefficients , level (X) coefficients and interaction (XT) coefficients for subject 2. 
Autoregressive Time Level Interaction 
Component' T X XT OQ-SD .079 .687 .282 OQ-IR . 147 .473 .053 OQ-SR .001 . 146 .85 1 .406 OQ-TOTAL .007 .936 .339 .512 BDI-TOTAL .031 .430 .002 .540 BAI-TOT . 108 .706 . 153 CAS3-C COL .011 .622 .000 .6 12 CAS3-C COL2 .005 . 154 .001 .446 CAS3-GOALS .0 12 .930 .097 .631 CAS3-BOND .008 .824 .000 .736 CAS3-DEDPT .002 .015 . 173 .028 CAS3-IDRX .039 .46 1 .000 .919 Note (a): Probability values are only given for those variables for which an ARIMA analysis was performed. 
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Table 9: Cross-correlation lags and r-values for symptom measures and the first three 
factors of the CAS3 for subject 2. 
OQ-SD 
OQ-IR 
OQ-SR 
OQ-TOTAL 
BDI-TOTAL 
BAI-TOT 
Confident 
Collaboration 
Lag = -3 (.343) 
Lag = 0 (.349) 
Confident 
Collaboration 2 
Goal and Task 
Agreement 
Lag = 1 ( .346) 
Lag = 0 (-.338) 
Table 10: Cross-correlation lags and r-values for symptom measures and the last three 
factors of the CAS3 for subject 2. 
Bond 
OQ-SD 
OQ-IR 
OQ-SR 
OQ-TOTAL 
BDI-TOTAL 
BAI-TOT 
Dedicated 
Patient 
Lag = -3 ( .336) 
Lag = 2 (.388) 
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Idealized 
Relationship 
Subject Three - Ciara The third subject , Ciara,  provided data across a baseline of 13 time-points and a treatment phase of 44 time-points (6½ weeks and 22 weeks respectively). There were no missing data. Figures 25-28 display , respectively , her self-ratings of symptom distress, interpersonal relationship functioning , social functioning and an overall measure of distress as assessed by the OQ-45. Figures  29 and 30 display , respectively, her self­ratings of depression as assessed by the BDI and her self-ratings of anxiety as assessed by the BAL Figures 3 1-36 di splay her self-ratings of components of therapeutic aHiance ; namely , confident collaboration , confident col laboration scale 2, goal & task agreement , bond , dedication as a patient , and idealization of the therapeutic relationship , respectively. The subject ' s  mean symptom scores (with standard deviat ions in brackets) at baseline were : OQ-SD = 29.69 (5.48), OQ-IR = 13.23 (2.00), OQ-SR = 10.61 ( 1.60), OQ-TOT = 53.54 (7.93), BDI = 8.85 (l.99), and BAI = 4.77 (2.15). Mean symptom scores in the treatment phase were : OQ-SD = 27.14 (2.47), OQ-IR = 1 2.95 (1.36), OQ-SR = 9.68 ( 1 .49), OQ-TOT = 49.77 (3.83), BDI = 8.61 (2.06), and BAI = 3.95 ( 1 . 1 1 ) . The subject 's  mean expected alliance scores at ba seline were : CCOL = 26.92 ( 1.21), COL2 = 36.85 (2.32), GOAL = 23.31 ( 1.86), BOND = 1 7.23 (0.58), DEDP = 26.23 ( 1 .62), and IDRX = 28 ( 1 .04). Mean a11iance scores in the treatment phase were : CCOL = 24.34 ( 1 .99), COL2 = 27.34 (3. 18), GOAL = 1 7.45 (1.90), BOND = 1 5.73 (1.39), DEDP = 19.77 (2.73), and IDRX = 25.02 (2.79). 
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Figure 31 : Self-ratings of Confident Collaboration as assessed by the CAS3 for baseline and treatment conditions for subject 3 .  
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Figure 32: Self-ratings of Confident Collaboration 2 as asses sed by the CAS3 for baseline and treatment conditions for subject 3. 
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Time Figure 33: Self-ratings of Goal and Task Agreement as assessed by the CAS3 for 
baseline and treatment conditions for subject 3. 
22 
20 
18  
-0 
I 1 6  
14 
12  
1 0  .---...----......... --------------------------------------r----
1 4 7 10 1 3  1 6  19 22 25 28 31 34 37 40 43 46 49 52 55 
Time Figure 34: Self-ratings of Bond as assessed by the CAS3 for baseline and treatment 
conditions for subject 3. 
90 
30 
28 
C: 
(I) 26 
-� 
°i 24 
N 
i 22 0 
I 
� 20 
(.) 
18  
1 4 7 10 13 16 1 9  22  25  28  31  34 37 40 43 46  49  52  55 
Time 
Figure 35: Self-ratings of Patient Dedication as assessed by the CAS3 for baseline and treatment conditions for subject 3. 
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Figure 36: Self-ratings of the Idealized Relationship as assessed by the CAS3 for baseline and treatment conditions for subject 3. 
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An initial analysis of treatment effects was conducted using Borckardt 's Simulation Method. The autocorrelation parameter, Spearman Rho-values, associated probabilities and effect sizes are presented in table 1 1. All probability values were obtained by running 10,000 iterations. There were 13 points in the baseline phase and 44 points in the treatment phase for each variable. The following equation, as described at the beginning of this chapter, was used for a regression analysis of each variable of interest : Ym = �o + �1 .T + �2.X + �3.XT + E where T is the value of the variable of interest at time T. For this patient, the sequential range of 57 values for T were (- 12, - 1 1, ... , - 1 ,  0, 1, ... , 43, 44) with -12 corresponding to the first data point , - 1 1 corresponding to the second data point , etc. The corresponding first 13 values of X were all 0, i.e., 0 for all baseline points, and 1 for each of the remaining 44 points in the treatment phase . The corresponding first 13 values of XT were also all 0, while the sequential range of values for the 44 points in the treatment phase were ( 1 ,  2, ... , 43, 44). The autocorrelation correlogram and partial autocorrelation correlogram created for each set of regression residuals using the SPSS autocorrelation graphing function indicated the presence of significant autocorrelation for several variables. Table 12 displays the ARIMA model parameters for those variables that were found to have significant autocorrelation in the regression residua]s. The parameter value given in these models represents the lag-value of the highest-lagged significant autocorrelation. ARIMA model 92 
Table 11 :  Rho-values, associated probabilities and parameters from Simulation Method analysis for Subject 3. 
Auto- Spearman Probability EtTect-Size 
correlation Rho 
OQ-SD 0.26 (3t -0.34 0.0 13 -0.47 
OQ-IR 0.28 -0.06 0.366 -0.14 
OQ-SR 0.63 -0.25 0. 163 -0.59 OQ-TOTAL 0. 12 -0.35 0.007 -0.47 BDI-TOTAL 0.40 -0.05 0.376 -0. 1 2  BAI-TOT 0.28 -0. 18 0. 147 -0.38 CAS3-CCOL 0.47 -0.54 0.002 -2. 14 CAS3-CCOL2 0.76 -0.71 0.000 -4. 1 1  CAS3-GOALS 0.7 1 -0.72 0.000 -3. 15 CAS3-BOND 0.63 -0.57 0.004 -2.6 1 CAS3-DEDPT 0.88 -0.65 0.0 12 -3.98 
CAS3-IDRX 0.62 -0.52 0.009 -2.87 
Note (a): Number in brackets indicates if a lag-value higher than 1 was used in analysis. In such cases, the 
autocorrelation value is derived from the higher lag. 
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Table 12: Statistics derived from linear regression and ARIMA analyses for subject 3. 
ARIMA R2 F-statistic ( dO Probability 
model8 OQ-SD . 109 2. 17 (3,53) . 1 02 OQ-IR . 165 3.49 (3,53) .022 OQ-SR 1 .460 1 1 .08 ( 4,52) .00 1  OQ-TOTAL . 109 2. 16  (3.53) . 104 BDI-TOTAL 3 .270 3.09 (6 ,50) .025 BAI-TOT .420 12.78 (3,53) .000 CAS3-CCOL 8 .474 3.69 ( 1 1 ,45) .010 CAS3-CCOL2 2 .76 1 32.48 (5,5 1 )  .000 CAS3-GOALS 10 .79 1 12.52 ( 13,43) .001 CAS3-BOND 1 .473 1 1 .69 ( 4,52) .001 CAS3-DEDPT 1 .848 72.46 ( 4,52) .000 CAS3-IDRX 2 .631 17.45 (5,5 1 )  .000 Note (a): ARIMA model parameters are given only for those variables for which an ARIMA analysis was performed. The R2 statistics, F statistics and associated probability values were calculated using the sums of squares and degrees of freedom from the regression analysis. For those variables for which an ARIMA analysis was used, the residual sum of squares and the degrees of freedom were derived from the ARIMA model. 
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parameters were omitted for those variables in which no autocorrelation was found present . An R2 statistic , F statistic and an associated probability value , derived from the l inear regression analys is , were given for each variable without significant autocorrelation in the regression residuals . For those variables with significant autocorrelation in the regression residuals , these statistics were calculated from the ARIMA analysis . The presence of stationarity in the data was ascertained by correlating the regression residuals for each variable with the time variable t .  No significant r-values were obtained , indicating the presence of stationarity . Table 13 displays the probabilities associated with the t-ratio statistics obtained for �­coefficients in either the ARIMA equations or the regression equations. For variables on which only a regression analysis was performed , no probability value is given for the ARIMA component . A cross-correlational analysis was performed on the residuals produced from either the regression analysis or the ARIMA analysis . Symptom measures - the three factors and total score of the QO45, the BDI and BAI - were cross-correlated with the six factors of the CAS3. Correlational values were included in the following tables if their absolute value was 2 standard errors greater than zero. Tables 14 and 15  display the lag-value and associated r-statistic in parentheses of these correlational values. In both tables , s ignificant predicted correlations are marked in bold. For N = 57 data-points , a = .10, and with a Bonferroni correction made for 11 correlations , to reach significance the r-value must be >0.338. Significant , but unpredicted , correlations are in italics. 
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Table 13: P-values from t-tests of autoregressive (AR) coefficients, time (T) coefficients , 
level (X) coefficients and interaction (XT) coefficients for subject 3 .  
Autoregressive Time Level Interaction 
Component" T X XT 
OQ-SD .704 . 179 .595 
OQ-IR .030 .344 .013  
OQ-SR .000 .883 .909 .860 
OQ-TOTAL .524 .209 .442 
BDI-TOTAL .025 .484 .502 .477 
BAI-TOT .000 .698 .000 
CAS3-CCOL .008 .475 .450 .588 
CAS3-CCOL2 .016  .734 .004 .4 15  
CAS3-GOALS .008 .000 .285 .000 
CAS3-BOND .00 1 .352 .7 1 1  .608 
CAS3-DEDPT .000 .029 .038 . 1 36 
CAS3-IDRX .008 .465 .272 .885 
Note (a): Probability values are only given for those variables for which an ARIMA analysis was performed. 
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Table 14: Cross-correlation lags and r-values for symptom measures and the first three factors of the CAS3 for subject 3. OQ-SD OQ-IR OQ-SR OQ-TOTAL BDI-TOTAL BAI-TOT Confident Collaboration Lag = 2 (.266) Lag = 2 (.288) Lag = 2 (.324) Confident Collaboration 2 Lag = 0 (.261) Lag = -5 (-.273) Lag = 2 (-.370) Goal and Task Agreement Lag = -2 (.315) Lag = 2 (.268) Lag = -4 ( .278) 
Table 15: Cross-correlation lags and r-values for symptom measures and the last three factors of the CAS3 for subject 3 .  OQ-SD OQ-IR OQ-SR OQ-TOTAL BDI-TOTAL BAI-TOT Bond Lag = 2 (-.286) Lag = l (.313) Dedicated Patient 
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Idealized 
Relationship Lag = 4 (- .298) Lag = 4 (.369) 
Subject Four - Deirdre The fourth subject, Deirdre, provided data across a baseline of 7 time-points and a treatment phase of 39 time-points (3½ weeks and 19½ weeks respectively). ). There were missing data for times 28 and 29 - data for these times were calculated as the average of the data from time points 27 and 30. Figures 37-40 display, respectively, her self-ratings of symptom distress, interpersonal relationship functioning, social functioning and an overall measure of distress as assessed by the OQ-45. Figures 41 and 42 display, respectively, her self-ratings of depression as assessed by the BDI and her self-ratings of anxiety as assessed by the BAI. Figures 43-48 display her self-ratings of components of therapeutic alliance; namely, confident collaboration, confident collaboration scale 2, goal & task agreement, bond, dedication as a patient, and idealization of the therapeutic relationship, respectively. The subject' s mean symptom scores (with standard deviations in brackets) at baseline were: OQ-SD = 50 (3.42), OQ-IR = 2 1 .28 (0.45), OQ-SR = 17 .29 ( 1 .67), OQ-TOT = 88.57 (5.07), BDI = 26.57 (3 .50), and BAI = 14 (3.30). Mean symptom scores in the treatment phase were: OQ-SD = 48.79 (1 .09), OQ-IR = 21 .05 (0.78), OQ-SR = 14.69 (0.64), OQ-TOT = 84.54 ( 1 .40), BDI = 25.56 ( 1 .03), and BAI = 14.69 ( 1 .78). The subject's mean expected alliance scores at baseline were: CCOL = 35 (0), COL2 = 56 (0), GOAL = 34.86 (0.35), BOND = 35 (0), DEDP = 33.29 (0.45), and IDRX = 35 (0). Mean alliance scores in the treatment phase were: CCOL = 28.67 (2.34), COL2 = 42.64 (4. 15), GOAL = 20. 18 (4.46), BOND = 30.38 (3.08), DEDP = 32.05 (0.75), and IDRX = 34.97 (0. 16). 
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Figure 37: Self-ratings of Symptoms Distress as assessed by the OQ-45 for baseline and treatment conditions for subject 4. 
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Figure 38: Self-ratings of Interpersonal Relationships as assessed by the OQ-45 for baseline and treatment conditions for subject 4. 99 
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Figure 41:  Self-ratings of Depression as assessed by the BDI for baseline and treatment conditions for subject 4. 
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Figure 42: Self-ratings of Anxiety as assessed by the BAI for baseline and treatment conditions for subject 4. 101 
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Figure 45: Self-ratings of Goal and Task Agreement as assessed by the CAS3 for baseline and treatment conditions for subject 4. 
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Figure 46: Self-ratings of Bond as assessed by the CAS3 for baseline and treatment conditions for subject 4. 103 
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Figure 47: Self-ratings of Patient Dedication as assessed by the CAS3 for baseline and treatment conditions for subject 4. 
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Figure 48: Self-ratings of the Idealized Relationship as assessed by the CAS3 for baseline and treatment conditions for subject 4. 
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An initial analysis of treatment effects was conducted using Borckardt's Simulation Method. The autocorrelation parameter, Spearman Rho-values, associated probabilities and effect sizes are presented in table 16. AH probability values were obtained by running 10,000 iterations. There were 7 points in the baseline phase and 39 points in the treatment phase for each variable. The following equation, as described at the beginning of this chapter, was used for a regression analysis of each variable of interest: Ym = �o + � 1 .T + p2.X + p3.XT + E where T is the value of the variable of interest at time T. For this patient, the sequential range of 46 values for T were (-6, -5, . . .  , - 1 ,  0, 1 ,  . . .  , 38, 39) with -6 corresponding to the first data point, -5 corresponding to the second data point, etc. The corresponding first 7 values of X were all 0, i .e . ,  0 for all baseline points, and 1 for each of the remaining 39 points in the treatment phase. The corresponding first 7 values of XT were also all 0, while the sequential range of values for the 39 points in the treatment phase were ( 1 ,  2, . . .  , 38, 39). The autocorrelation correlogram and partial autocorrelation correlogram created for each set of regression residuals using the SPSS autocorrelation graphing function indicated the presence of significant autocorrelation for several variables. Table 17 displays the ARIMA model parameters for those variables that were found to have significant autocorrelation in the regression residuals. The parameter value given in these models represents the lag-value of the highest-lagged significant autocorrelation. ARIMA model 
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Table 16: Rho-values , associated probabilities and parameters from Simulation Method analysis for Subject 4. Auto- Spearman Probability Effect-Size correlation Rho OQ-SD 0.33 -0.04 0.418 -0.35 OQ-IR 0. 12 -0. 19 0.075 -0.52 OQ-SR 0.66 -0.59 0.000 -1.56 OQ-TOTAL 0.47 -0.32 0.060 -0.80 BDI-TOTAL 0. 14 -0.01 0.482 -0.29 BAI-TOT 0.29 0.07 0.355 0.21 CAS3-CCOL 0.83 -0.60 0.001 <-20.00 CAS3-CCOL2 0.77 -0.59 0.00 1 <-20.00 CAS3-GOALS 0.76 -0.60 0.000 <-20.00 CAS3-BOND 0.85 -0.49 0.035 <-20.00 CAS3-DEDPT 0.36 -0.69 0.000 -2.73 CAS3-IDRX 0.02 -0.06 0.331 <-20.00 106 
Table 17: Statistics derived from linear regression and ARIMA analyses for subject 4. 
ARIMA R2 F-statistic ( df) Probability 
model• OQ-SD 3 .529 7 .29 (6,39) .001 OQ-IR .060 0.90 (3,42) .450 OQ-SR 3 .8 17 29.05 (6,39) .000 OQ-TOTAL 3 .692 14.58 (6,39) .000 BDI-TOTAL .429 10.53 (3,42) .000 BAI-TOT .343 7 .32 (3,42) .000 CAS3-CCOL .825 65.92 (3,42) .000 CAS3-CCOL2 .776 48.50 (3,42) .000 CAS3-GOALS 4 .776 18.78 (7 ,38) .000 CAS3-BOND 1 .801 41 . 19 (4,41) .000 CAS3-DEDPT .327 6.79 (3,42) .001 CAS3-IDRX .057 0.85 (3,42) .477 
Note (a): ARIMA model parameters are given on]y for those variables for which an ARIMA analysis was performed. 
The R2 statistics, F statistics and associated probability values were calculated using the sums of squares and degrees of 
freedom from the regression analysis. For those variables for which an ARIMA analysis was used, the residual sum of 
squares and the degrees of freedom were derived from the ARIMA model. 
107 
parameters were omitted for those variables in which no autocorrelation was found 
present. An R2 statistic, F statistic and an associated probability value, derived from the 
linear regression analysis, were given for each variable without significant 
autocorrelation in the regression residuals. For those variables with significant 
autocorrelation in the regression residuals, these statistics were calculated from the 
ARIMA analysis. The presence of stationarity in the data was ascertained by correlating 
the regression residuals for each variable with the time variable t. No significant r-values 
were obtained, indicating the presence of stationarity. 
Table 18 displays the probabilities associated with the t-ratio statistics obtained for P­
coefficients in either the ARIMA equations or the regression equations. For variables on 
which only a regression analysis was performed, no probability value is given for the 
ARIMA component. 
A cross-correlational analysis was performed on the residuals produced from either the 
regression analysis or the ARIMA analysis. Symptom measures - the three factors and 
total score of the QO45, the BDI and BAI - were cross-correlated with the six factors of 
the CAS3. Correlational values were included in the following tables if their absolute 
value was 2 standard errors greater than zero . Tables 19 and 20 display the lag-value and 
associated r-statistic in parentheses of these correlational values. In both tables, 
significant predicted correlations are marked in bold . For N = 46 data-points, a = .10, and 
with a Bonferroni correction made for 11 correlations, to reach significance the r-value 
must be >0.377. Significant, but unpredicted, correlations are in italics. 
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Table 18: P-values from t-tests of autoregressive (AR) coefficients, time (T) coefficients, level (X) coefficients and interaction (XT) coefficients for subject 4. Autoregressive Time Level Interaction Componenfl T X XT OQ-SD .01 1  .000 .007 .000 OQ-IR .620 .584 .55 1 OQ-SR .006 .000 .788 .000 OQ-TOTAL .007 .000 .108 .000 BDI-TOTAL .000 .349 .000 BAI-TOT .000 .006 .000 CAS3-CCOL .999 .006 .529 CAS3-CCOL2 .999 .00 1 .680 CAS3-GOALS .020 .634 .000 .625 CAS3-BOND .003 .930 .964 .639 CAS3-DEDPT .197 .391 .227 CAS3-IDRX .999 .424 .909 
Note (a): Probability values are only given for those variables for which an ARIMA analysis was performed. 
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Table 19: Cross-correlation lags and r-values for symptom measures and the first three factors of the CAS3 for subject 4. OQ-SD OQ-IR OQ-SR OQ-TOTAL BDI-TOTAL BAI-TOT Confident Collaboration Lag = 2 (.368) Confident Collaboration 2 Lag = 0 (-.330) Lag = 0 (.292) Lag = 2 (.366) Lag = 2 (.361) Goal and Task Agreement Lag = 0 (-.403) Lag = -2 (-.337) Lag = 0 (- .239) Table 20: Cross-correlation lags and r-values for symptom measures and the last three factors of the CAS3 for subject 4. Bond OQ-SD OQ-IR Lag = -4 (-.320) OQ-SR Lag = 1 (-.397) OQ-TOTAL BDI-TOTAL BAI-TOT Dedicated Patient Lag = -1 (-.413) Lag = -5 (.308) Lag = -2 (.298) Lag = 3 (-.310) 
1 10 
Idealized Relationship Lag = 3 (.358) Lag = 1 (.403) Lag = -1 (.328) Lag = 3 ( .317) Lag = 3 (.32 1 )  
Subject Five - Elaine The fifth subject, Elaine, provided data across a baseline of 10 time-points and a treatment phase of 30 time-points (5 weeks and 15 weeks respectively). ). There were missing data for times 1 9, 26, 29 and 34 - data for these times were calculated as the average of the data from the preceding and succeeding time points. Figures 49-52 display, respectively, her self-ratings of symptom distress, interpersonal relationship functioning, social functioning and an overall measure of distress as assessed by the OQ-45 . Figures 53 and 54 display, respectively, her self-ratings of depression as assessed by the BDI and her self-ratings of anxiety as assessed by the BAI. Figures 55-60 display her self-ratings of components of therapeutic alliance ; namely, confident collaboration, confident collaboration scale 2, goal & task agreement, bond, dedication as a patient , and idealization of the therapeutic relationship, respectively. The subject 's mean symptom scores (with standard deviations in brackets) at baseline were: OQ-SD = 55 .2 (6.05), OQ-IR = 29.3 (2. 19), OQ-SR = 17.3 (2.72), OQ-TOT = 101 .8 (9 .95), BDI = 43.6 (3.26), and BAI = 12. 1 (7.20). Mean symptom scores in the treatment phase were: OQ-SD = 33.4 (7.96), OQ-IR = 28. 17  (2.46), OQ-SR = 13.2 (2.8 1), OQ-TOT = 74.77 ( 1 2.59), BDI = 26. 1 8  (8.1 1), and BAI = 2 ( 1 .89). The subject 's mean expected alliance scores at baseline were : CCOL = 33.5 ( 1.12), COL2 = 53.2 ( 1 .54), GOAL = 32 (0.89), BOND = 27.8  ( 1 .4), DEDP = 33.2 (0.98), and IDRX = 34.9 (0.3). Mean alliance scores in the treatment phase were: CCOL = 31 .73 ( 1 .55}, COL2 = 48.3 ( 1 .35), GOAL = 29.83 ( 1 .53), BOND = 25 .78 ( 1 .05}, DEDP = 33.9 (0.47), and IDRX = 35 (0). 
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Time Figure 54: Self-ratings of Anxiety as assessed by the BAI for baseline and treatment conditions for subject 5. 
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An initial analysis of treatment effects was conducted using Borckardt 's Simulation Method. The autocorrelation parameter , Spearman Rho-values , associated probabi lities and effect sizes are presented in table 21. All probabi lity values were obtained by running 10,000 iterations. There were 10 points in the baseline phase and 30 points in the treatment phase for each variable. The following equation, as described at the beginning of this chapter , was used for a regression analysis of each variable of interest : Yen = (3o + �t .T + �2.X + �3.XT + e where T is the value of the variable of interest at time T. For this patient, the sequential range of 40 values for T were (-9, -8, .. , - 1, 0, 1, ... , 29, 30) with -9 corresponding to the first data point , -8 corresponding to the second data point , etc. The corresponding first 10 values of X were all 0, i.e., 0 for all baseline points , and 1 for each of the remaining 30 points in the treatment phase. The corresponding first 10 values of XT were also all 0, while the sequentia l range of values for the 30 points in the treatment phase were ( 1, 2, . . .  , 29, 30). The autocorrelation correlogram and partial autocorrelation correlogram created for each set of regression residuals using the SPSS autocorrelation graphing funct ion indicated the presence of significant autocorrelation for several variables. Table 22 displays the ARIMA model parameters for those variables that were found to have significant autocorrelation in the regression residuals. The parameter value given in these models represents the lag-value of the highest-lagged significant autocorrelation. ARIMA model 
1 1 8 
Table 21: Rho-values, associated probabilities and parameters from Simulation Method analysis for Subject 5. 
Auto- Spearman Probability Effect-Size 
correlation Rho OQ-SD 0.82 -0.73 0.003 -3.6 1 OQ-IR 0.45 -0.20 0. 185 -0.52 
OQ-SR 0.63 -0.56 0.0 18 - 1.5 1  OQ-TOTAL 0.80 -0.69 0.006 -2.72 BDI-TOTAL 0.90 -0.70 0.0 14 -5.34 BAI-TOT 0.75 -0.72 0.003 - 1.40 CAS3-CCOL 0.43 -0.46 0.023 - 1 .58 CAS3-CCOL2 0.60 -0.74 0.000 -3.19 CAS3-GOALS 0.25 -0.6 1 0.002 -2.42 CAS3-BOND 0.5 1 -0.58 0.007 - 1 .44 CAS3-DEDPT 0. 10 0.44 0.005 0.7 1 
CAS3-IDRX 0.03 0.28 0.033 0.33 1 19 
Table 22: Statistics derived from linear regression and ARIMA analyses for subject 5. 
ARIMA R2 F-statistic ( dO Probability 
modela OQ-SD .881 89.19 (3,36) .000 OQ-IR 2 .573 9. 12 (5,34) .001 OQ-SR .660 23.31 (3,36) .000 OQ-TOTAL .830 58.58 (3,36) .000 BDI-TOTAL .927 15 1 .72 (3,36) .000 BAI-TOT .860 73.85 (3,36) .000 CAS3-CCOL 8 .660 4.95 (11,28) .001 CAS3-CCOL2 .7 10 29.33 (3,36) .000 CAS3-GOALS 9 .744 6.52 ( 12,27) .001 CAS3-BOND 1 .604 13.33 (4,35) .001 CAS3-DEDPT .36 1  6.77 (3,36) .001 CAS3-IDRX 1 .379 5.35 (4,35) .005 Note (a): ARIMA model parameters are given only for those variables for which an ARIMA analysis was performed. The R2 statistics, F statistics and associated probability values were calculated using the sums of squares and degrees of freedom from the regression analysis. For those variables for which an ARIMA analysis was used, the residua] sum of squares and the degrees of freedom were derived from the ARIMA model . 
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parameters were omitted for those variables in which no autocorrelation was found present. An R2 statistic, F statistic and an associated probability value, derived from the linear regression analysis, were given for each variable without significant autocorrelation in the regression residuals. For those variables with significant autocorrelation in the regression residuals, these statistics were calcu]ated from the ARIMA analysis. The presence of stationarity in the data was ascertained by correlating the regression residuals for each variable with the time variable t. No significant r-values were obtained, indicating the presence of stationarity. Table 23 displays the probabilities associated with the t-ratio statistics obtained for �­coefficients in either the ARIMA equations or the regression equations . For variables on which only a regression analysis was performed, no probability value is given for the ARIMA component. A cross-correlational analysis was performed on the residuals produced from either the regression analysis or the ARIMA analysis. Symptom measures - the three factors and total score of the QO45, the BDI and BAI - were cross-correlated with the six factors of the CAS3. Correlational values were included in the following tables if their absolute value was 2 standard errors greater than zero. Tables 24 and 25 display the lag-value and associated r-statistic in parentheses of these correlational values . In both tables, significant predicted correlations are marked in bold. For N = 40 data-points , a =  . 10, and with a Bonferroni correction made for 11 correlations, to reach significance the r-value must be >0.403. Significant, but unpredicted, correlations are in italics. 
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Table 23: P-values from t-tests of autoregressive (AR) coefficients, time (T) coefficients, level (X) coefficients and interaction (XT) coefficients for subject 5. 
Autoregressive Time Level Interaction 
Component" T X XT OQ-SD .019 .202 .442 OQ-IR .003 .655 .255 .178 OQ-SR .005 .077 .063 OQ-TOTAL .027 .882 .479 BDI-TOTAL .275 .014 .001 BAI-TOT .000 .262 .000 CAS3-CCOL .055 .926 .931 .384 CAS3-CCOL2 .497 .000 .639 CAS3-GOALS .010 .024 .075 .014 CAS3-BOND .000 .086 .050 .074 CAS3-DEDPT .009 .328 .020 CAS3-IDRX .002 .000 .067 .000 
Note (a): Probability values are only given for those variables for which an ARIMA analysis was performed. 122 
Table 24: Cross-correlation lags and r-values for symptom measures and the first three factors of the CAS3 for subject 5. 
Confident Confident Goal and Task 
Collaboration Collaboration 2 Agreement OQ-SD OQ-IR OQ-SR Lag = -2 (-.402) Lag = - 1  (- .339) OQ-TOTAL BDI-TOTAL Lag = -3 (-.336) Lag = 2 (.367) BAI-TOT Lag = 4 (.343) Lag = 0 (- .334) Lag = 5 (.383) 
Table 25: Cross-correlation lags and r-values for symptom measures and the last three factors of the CAS3 for subject 5. 
Bond OQ-SD Lag = 0 (- .342) OQ-IR OQ-SR OQ-TOTAL BDI-TOTAL BAI-TOT Lag = 0 (-.511) Dedicated Patient Lag = 1 (-.385) Lag = 1 (-.512) Lag = 1 (-.378) Lag = 1 (-.338) 
Lag = 5 (.484) 
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Idealized 
Relationship 
Lag = 1 (.426) Lag = 1 (.359) 
Lag = 1 (.404) Lag = -3 (.322) 
Lag = 0 (-.697) 
Subject Six - Fiona The sixth subject, Fiona, provided data across a baseline of 7 time-points and a treatment phase of 40 time-points (3½ weeks and 20 weeks respectively). There were no missing data. Figures 61-64 display, respectively, her self-ratings of symptom distress, interpersonal relationship functioning, social functioning and an overall measure of distress as assessed by the OQ-45. Figures 65 and 66 display, respectively, her self­ratings of depression as assessed by the BDI and her self-ratings of anxiety as assessed by the BAI. Figures 67-72 display her self-ratings of components of therapeutic alliance; namely, confident collaboration, confident collaboration scale 2, goal & task agreement, bond, dedication as a patient, and idealization of the therapeutic relationship, respectively. The subject 's mean symptom scores (with standard deviations in brackets) at baseline were: OQ-SD = 12.86 (2.90), OQ-IR = 2.57 (0.49), OQ-SR = 10.43 (1.50), OQ-TOT = 25 (4.81), BDI = 8 ( 1.07), and BAI = 1 (0.76). Mean symptom scores in the treatment phase were: OQ-SD = 12.82 (3.44), OQ-IR = 3.77 ( 1.80), OQ-SR = 8.25 (1.62), OQ-TOT = 24.85 (4.90), BDI = 4.575 (2. 18), and BAI = 1.35 ( 1.82). The subject's mean expected alliance scores at baseline were : CCOL = 34.86 (0.35), COL2 = 55.57 (0.73), GOAL = 34 .71 (0.45), BOND = 34 .71 (0.70), DEDP = 32.14 (0.35), and IDRX = 33.29 (2.71). Mean alliance scores in the treatment phase were: CCOL = 35 (0), COL2 = 56 (0), GOAL = 34 . 12 ( l.96), BOND = 35 (0), DEDP = 31.57 (1.09), and IDRX = 34.5 ( 1.58). 
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Figure 61 : Self-ratings of Symptoms Distress as assessed by the OQ-45 for baseline and treatment conditions for subject 6. 
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Figure 62: Self-ratings of Interpersonal Relationships as assessed by the OQ-45 for baseline and treatment conditions for subject 6. 125 
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Figure 63: Self-ratings of Social Roles as assessed by the OQ-45 for baseline and treatment conditions for subject 6. 
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Figure 64: Total Score as assessed by the OQ-45 for baseline and treatment conditions for subject 6. 126 
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Time Figure 65: Self-ratings of Depression as assessed by the BDI for baseline and treatment conditions for subject 6. 
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Time Figure 66: Self-ratings of Anxiety as assessed by the BAI for baseline and treatment conditions for subject 6. 
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nme Figure 67: Self-ratings of Confident Collaboration as assessed by the CAS3 for baseline and treatment conditions for subject 6. 
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Figure 69: Self-ratings of Goal and Task Agreement as assessed by the CAS3 for 
baseline and treatment conditions for subject 6 .  
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Figure 70: Self-ratings of Bond as assessed by the CAS3 for baseline and treatment 
conditions for subject 6 .  129 
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Figure 71 : Self-ratings of Patient Dedication as assessed by the CAS3 for baseline 
and treatment conditions for subject 6. 
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Figure 72: Self-ratings of the Idealized Relationship as assessed by the CAS3 for 
baseline and treatment conditions for subject 6. 
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An initial analysis of treatment effects was conducted using Borckardt' s Simulation Method. The autocorrelation parameter, Spearman Rho-values, associated probabilities and effect sizes are presented in table 26. All probability values were obtained by running 10,000 iterations. There were 7 points in the baseline phase and 40 points in the treatment phase for each variable. The following equation, as described at the beginning of this chapter, was used for a regression analysis of each variable of interest: 
Y<n = Po +  P 1 .T + P2.X + p3.XT + e where T is the value of the variable of interest at time T. For this patient, the sequential range of 47 values for T were (-6, -5 , . . .  , - 1, 0, 1, . . .  , 39, 40) with -6 corresponding to the first data point, -5 corresponding to the second data point, etc. The corresponding first 7 values of X were all 0, i.e., 0 for al 1 baseline points, and 1 for each of the remaining 40 points in the treatment phase . The corresponding first 7 values of XT were also all 0, while the sequential range of values for the 40 points in the treatment phase were ( 1 ,  2, . . .  , 29, 30). The autocorrelation correlogram and partial autocorrelation correlogram created for each set of regression residuals using the SPSS autocorrelation graphing function indicated the presence of significant autocorrelation for several variables. Table 27 displays the ARIMA model parameters for those variables that were found to have significant autocorrelation in the regression residuals. The parameter value given in these models represents the lag-value of the highest-lagged significant autocorrelation. ARIMA model 
13 1  
Table 26: Rho-values , associated probabilities and parameters from Simulation Method analysis for subject 6. Auto- Spearman Probability Effect-Size correlation Rho OQ-SD 0.02 -0.01 0.999 -0.01 OQ-IR 0.47 0.31 0.070 2.43 OQ-SR 0.41 -0.41 0.011 -1.45 OQ-TOTAL 0.01 -0.06 0.344 -0.24 BDI-TOTAL 0.25 -0.52 0.000 -3.20 BAI-TOT 0.59 -0.04 0.437 0.46 CAS3-CCOL 0.00 0.35 0.004 0.41  CAS3-CCOL2 0.40 0.50 0.001 0.59 CAS3-GOALS 0.07 0.00 0.999 -1.30 CAS3-BOND 0.00 0.35 0.005 0.41 CAS3-DEDPT 0.11 -0.27 0.038 -1.62 CAS3-IDRX 0.33 (3)9 0.17 0.015 0.45 
Note (a): Number in brackets indicates if a lag-value higher than 1 was used in analysis. In such cases, the 
autocorrelation value is derived from the higher lag. 132 
Table 27: Statis_tics derived from linear regression and ARIMA analyses for subject 6. 
ARIMA Rl F-statistic (dO Probability 
moder OQ-SD .060 0.92 (3,43) .439 OQ-IR 8 .553 3.94 (11 ,35) .005 OQ-SR .298 6.07 (3,43) .002 OQ-TOTAL .115 1.86 (3,43) .151 BDI-TOTAL .263 5.12 (3,43) .004 BAI-TOT 8 .653 5.99 (11 ,35)) .001 CAS3-CCOL 4 .651  10.38 (7 ,39) .001 CAS3-CCOL2 4 .909 55.32 (7 ,39) .000 CAS3-GOALS .014 0.20 (3,43)) .894 CAS3-BOND 4 .650 10.36 (7 ,39) .001 CAS3-DEDPT .070 1.08 (3,43) .367 CAS3-IDRX 3 .239 2. 10 (6,40) .100 Note (a): ARIMA model parameters are given only for those variables for which an ARIMA analysis was performed. The R2 statistics, F statistics and associated probability values were calculated using the sums of squares and degrees of freedom from the regression analysis. For those variables for which an ARIMA analysis was used, the residual sum of squares and the degrees of freedom were derived from the ARIMA model. 
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parameters were omitted for those variables in which no autocorrelation was found present . An R2 statistic, F statistic and an associated probability value, derived from the linear regression analysis, were given for each variable without significant autocorrelation in the regression residuals. For those variables with significant autocorrelation in the regression residuals, these statistics were calculated from the ARIMA analysis. The presence of stationarity in the data was ascertained by correlating the regression residuals for each variable with the time variable t. No significant r-values were obtained, indicating the presence of stationarity. Table 28 displays the probabilities associated with the t-ratio statistics obtained for �­coefficients in either the ARIMA equations or the regression equations . For variables on which only a regression analysis was performed, no probability value is given for the ARIMA component. A cross-correlational analysis was performed on the residuals produced from either the regression analysis or the ARIMA analysis. Symptom measures - the three factors and total score of the Q045, the BDI and BAI - were cross-correlated with the six factors of the CAS3. Correlational values were included in the following tables if their absolute value was 2 standard errors greater than zero. Tables 29 and 30 display the lag-value and associated r-statistic in parentheses of these correlational values. In both tables, significant predicted correlations are marked in bold. For N = 47 data-points, a =  . 10, and with a Bonferroni correction made for 1 1  correlations, to reach significance the r-value must be >0.372. Significant, but unpredicted, correlations are in italics. 
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Table 28: P-va�ues from t-tests of autoregressive (AR) coefficients , time (T) coefficients, level (X) coefficients and interaction (XT) coefficients for subject 6. 
Autoregressive Time Level Interaction 
Component" · T X XT OQ-SD .72 1 .721 .239 OQ-IR .044 .960 .906 .708 OQ-SR .046 .785 .059 OQ-TOTAL . 169 .931 . 134 BDI-TOTAL .726 .068 .725 BAI-TOT .009 . 190 .014 .26 1 CAS3-CCOL .000 .000 .000 .000 CAS3-CCOL2 .000 .000 .000 .000 CAS3-GOALS .92 1  .588 .931  CAS3-BOND .000 .000 .000 .000 CAS3-DEDPT .590 .475 .539 CAS3-IDRX .01 1  .200 .939 .200 Note (a): Probability values are only given for those variables for which an ARIMA analysis was performed. 
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Table 29: Cross-correlation lags and r-values for symptom measures and the first three 
factors of the CAS3 for subject 6. 
OQ-SD 
OQ-IR 
OQ-SR 
OQ-TOTAL 
BDI-TOTAL 
BAI-TOT 
Confident 
Collaboration 
Confident 
Collaboration 2 
Goal and Task 
Agreement 
Lag = -4 (-.326) 
Lag = 1 (-.490) 
Lag = -3 (-.364) 
Lag = 0 (.485) 
Lag = 5 (.3 1 1 )  
Lag = -4 (-.3 1 1 ) 
Lag = 1 (-.366) 
Lag = - 1  (-.342) 
Table 30: Cross-correlation lags and r-values for symptom measures and the last three 
factors of the CAS3 for subject 6.  
Bond 
OQ-SD 
OQ-IR 
OQ-SR 
OQ-TOTAL 
BDI-TOTAL 
BAI-TOT 
Dedicated 
Patient 
Lag = -2 (-.383) 
Lag = 1 (.306) 
136 
Idealized 
Relationship 
Lag = 0 (-.522) 
Lag = 5 (-.318) 
Lag = -1 (.404) 
Lag = 4 ( .3 16) 
Lag = 0 (-.524) 
Lag = -2 ( .340) 
Lag = -3 (- .329) 
Subject Seven - Gerald The seventh subject, Gerald, provided data across a baseline of 10 time-points and a treatment phase of 42 time-points (5 weeks and 2 1  weeks respectively). There were missing data for times 7 and time 23 - data for these times were calculated as the average of the data from the preceding and succeeding time points. Figures 73-76 display, respectively, self-ratings of symptom distress, interpersonal relationship functioning, social functioning and an overall measure of distress as assessed by the OQ-45 . Figures 77 and 78 display, respectively, self-ratings of depression as assessed by the BDI and self-ratings of anxiety as assessed by the BAI. Figures 79-84 display his self-ratings of therapeutic alliance: confident collaboration, confident collaboration scale 2, goal & task agreement, bond, dedication as a patient , and idealization of the therapeutic relationship. The subject' s  mean symptom scores (with standard deviations in brackets) at baseline were: OQ-SD = 36.55 (2.80), OQ-IR = 19.7 ( 1.55), OQ-SR = 16 . 1 (0.94), OQ-TOT = 72.35 (4.22), BDI = 15 .75 (3.46), and BAI = 5.9 ( 1.76). Mean symptom scores in the treatment phase were: OQ-SD = 36.98 (4.30}, OQ-IR = 19. 15 (2.04), OQ-SR = 15.27 ( 1 .50), OQ-TOT = 7 1 .40 (5 .81), BDI = 13.62 (5 .66), and BAI = 3.79 (2.46). The subject' s mean expected alliance scores at baseline were: CCOL = 13 . 1  (4.66), COL2 = 22.85 (6.20), GOAL = 17.3 (2.05), BOND = 14.75 (3.61), DEDP = 20.15 ( 1 .95), and IDRX = 2 1 .45 (2. 15). Mean alliance scores in the treatment phase were : CCOL = 9.69 ( 1 .79), COL2 = 18.93 ( 1 .92), GOAL = 14.64 ( 1 .73), BOND = 13.38 ( 1 .62), DEDP = 28.07 (2.21 ), and IDRX = 25.26 (2.88). 
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Figure 73: Self-ratings of Symptoms Distress as assessed by the OQ-45 for baseline and treatment conditions for subject 7. 
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Figure 74: Self-ratings of Interpersonal Relationships as assessed by the OQ-45 for baseline and treatment conditions for subject 7. 
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Figure 75: Self-ratings of Social Roles as assessed by the OQ-45 for baseline and treatment conditions for subject 7. 
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Figure 76: Total Score as assessed by the OQ-45 for baseline and treatment conditions for subject 7. 
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Time Figure 78: Self-ratings of Anxiety as assessed by the BAI for baseline and treatment conditions for subject 7. 
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Figure 79: Self-ratings of Confident Collaboration as assessed by the CAS3 for baseline and treatment conditions for subject 7. 
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Figure 80: Self-ratings of Confident Collaboration 2 as assessed by the CAS3 for baseline and treatment conditions for subject 7. 
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Time Figure 81 : Self-ratings of Goal and Task Agreement as assessed by the CAS3 for baseline and treatment conditions for subject 7. 
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Figure 83: Self-ratings of Patient Dedication as assessed by the CAS3 for basel ine and treatment conditions for subject 7 .  
32 
30 
Q. 
i 2B 
C: 
0 
i 26 
(I) 
i 24 
.!::! 
:2 22 . 
� <( 20 
(.) 
18  
1 4 7 1 0  1 3  16 19  22  25  2B  31  34 37 40 43 46  49  52 
Time 
Figure 84: Se lf-ratings of the Idealized Relationship as assessed by the CAS3 for baseline and treatment conditions for subject 7. 
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An initial analysis of treatment effects was conducted using Borckardt's Simulation Method. The autocorrelation parameter, Spearman Rho-values, associated probabilities and effect sizes are presented in table 31. All probability values were obtained by running 10,000 iterations. There were 10 points in the baseline phase and 42 points in the treatment phase for each variable. The following equation, as described at the beginning of this chapter, was used for a regression analysis of each variable of interest: 
Yen = J3o + p r .T + p2.x + p3.XT + E where T is the value of the variable of interest at time T. For this patient, the sequential range of 52 values for T were (-9, -8, .. . , - 1 ,  0, 1, ... , 41, 42) with -9 corresponding to the first data point, -8 corresponding to the second data point, etc. The corresponding first 10 values of X were all 0, i.e., 0 for all baseline points , and 1 for each of the remaining 42 points in the treatment phase. The corresponding first 10 values of XT were also all 0, while the sequential range of values for the 42 points in the treatment phase were ( 1, 2, 
. . .  , 4 1 ,  42). The autocorrelation correlogram and partial autocorrelation correlogram created for each set of regression residuals using the SPSS autocorrelation graphing function indicated the presence of significant autocorrelation for several variables. Table 32 displays the AR™A model parameters for those variables that were found to have significant autocorrelation in the regression residuals. The parameter value given in these models represents the lag-value of the highest-lagged significant autocorrelation. AR™A model 
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Table 31: Rho-yalues , associated probabilities and parameters from Simulation Method analysis for subject 7. 
Auto- Spearman Probability EtTect-Size 
correlation Rho OQ-SD 0.24 0.04 0.4 14 0. 15 OQ-IR 0.13 -0.31 0.042 -0.35 OQ-SR 0.42 -0.27 0.1 18 -0.88 OQ-TOTAL 0. 12 -0. 14 0.211 -0.22 BDI-TOTAL 0.17 -0.22 0.085 -0.62 BAI-TOT 0.45 -0.37 0.033 -1 .20 CAS3-CCOL 0.38 -0.30 0.077 -0.73 CAS3-CCOL2 0.51 -0.20 0. 192 -0.63 CAS3-GOALS 0.46 -0.45 0.010 -1.30 CAS3-BOND 0.53 -0.06 0.393 -0.38 CAS3-DEDPT 0.82 0.68 0.001 4.06 CAS3-IDRX 0.69 0.47 0.029 1 .77 
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Table 32: Statistics derived from linear regression and ARIMA analyses for subject 7. 
ARIMA R2 F -statistic ( dO Probability 
model• OQ-SD 9 .378 1.98 (12,39) . 100 OQ-IR 1 . 170 2.41 (4,47) . 100 OQ-SR 1 .4 1 1  8.20 (4,47) .001 OQ-TOTAL 3 .240 2.37 (6,45) .050 BDI-TOTAL .047 0.80 (3,48) .502 BAI-TOT 1 .300 5 .02 (4,47) .0 10 CAS3-CCOL .485 15 .08 (3,48) .000 CAS3-CCOL2 1 .523 12.89 (4,47) .000 CAS3-GOALS 16 .746 4.94 (19,32) .001 CAS3-BOND 8 .59 1 5.25 ( 1 1 ,40) .00 1 CAS3-DEDPT 1 .865 75 .33 (4,47) .000 CAS3-IDRX 14 .761 6.36 (17,34) .001  
Note (a): ARIMA model parameters are given only for those variables for which an ARIMA analysis was performed. 
The R2 statistics, F statistics and associated probability values were calculated using the sums of squares and degrees of 
freedom from the regression analysis. For those variables for which an ARIMA analysis was used, the residual sum of 
squares and the degrees of freedom were derived from the ARIMA model. 
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parameters wer� omitted for those variables in which no autocorrelation was found present. An R2 statistic, F statistic and an associated probability value, derived from the linear regression analysis, were given for each variable without significant autocorrelation in the regression residuals. For those variables with significant autocorrelation in the regression residuals, these statistics were calculated from the ARIMA analysis. The presence of stationarity in the data was ascertained by correlating the regression residuals for each variable with the time variable t. No significant r-values were obtained, indicating the presence of stationarity. Table 33 displays the probabilities associated with the t-ratio statistics obtained for P­coefficients in either the ARIMA equations or the regression equations. For variables on which only a regression analysis was performed, no probability value is given for the ARIMA component. A cross-correlational analysis was performed on the residuals produced from either the regression analysis or the ARIMA analysis. Symptom measures - the three factors and total score of the Q045, the BDI and BAI - were cross-correlated with the six factors of the CAS3. Correlational values were included in the following tables if their absolute value was 2 standard errors greater than zero. Tables 34 and 35 display the lag-value and associated r-statistic in parentheses of these correlational values . In both tables, significant predicted correlations are marked in bold. For N = 52 data-points, a. =  . 10, and with a Bonferroni correction made for 1 1  correlations, to reach significance the r-value must be >0.354. Significant, but unpredicted, correlations are in italics . 
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Table 33: P-values from t-tests of autoregressive (AR) coefficients, time (T) coefficients, level (X) coefficients and interaction (XT) coefficients for subject 7. 
Autoregressive Time Level Interaction 
Component" T X XT OQ-SD .041 .170 .339 .157 OQ-IR .032 .845 .274 .996 OQ-SR .003 .949 .504 .746 OQ-TOTAL .002 .063 .085 .054 BDI-TOTAL .288 .182 .288 BAI-TOT .055 .604 .812 .804 CAS3-CCOL .000 .492 .000 CAS3-CCOL2 .035 .000 .701 .000 CAS3-GOALS .000 .000 .368 .000 CAS3-BOND .000 .031  .840 .032 CAS3-DEDPT .000 .103 .445 .247 CAS3-IDRX .017  .014 .032 .153 
Note (a): Probability values are only given for those variables for which an ARIMA analysis was performed. 
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Table 34: Cross-correlation lags and r-values for symptom measures and the first three factors of the CAS3 for subject 7. OQ-SD OQ-IR OQ-SR OQ-TOTAL BDI-TOTAL BAI-TOT Confident Collaboration Lag = -3 (.297) Lag = -3 (.301) Lag = -2 (-.310) Confident Collaboration 2 Lag = 0 (.396) Goal and Task Agreement Lag = 1 (.401) Table 35: Cross-correlation lags and r-values for symptom measures and the last three factors of the CAS3 for subject 7. OQ-SD OQ-IR OQ-SR OQ-TOTAL BDI-TOTAL BAI-TOT Bond Lag = 0 (.326) Lag = 1 (-.295) Lag = -2 (-.359) Lag = 0 (.318) Dedicated Patient Lag = -2 (-.284) 
149 
Idealized Relationship Lag = 3 (.284) 
Subject Eight - Hilda The eighth subject, Hilda provided data across a baseline of 7 time-points and a treatment phase of 26 time-points (3½ weeks and 13 weeks respectively). ). There were missing data for times 5, 1 1  and 17 - data for these times were calculated as the average of the data from the preceding and succeeding time points. Figures 85-88 display, respectively, her self-ratings of symptom distress, interpersonal relationship functioning, social functioning and an overall measure of distress as assessed by the OQ-45. Figures 89 and 90 display, respectively, her self-ratings of depression as assessed by the BDI and her self-ratings of anxiety as assessed by the BAI. Figures 91-96 display her self-ratings of components of therapeutic alliance; namely, confident collaboration, confident collaboration scale 2, goal & task agreement , bond, dedication as a patient, and idealization of the therapeutic relationship, respectively. The subject 's mean symptom scores (with standard deviations in brackets) at baseline were: OQ-SD = 52 (6.14), OQ-IR = 22.79 (3.40), OQ-SR = 21.14 (2.90), OQ-TOT = 95.93 ( 1 1 .82), BDI = 21 .29 (4.53), and BAI = 23.79 (4 .69). Mean symptom scores in the treatment phase were: OQ-SD = 27.37 (7.28), OQ-IR = 10.38 (3. 18), OQ-SR = 12.27 (3.22), OQ-TOT = 50.02 (1 1.89), BDI = 7.04 (4.58), and BAI = 10.15 (3.64). The subject's mean expected alliance scores at baseline were: CCOL = 30.14 ( 1 .36), COL2 = 40.36 (3.26), GOAL = 27.2 1  (2. 17), BOND = 28.43 ( 1 .40), DEDP = 29.21 (2.33), and IDRX = 35 (0). Mean alliance scores in the treatment phase were : CCOL = 30.83 ( 1.26), COL2 = 47.37 ( 1 .76), GOAL = 30.04 (1.08), BOND = 29.85 ( 1 .06), DEDP = 29.69 ( 1 .83), and IDRX = 31.92 ( 1.84). 
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Figure 85 : Self-ratings of Symptoms Distress as assessed by the OQ-45 for baseline and treatment conditions for subject 8. 
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Figure 86: Self-ratings of Interpersonal Relationships as assessed by the OQ-45 for baseline and treatment conditions for subject 8. 
1 5 1  
4 7 10 13 16 19 22 25 28 31 
Time Figure 87: Self-ratings of Social Roles as assessed by the OQ-45 for baseline and treatment conditions for subject 8 .  
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Figure 89: Self-ratings of Depression as assessed by the BDI for baseline and treatment conditions for subject 8. 
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Figure 90: Self-ratings of Anxiety as assessed by the BAI for baseline and treatment conditions for subject 8. 
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Figure 93: Self-ratings of Goal and Task Agreement as assessed by the CAS3 for baseline and treatment conditions for subject 8. 
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Figure 94: Self-ratings of Bond as assessed by the CAS3 for baseline and treatment conditions for subject 8. 
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Time Figure 95: Self-ratings of Patient Dedication as assessed by the CAS3 for baseline and treatment conditions for subject 8. 
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An initial ana�_ysis of treatment effects was conducted using Borckardt ' s Simulation Method. The autocorrelation parameter, Spearman Rho-values, associated probabilities and effect sizes are presented in table 36. All probability values were obtained by running 10,000 iterations. There were 7 points in the baseline phase and 26 points in the treatment phase for each variable. The following equation, as described at the beginning of this chapter, was used for a regression analysis of each variable of interest : Yen = �o + � 1 .T + �2.X + �3.XT + e where T is the value of the variable of interest at time T. For this patient , the sequential range of 33 values for T were (-6, -5 , . . .  , - 1, 0, l, . . .  , 25, 26) with -6 corresponding to the first data point, -5 corresponding to the second data point, etc. The corresponding first 7 values of X were all 0, i .e., 0 for all baseline points , and l for each of the remaining 26 points in the treatment phase. The corresponding first 7 values of XT were also all 0, while the sequential range of values for the 26 points in the treatment phase were ( l , 2, . . .  , 4 1, 42). The autocorrelation correlogram and partial autocorrelation correlogram created for each set of regression residuals using the SPSS autocorrelation graphing function indicated the presence of significant autocorrelation for several variables. Table 37 displays the ARIMA model parameters for those variables that were found to have significant autocorrelation in the regression residuals. The parameter value given in these models represents the lag-value of the highest-lagged significant autocorrelation. ARIMA model 
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Table 36: Rho-values , associated probabilities and parameters from simulation method analysis for subject 8 Auto- Spearman Probability Effect-Size correlation Rho OQ-SD 0.83 -0.69 0.002 -4.01 OQ-IR 0.84 -0.70 0.002 -3.65 OQ-SR 0.82 -0.71 0.000 -3 .06 OQ-TOTAL 0.85 -0.69 0.005 -3.89 BDI-TOTAL 0.81 -0.68 0.003 -3. 15 BAI-TOT 0.81 -0.68 0.003 -2.91 CAS3-CCOL 0.23 0.20 0 . 172 0.50 CAS3-CCOL2 0.66 0.67 0.000 2. 15 CAS3-GOALS 0.42 0.52 0.009 1.30 CAS3-BOND 0.23 0.47 0.007 1.01 CAS3-DEDPT 0.53 0.06 0.434 0.21 CAS3-IDRX 0.79 -0.67 0.004 <-20.00 
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Table 37: Statistics derived from linear regression and ARIMA analyses for subject 8 
ARIMA Rl F-statistic ( dO Probability 
modela OQ-SD 1 .869 46.49 (4,28) .000 OQ-IR 1 .847 38.77 (4,28) .000 OQ-SR 1 .923 84.34 ( 4,28) .000 OQ-TOTAL 1 .907 68.56 ( 4,28) .000 BDI-TOTAL 1 .868 45.86 (4,28) .000 BAI-TOT 1 .868 46 . 16 (4,28) .000 CAS3-CCOL 3 .476 3.94 (6,26) .0 10 CAS3-CCOL2 .7 13 24.05 (3,29) .000 CAS3-GOALS .459 8.20 (3,29) .000 CAS3-BOND .228 2.86 (3,29) .054 CAS3-DEDPT 3 .705 10.36 (6,26) .001 CAS3-IDRX 4 .856 21.19 (7,25) .000 Note (a): ARIMA model parameters are given only for those variables for which an ARIMA analysis was performed. The R2 statistics, F statistics and associated probability values were calculated using the sums of squares and degrees of freedom from the regression analysis. For those variables for which an ARIMA analysis was used, the residual sum of squares and the degrees of freedom were derived from the AR IMA model . 1 59 
parameters were omitted for those variables in which no autocorrelation was found present. An R2 statistic, F statistic and an associated probability value, derived from the linear regression analysis, were given for each variable without significant autocorrelation in the regression residuals . For those variables with significant autocorrelation in the regression residuals, these statistics were calculated from the ARIMA analysis. The presence of stationarity in the data was ascertained by correlating the regression residuals for each variable with the time variable t. No significant r-values were obtained, indicating the presence of stationarity. Table 38 displays the probabilities associated with the t-ratio statistics obtained for �­coefficients in either the ARIMA equations or the regression equations. For variables on which only a regression analysis was performed, no probability value is given for the ARIMA component . A cross-correlational analysis was performed on the residuals produced from either the regression analysis or the ARIMA analysis. Symptom measures - the three factors and total score of the QO45, the BDI and BAI - were cross-correlated with the six factors of the CAS3. Correlational values were included in the following tables if their absolute value was 2 standard errors greater than zero. Tables 39 and 40 display the lag-value and associated r-statistic in parentheses of these correlational values. In both tables, significant predicted correlations are marked in bold. For N = 33 data-points, a = . 10, and with a Bonferroni correction made for 1 1  correlations, to reach significance the r-value must be >0.443. Significant , but unpredicted, correlations are in italics. 
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Table 38: P-values from t-tests of autoregressive (AR) coefficients, time (T) coefficients, level (X) coefficients and interaction (XT) coefficients for subject 8 
Autoregressive Time Level Interaction 
Component" T X XT OQ-SD .000 .014 .914 .055 OQ-IR .000 .0 1 8  .292 .05 1  OQ-SR .040 .00 1  .970 .012 OQ-TOTAL .000 .003 .621  .01 8  BDI-TOTAL .000 .003 .097 .026 BAI-TOT .000 .004 .005 .027 CAS3-CCOL .007 .015 .014 .04 1  CAS3-CCOL2 .047 .056 .083 CAS3-GOALS .393 .018 .303 CAS3-BOND .353 .427 .359 CAS3-DEDPT .001  .000 .363 .000 CAS3-IDRX .006 .190 .061  .045 
Note (a): Probability values are only given for those variables for which an ARJMA analysis was performed. 
161  
Table 39: Cross-correlation lags and r-values for symptom measures and the first three 
factors of the CAS3 for subject 8 
Confident Confident Goal and Task 
Collaboration Collaboration 2 Agreement 
OQ-SD Lag = 2 (-.443) Lag = -2 (-.417) 
OQ-IR Lag = 4 (-.372) Lag = 4 (-.398) 
OQ-SR Lag = 3 (.404) Lag = 3 (-.476) 
OQ-TOTAL Lag = 2 (- .398) Lag = -2 (-.370) 
BDI-TOTAL Lag = -2 (-.428) Lag = -2 (-.449) 
BAI-TOT 
Table 40: Cross-correlation lags and r-values for symptom measures and the last three 
factors of the CAS3 for subject 8 
Bond Dedicated Idealized 
Patient Relationship 
OQ-SD Lag = 1 (-.572) 
OQ-m Lag = 0 (- .4 17) 
Lag = l (- .357) 
Lag = 4 (- .388) 
OQ-SR 
OQ-TOTAL Lag = 0 (- .372) 
Lag = 1 (-.562) 
BDI-TOTAL 
BAI-TOT Lag = - 1  (.403) Lag = 5 (-.485) 
Lag = 5 (-.509) 
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Collated Results This section presents an overview of the results of the study. Table 41 presents a summary of the significant results obtained for the therapeutic alliance factor, Confident Collaboration (CCOL), across all subjects. For five subjects there was a significant effect for treatment on either the mean level or the slope of the CCOL factor, beyond the effect of auto-regression (if present) or baseline slope. A binomial test with an expected proportion of non-significant treatment components equal to 0.25, indicated that the number of subjects with one or more significant treatment effect components was more than would be expected by chance alone (p = .027). The mean effect size was -1.44. 
Table 41 : Summary of analyses for the Confident Collaboration CAS3 subscale 
Simulation EtTect Size1 Phase A Phase B Phase B 
Method Slope Mean A Slope A Ailish Significant -1.21 Significant N.S .  Significant Brianna N.S. 0.05 N.S. Significant N.S. Ciara Significant -2.14 N.S. N.S. N.S. Deirdre Significant -5.00 N.S. Significant N.S .  Elaine Significant -1.58 N.S. N.S. N.S. Fiona2 Gerald N.S. -0.73 Significant N.S .  Significant 
Hilda N.S. 0.50 Significant Significant Significant 
Total 4 -10.11  3 3 3 
Note ( I ): Effect sizes greater than 5.00 were reduced to 5.00 in order to reduce skew. 
Note (2): Results from subject 6, Fiona. were omitted because of lack of variability in CCOL. 163 
A summary of the significant results obtained across all subjects for the therapeutic 
alliance factor, Confident CoJlaboration 2 (COL2) is presented in Table 42. For six 
subjects there was a significant effect for treatment on either the mean level or the slope 
of the COL2 factor, beyond the effect of auto-regression (if present) or baseline slope. A 
binomial test with an expected proportion of non-significant treatment components equal 
to 0.25, indicated that the number of subjects with one or more significant treatment 
effect components was more than would be expected by chance alone (p = .004). The 
mean effect size was -1 .43. 
Table 42: Summary of analyses for the Confident Collaboration 2 CAS3 subscale 
Simulation Effect Size1 Phase A Phase B Phase B 
Method Slope Mean A Slope A 
Ailish N.S. -0.28 Significant Significant Significant 
Brianna N.S. 1 .02 N.S. Significant N.S. 
Ciara Significant -4. 1 1  N.S. Significant N.S. 
Deirdre Significant -5.00 N.S. Significant N.S. 
Elaine Significant -3. 19 N.S. Significant N.S. 
Fiona2 
Gerald N.S. -0.63 Significant N.S. Significant 
Hilda Significant 2. 1 5  Significant N.S. N.S. 
Total 4 - 10.04 3 5 2 Note ( I ): Effect sizes greater than 5.00 were reduced to 5.00 in order to reduce skew. Note (2): Results from subject 6, Fiona, were omitted because of lack of variability in COL2. 164 
A summary of . the significant results obtained across all subjects for the therapeutic alliance factor, Goal and Task Agreement (GOAL) is presented in Table 43. For six subjects there was a significant effect for treatment on either the mean level or the slope of the GOAL factor, beyond the effect of auto-regression (if present) or baseline slope. A binomial test with an expected proportion of non-significant treatment components equal to 0.25 , indicated that the number of subjects with one or more significant treatment effect components was more than would be expected by chance alone (p = .004 ). The mean effect size was -1.33. 
Table 43: Summary of analyses for the Goal & Task Agreement CAS3 subscale 
Simulation Effect Size1 Phase A Phase B Phase B 
Method Slope Mean A Slope A 
Ailish N.S. 0.42 Significant Significant Significant 
Brianna N.S. 0.83 N.S. N.S. N.S. 
Ciara Significant -3.15 Significant N.S. Significant 
Deirdre Significant -5 .00 N.S. Significant N.S. 
Elaine Significant -2.42 Significant N.S. Significant 
Fiona N.S. - 1 .30 N.S. N.S. N.S. 
Gerald Significant - 1.30 Significant N.S. Significant 
Hilda Significant 1.30 N.S. Significant N.S. 
Total 5 - 10.62 4 3 4 
Note (1 ): Effect sizes greater than 5.00 were reduced to 5 .00 in order to reduce skew 165 
A summary of the significant results obtained across all subjects for the therapeutic 
alliance factor, Bond (BOND) is presented in Table 44. For four subjects there was a 
significant effect for treatment on either the mean level or the slope of the BOND factor, 
beyond the effect of auto-regression (if present) or baseline slope. A binomial test with an 
expected proportion of non-significant treatment components equal to 0.25, indicated that 
the number of subjects with one or more significant treatment effect components was no 
more than would be expected by chance alone (p = . 1 14 ) .  The estimated mean effect size 
was -0.70. 
Table 44: Summary of analyses for the Bond CAS3 subscale 
Simulation Effect Size1 Phase A Phase B Phase B 
Method Slope Mean A Slope A Ailish Significant - 1 .04 N.S. N.S. Significant Brianna Significant 4.55 N.S. Significant N.S. Ciara Significant -2.6 1 N.S. N.S. N.S. Deirdre Significant -5 .00 N.S. N.S .  N.S.  Elaine Significant - 1 .44 N.S . Significant N.S. Fiona2 Gerald N.S. -0.38 Significant N.S .  Significant Hilda Significant 1 .01  N.S. N.S. N.S. 
Total 6 -4.9 1 1 2 2 
Note ( 1 ): Effect sizes greater than 5.00 were reduced to 5.00 in order to reduce skew. 
Note (2): Results from subject 6, Fiona, were omitted because of lack of variability in BOND. 166 
A summary of . the significant results obtained across all subjects for the therapeutic alliance factor, Patient Dedication (DEDP) is presented in Table 45. In the case of four subjects there was a significant effect for treatment on either the mean level or the slope of the DEDP factor, beyond the effect of auto-regression (if present) or baseline slope. A binomial test with an expected proportion of non-significant treatment components equal to 0.25, indicated that the number of subjects with one or more significant treatment effect components was no more than would be expected by chance alone (p = . 114). The mean effect size was --0.48. 
Table 45: Summary of analyses for the Patient Dedication CAS3 subscale 
Simulation Effect Size1 Phase A Phase B Phase B 
Method Slope Mean A Slope A Ailish Significant -0.04 N.S. N.S. N.S. Brianna N.S. -0.45 Significant N.S. Significant Ciara Significant -3.98 N.S. N.S.  Significant Deirdre Significant -2.73 N.S. N.S. N.S. Elaine Significant 0.7 1 Significant N.S. Significant Fiona Significant - 1.62 N.S. N.S .  N.S. Gerald Significant 4 .06 N.S. N.S. N.S. Hilda N.S. 0.2 1 Significant N.S. Significant 
Total 6 -3.84 3 0 4 Note ( 1 ) : Effect sizes greater than 5.00 were reduced to 5 .00 in order to reduce skew 167 
A summary of the significant results obtained across all subjects for the therapeutic 
alliance factor , Idealized Relationship (IDRX) is presented in Table 46. For 4 subjects 
there was a significant effect for treatment on either the mean level or the slope of the 
IDRX factor, beyond the effect of auto-regression (if present) or baseline slope. A 
binomial test with an expected proportion of non-significant treatment components equal 
to 0.25, indicated that the number of subjects with one or more significant treatment 
effect components was no more than would be expected by chance alone (p = .114). The 
estimated mean effect size was -0.05. 
Table 46: Summary of analyses for the Idealized Relationship CAS3 subscale 
Simulation Effect Size1 Phase A Phase B Phase B 
Method Slope Mean A Slope A Ailish Significant 1.02 N.S .  N.S. Significant Brianna Significant 4.32 N.S. Significant N.S. Ciara Significant -2.87 N.S. N.S. N. S. Deirdre2 Elaine2 Fiona Significant 0.45 N.S. N.S. N.S.  Gerald Significant 1.77 Significant Significant N.S.  Hilda Significant -5.00 N.S.  N.S. Significant 
Total 6 -0.31 l 2 2 Note ( l ): Effect sizes greater than 5.00 were reduced to 5.00 in order to reduce skew. Note (2): Results from subject 4, Deirdre, and subject 5, Elaine, were omitted because of lack of variability in IDRX. 
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Regarding the .frequency of significant slope parameters in either the baseline or treatment phase, a series of binomial tests indicated that there were no more significant slope parameters than would be expected by chance. Four of eight subjects had no significant change in slope in either phase (as indicated by non-significant slope parameters) for the variables CCOL, COL2, GOAL, DEDP and IDRX (p = . 1 14). For the variable BOND, five of eight subjects had no significant change in slope in either phase In analyzing across all eight subjects, of the 26 lead-lag relationships hypothesized to exist between the alliance subscales and outcome measures , 14 such relationships were found to include at least one significant cross-correlational r-statistic, somewhere between the lag-values of +5 and -5 . Within these 14 relationships, there were a total of 28 significant cross-correlations, but 4 of these cross-correlation were dropped from any further consideration because of a lack of variance in that particular alliance factor for that particular subject. These 4 omitted cross-correlations were OQSD-+ IDRX (Lag = 1 ), OQ-Total-+IDRX (Lag = 1) and BAI�IDRX (Lag = 0) from subject 5, Elaine ; and OQIR-+IDRX (Lag = 1) from subject 4, Deirdre. For both subjects, there was nearly zero variance on the IDRX subscale. Omission of these four correlations resulted in 12 significant lead-lag relationships consisting of 5 significant negative-lag correlations, 5 significant zero-lag correlations and 14 positive-lag correlations. Two subjects had a significant cross-correlation for the same relationship (BAl-+DEDP) at the same lag-value (Lag = 5), resulting in 23 distinct lag-values . All cross-correlational r-values for those 23 specific lag-values and their 
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associated variable relationship were converted to Fisher' s Z for each subject. A mean 
Fisher' s Z was then obtain_ed and converted to an effect size estimate (r). Of the 23 
specific lag relationships thus analyzed, nine produced an effect size r >. 10 (i .e., a small 
effect size). These nine relationships with their associated lags are presented in Table 47. 
Arrows between variables in the first column indicate the direction of the relationship, as 
do the signs of the lags with positive lags indicating that an alliance measure is  being 
predicted by an outcome measure. l:Z is the sum of the Fisher' s Z-values and N 
represents the number of subjects used in the analysis. 
Table 47: Significant effect-sizes for variable relationships at specific lags 
Lag "£Z N R 
OQSD+-+IDRX 0 -0.676 71 -0. 1 1 3 
OQJR--.DEDP +4 -1 .07 1 8 -0. 1 33 
OQSR--.COL2 +2 -1 .02 1 72 -0. 145 
OQSR+-+GOAL 0 0.905 8 0. 1 1 2 
OQSR-+DEDP +l -0.876 8 -0. 109 
OQSR+-IDRX - 1  0.653 61 0. 109 
OQTOT+-+IDRX 0 -0 .845 61 -0. 140 
OQTOT-+IDRX +1  -0.950 61 -0. 1 57 
BAI-+DEDP +1  - 1 . 105 8 -0. 137 
Note ( l ): Cross-correlational r-statistics for relationships involving the alliance subscale IDRX were not included in 
calculating I:Z for subject 4, Deirdre, and subject 5, Elaine, because of lack of variability. 
Note (2): Cross-correlational r-statistics for relationships involving the alliance subscales CCOL, COL2 & BOND were 
not included in calculating I:Z for subject 6, Fiona, because of lack of variability. 
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CHAPTER IV 
DISCUSSION 
Ailish Ailish presented with a primary complaint of "chronic moodiness" and general anxiety. Depression, anger and low self-esteem were typical experiences for her. She relied on her considerable intellectual resources to cope with these feelings, but often to the detriment of free expression of her experience. The therapist sought to focus on helping alleviate her depressed mood, and to address unmet dependency needs and feelings of loss and separation. The data on Ailish extended over a 7-week baseline and 1 1  weeks of therapy. Prior to beginning therapy, her mean BDI total score was 15.7 1 (mild) and her mean BAI score was 5.36 (minimal); both of which were surprisingly low for a presentation of Dysthymic disorder and Generalized Anxiety. Also none of her scores on the OQ-45 were in the clinical range. A quick scan of Table l for an initial evaluation of treatment effects indicates that there was a significant reduction in symptom distress and overall functioning as measured by the OQ-45. However, the decrease in overall functioning (OQ-Tot) was approximately 8.5 points, far short of the reliable change index of 1 5  points estimated Lambert et al . (1998). Nor was there a hoped for reduction in either depression or anxiety. Rather, the majority of significant decreases came in the realm of alliance rather than symptomatology, with 17 1 
significant decreases in a ll alliance factors, except Goal and Task Agreement , which did not seem to change to any significant degree, and Idealized Relationship ,  which significantly increased . Thus there was seemingly an effect for treatment on alliance in five out of six cases , supporting rejection of the null hypothesis of no change in alliance across the two phases . It is plausible that the decrease in alliance reflected either lack of confidence and comfort with the therapist (which could speak to a use of inte llectualized defenses such as disparagement and emotional distancing) or a response to lack of improvement. Only two of the models applied to a11 12 variables were not a good fit : the regression model for the outcome measure OQ-IR and the ARIMA model for the alliance measure DEDP . Visual analysis of these variables offer little clear insight into why this mode ls were not good fits , although there may be a sine-wave periodicity to the OQ-IR variable that is difficult to ascertain without a longer data-stream. Also the outlying point in the baseline phase for DEDP at time- point 9 is strikingly out of place with the rest of the data - one can only speculate that perhaps after four weeks of waiting there was a experience of resentment or disappointment with the imagined therapist. It is informative to consider the components of the various models that were responsible for change in a lliance factors. In four of the five cases in which there was a significant Spearman Rho indicat ing a change in alliance with the introduction of treatment , there was also a significant treatment parameter of change (either a change in mean or slope) explaining additional variance beyond that accounted for by either autoregressive or 
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baseline slope parameters. Furthermore, a fifth variable, GOAL, despite producing a non­significant Spearman Rho, contained significant treatment parameters in it ARIMA model. Thus, the data from this first subject lend strong support to a rejection of the null hypothesis of no change in alliance with the introduction of therapy, suggesting that there is a "real" rather than transference component to therapeutic alliance. Also, in all but one case (DEDP), there was a significant slope component in the treatment or baseline phase, indicating rejection of the second null hypothesis, for five alliance factors , that alliance would stabilize rapidly. Finally, in considering lead-lag relationships between alliance factors and outcome measures , there were several cross-correlational r-values that were greater than 2 standard errors (SE), with a predominance of correlations appearing significant for the Confident Collaboration 2 alliance factor. However, with a Bonferroni correction applied to adjust for the 11 correlations necessary to evaluate across 5 lags, only 3 correlations remained significant. These were Confident Collaboration 2 (COL2) predicting social functioning on the OQ-45 (OQSR) at lag 2 ( 1  week interval), and Patient Dedication being predicted by interpersonal functioning (OQIR) at lag 4 (2 week interval) and by anxiety (BAI) at lag 1 (½ week interval). The relationship between COL2 was OQSR was positive, indicating that as Ailish's confidence in the therapist declined across treatment so did her functioning in social settings. Why this relationship was evident in social settings only and not interpersonal experiences is difficult to explain. Although it is purely speculation, from a clinical 
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perspective perhaps failing confidence in the therapist necessitated greater involvement in other existing relationships, thus offsetting any potential decline in the arena of interpersonal functioning. After all, a patient 's hope in psychotherapy is the hope that a new and different form of relationship can provide help; if that new relationship is discouraging then one solution may be to work harder on pre-existing relationships. The relationship between interpersonal functioning (OQIR) and patient dedication (DEDP) was negative, indicating that as Ailish's interpersonal problems worsened, her dedication to therapy increased at a delayed point two weeks later. If her interpersonal functioning improved then her dedication to therapy lessened. A similar relationship held for anxiety (BAI) and DEDP: as Aili sh ' s anxiety decreased, dedication to therapy increased 3-4 days later which can also be understood as her resistance decreasing (e.g., sharing important things with her therapist rather than keeping them to herself). In conclusion, the data collected from Ailish's course of treatment indicated that (l) with the exception of Patient Dedication, alliance does change in response to the introduction of therapy; (2) it does not remain stable over time; and (3) there are some significant lead-lag relationships between alliance and outcome; namely, that her confidence in the therapist is positively related to social functioning, and that her dedication to the therapy is increased as her interpersonal functioning and/or anxiety improve 
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Brianna 
Brianna presented to the clinic seeking relief from primarily depressive symptoms, and 
also some anxiety symptoms. With the recent death of her mother, she was also seeking 
help for deciding on a new direction in her life, but was meeting considerable resistance 
from relatives. Her prior experience of therapy had been sporadic and her commitment in 
the past was unclear. She also appeared to have clear goals and expectations for the 
therapy. Her baseline period was 4½ weeks and her treatment phase was 14 weeks. 
Before the introduction of therapy, her mean BDI score was 7.11 (minimal) and her mean 
BAI score was 6.11 (minimal), which, akin to subject one, were lower than expected for a 
clinical presentation of depression and anxiety. On only three occasions during baseline, 
did her BAI score reach the mild range of anxiety, her BDI score remained minimal at all 
time points. Given her family difficulties, elevations were expected on interpersonal and 
social functioning scales (OQIR & OQSR). Her mean OQIR score at baseline was 14 .33, 
which is close to the clinically significant score of 15 (indeed, 6 of nine baseline points 
were at or above this clinical cut-off point). Her mean OQSR score at baseline was 12 .44, 
which was above the clinically significant cut-off of 12 . 
After the introduction of therapy, OQIR improved by dropping to a mean of 11.96 and 
the OQSR also improved by dropping to a mean of 8.30, each improving by 
approximately 2 and 4 points respectively. These improvements, however, were less than 
the reliable change index of 15 points. Table 6 indicated a statistically significant 
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improvement in social functioning and a near-significant improvement (p = 0.058) in 
interpersonal functioning. In fact there were significant improvements in a11 other 
symptom measures, despite generally non-clinical levels of distress reported by Brianna 
prior to therapy. Despite a mean decrease in only one alliance scale, Patient Dedication, 
only two alliance scales appeared to change significantly with the introduction of therapy 
- Bond (BOND) and Idealized Relationship (IDRX); both increasing with the 
introduction of therapy. Thus, for four of the six alliance factors, the initial stati stical 
analysis suggested retention of the null hypothesis of no change in alliance with the 
introduction of therapy. 
However, a closer examination of the components of the models applied to the six 
alliance variables indicated that for five alliance scales, there was a significant treatment 
parameter. There were significant mean level changes in the treatment for both Confident 
Collaboration scales, for Bond and for Idealized Relationship scales. There was also a 
significant slope change in the treatment phase for Patient Dedication . Only Goal and 
Task Agreement failed to change with the introduction of therapy. Thus, as with subject 
one, for a clear majority (5 out of 6) of alliance factors, there is a significant change with 
the introduction of therapy, again indicating a rejection of the null hypothesis of no 
change in alliance with the introduction of therapy. 
Contrary to subject one, however, an analysis of the data from Brianna strongly suggests 
retention of the nul l hypothesis that alliance is stable over time. The only variable for 
which there was a significant slope parameter in either the baseline or treatment phase 
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was Patient Dedication. For four of the remaining five alliance scales, even though there 
were significant changes in mean levels with the introduction of therapy, there was no 
significant trend in either phase (in the case of the fifth measure, GOAL, mean change 
and slope parameters for the treatment phase were insignificant). Therefore, even though 
therapy may create a mean increase/improvement in alliance, its impact does not change 
over time. 
Although there were some cross-correlational statistics observed that were greater than 2 
standard errors, none were significant when a Bonferroni correction was applied. Not 
only does such a result lend itself to retention of the null hypothesis of no time-contingent 
relationship between alliance and symptom change, it also indicates a Jack of any 
relationship between al1 iance and outcome for this subject. Any attempts on the 
therapist' s behalf to faci litate change through an initial focus on the al liance would likely 
be misguided - given that Brianna had set goals when she began therapy and she made 
her needs known, clear direction and a solution-focused approach would likely entail 
quick short-term results that were satisfying to the patient. 
Thus, Brianna' s data indicated that ( 1) with the exception of Goal and Task Agreement, 
alliance changes with the introduction of therapy; (2) alliance appears to remain stable 
over time, once the effect of therapy on the mean level of alliance is accounted for; and 
(3) there is no statistically significant time contingent nor simultaneous relationship 
between alliance and symptom change. 
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Ciara 
Ciara presented to the clinic looking for ways to develop better coping skills and to set 
better boundaries with others. Although she reported some close friendships, she was 
careful to keep a distance in relationships. She also had an extensive history of depression 
and sought relief from her depressive symptoms. Data was collected for 6½ weeks prior 
to therapy and for a further 22 weeks during therapy. 
None of Ciara's outcome measures taken prior to therapy suggested clinical level of 
distress. The two symptom measures closest to clinical significance were those assessing 
interpersonal and social functioning (OQIR & OQSR respectively). Her mean OQIR 
score during the baseline phase was 1 3 .23 (SD = 2) compared to a clinical cutoff score of 
15 ;  scores at four time-point out of fourteen total baseline points were equal to or greater 
than 1 5. Her mean OQSR was 10.6 1 (SD = 1 .60) and for five time-points out of fourteen, 
her OQSR score was equal or greater than the clinical cutoff score of 12.  Results in Table 
1 1  indicate that only symptom distress (OQ-SD) and OQ-Total scores responded 
significantly to treatment. AH six alliance scales, however, significantly decreased with 
the introduction of treatment, which is initial support for rejection of the null hypothesis 
that alliance does not change in response to the introduction of treatment. 
All six models for the alliance scores were ARIMA models and all were significant fits to 
the data. However, only three of the variables, COL2, GOALS and DEDP, had a 
significant treatment parameter in the model that indicated an effect for treatment beyond 
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that of the autoregressive (AR) component. Thus for the remaining alliance factors, 
CCOL, BOND, and IDRX, any observed decrease in alliance during treatment (as 
suggested by the results of the initial Simulation Method analysis) was accounted for by 
the AR component and for these al liance factors, we fail to reject the nu1 1  hypothesis that 
alliance does not change with the introduction of therapy. Furthermore, in only two cases, 
GOAL and DEDP, was there a significant slope parameter for either the baseline or 
treatment phase. Thus, for the remaining four alliance scales, we fai l  to reject the null 
hypothesis that alliance is stable over time. 
There were two significant time-contingent relationships detected, once Bonferroni 
corrections had been made. Social functioning (OQSR) predicted the alliance factor 
Confident Collaboration at lag 2;  the correlation was negative. Thus as social functioning 
improved, a week later Ciara's confidence in the therapist correspondingly decreased. 
Perhaps this reflected a pattern whereby a growing sense of confidence in her own ability 
to function social ly at work or school made the work of the therapist appear less 
necessary or appropriate. 
Depression scores (BDI) predicted the idealization of the relationship (IDRX) at lag 4; 
the relationship was positive. Thus as Ciara became less depressed, 2 weeks later she 
would report a lessened sense of mutual collaboration with the therapist and an increased 
tendency to disagree with the therapist. The literature has indicated that some degree of 
devaluing the therapist is healthy and conducive to positive change - the direction of the 
relationship detected in Ciara's case, however, suggests that it may not be conducive to 179 
positive change but rather reflective of change already occurring (Hatcher & Barends, 
1996). Ciara initially sought help in setting appropriate boundaries with friends, and it 
would seem that if she is to avail of the opportunity to practice doing so with the 
therapist, the therapy must first work to alleviate her depression. 
Thus, overall, the data from Ciara indicate that for the six alliance factors ( 1 )  alliance 
changes in response to the introduction of treatment in only three cases (COL2, GOAL, 
& DEDP); (2) alliance fails to remain stable across time in only two cases (GOAL & 
DEDP); and (3) there are two significant time contingent relationships between alliance 
and symptoms, namely, that as Ciara's social functioning improves her confidence in the 
therapist decreases and that as her depression improves, she idealizes the therapist less. 
Deirdre 
Deirdre presented with complaints of dysthymia, as well an experience of relationship as 
"draining," because she felt that she was always listening to other people's problems. The 
therapy focused on her general lack of motivation, feelings of indifference and 
indecision . The short-term goal of therapy was to reduce her depressive symptoms. 
Deirdre was anxious about participating in therapy and so the therapist strived to 
establish a solid alliance, and specifically a strong bond, so that the patient might feel 
safer in the therapy. Data was collected across 3½ weeks prior to the start of therapy and 
for 19½ weeks during therapy. 
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During the baseline phase, Deirdre 's symptom measures were a11 significantly elevated. Her depression score on the BDI was 26.57, placing her in the moderate range of depression, and her anxiety score on the BAI was 14, placing her in the mild range. All of her scores on the OQ-45 were in the clinical1y significant range, indicating elevated symptom distress and difficulties in interpersonal and social functioning. There was little improvement in these score with the introduction of therapy; and none of them moved out of the clinical range or into a less severe category of distress. Table 16  shows only one significant improvement in the treatment phase and that was for social functioning (OQSR). A visual analysis of the graph of the alliance factor, Idealized Relationship, indicated an extreme lack of variance, so this variable was excluded from consideration in later statistical analyses . Table 16 indicated that there were highly significant decreases in the remaining five alliance variables with the introduction of treatment, due in large part to minimal variance in alliance scores during the baseline period. The presence of significant change in five of six cases, strongly suggested rejection of the null hypothesis that alliance does not change with the introduction of therapy. However, when specific parameters were considered, only the models of three variables (CCOL, COL2, and GOAL) contained significant treatment phase parameters. Thus the null hypothesis was only rejected for these three alliance factors. Also the null hypothesis that alliance was stable over time was retained for all six alliance factors (including IDRX because of the 
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clear lack of variance), as no model contained significant slope parameters for either the 
baseline or treatment phases. 
With IDRX excluded from the analysis due to lack of variance, two significant lead-lag 
relationships were detected between alliance measures and symptom measures. Social 
functioning (OQSR) predicted the alliance factor bond (BOND) at lag 1 ,  and the two 
variables were negatively correlated. Thus, as Deirdre improved her social functioning 
her sense of attachment to the therapist increased 3-4 days later. This is a strikingly 
interesting result as the therapist deliberately aimed to improve the bond in therapy, yet 
doing so apparently had no causative effect on symptoms (including an expected effect 
on reducing anxiety); rather it was an initial change in a symptom area (social 
functioning) that seemingly brought about a change in the therapeutic bond. 
Patient dedication (DEDP) predicted interpersonal functioning (OQIR) at lag 1 ,  and this 
relationship was negatively correlated. As Deirdre felt more engaged in the therapy and 
became less resistant to the process of therapy, 3-4 days later she reaped the benefits in 
terms of improved interpersonal functioning. The observed effect of increased 
engagement in therapy appears to support the claim that a focus on the in-session, "here­
and-now" process has positive therapeutic effects beyond the immediate therapy session . 
Deirdre's  data indicated that ( 1 )  alliance changed in response to treatment for three 
alliance variables (CCOL, COL2, & GOAL); (2) alliance remained stable across time for 
all five alliance variables; and (3) if Deirdre' s  soci al functioning improved, then her sense 
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of attachment t� '.the therapist later improved, and if she became more engaged and active in therapy her interpersonal functioning later improved. 
Elaine Elaine presented to the clinic with a desire to develop greater emotional stability and greater control over aspects of her bipolar disorder (she presented with depressive symptoms). She also wished to develop better coping skills and to understand her recently developed desire for increasing social isolation. At the time of presentation she was experiencing interpersonal difficulties with her daughter. She reported a pattern of initial idealization of men in relationships followed by harsh disappointment. Thus, it is important to note that her therapist was male. Data was collected from Elaine for a period of 5 weeks before therapy and a period of 15 weeks during therapy . Before therapy began, Elaine's mean depression score on the BDI was 43.6, placing her in the severe range, and her anxiety score on the BAI was 12.1, placing her in the mild range. All her scores on the OQ-45 were elevated well above the clinical cut-off points. During the treatment phase, her mean measure of symptom distress (OQSD) dropped by approximately 22 points to below the clinical cut-off point; this decrease was greater than the suggested reliable change index of 1 5, signifying clinically meaningful change. There was little change in interpersonal functioning (OQIR) and social functioning (OQSR) and they both remained in the clinical range . Her mean depression score dropped to 26.18, 
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moving her from -the severe range to the moderate range of depression. Her mean anxiety 
score dropped to 2, placing her in the minimal range of anxiety. Thus, there were 
important therapeutic gains in the areas of anxiety and depression and general symptoms, 
but little change in interpersonal or social functioning. 
There was an extreme lack of variance in her idealization of the therapist (as can be seen 
in Figure 60). She entered therapy with a stable and extremely high IDRX score, but 
fortunately her predicted disappointment (as experienced in previous relationships with 
idealized males) did not occur during therapy and her IDRX remained unvarying 
throughout therapy. This variable will be excluded from further analyses. Table 21 shows 
that there was a significant decrease in four al liance factors : CCOL, COL2, GOALS, and 
BOND; and a significant increase in Patient Dedication (DEDP) with the introduction of 
therapy. 
For these five alliance factors, the presence of significant change in alliance suggests 
rejection of the nu11 hypothesis that a11iance does not change with the introduction of 
treatment. Analysis of the model parameters indicates that there are significant treatment 
parameters for four alliance factors: the exceptions were CCOL and IDRX (which 
displayed zero variance during treatment). Thus, for four out of six alliance variables, the 
models indicate that alliance does change with the introduction of treatment,  thus 
indicating rejection of the null hypothesis for those alliance factors . Significant slope 
parameters were only detected for two alliance variables: GOAL and DEDP, indicating 
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rejection of the null hypothesis that alliance is stable over time in only two of six possible cases. Three significant cross-correlational statistics were obtained. A negative correlation between anxiety (BAI) and therapeutic bond (BOND) was detected at lag zero, indicating simultaneous covariance, rather than a time-contingent relationship between these variables. These variables co-varied in such a manner that as anxiety was improving, Elaine 's perception of the therapeutic bond was also improving. It is important to stress that there is no implied directional causality in this relationship - it is more likely that a third mediating variable was creating simultaneous change in these variables. In two cases, patient dedication was predicted by earlier symptom change. Social functioning (OQSR) was predictive of patient dedication at lag. This relationship was a negative correlation, indicating that as social functioning improved, 3-4 days later patient dedication increased, so that Elaine became less resistant in therapy and experienced a greater sense of collaboration with the therapist. Anxiety as assessed by BAI scores also predicted dedication, but at lag 5 and with a positive correlation. Thus, as anxiety decreased, 2½ weeks later patient dedication also decreased. Lessening of anxiety was thus associated with a later increase in resistance to therapy. It appears that in Elaine's case, a certain amount of anxiety was likely to contribute to progress in therapy -supporting the notion that patients benefit from a certain minimal amount of distress if they are to actively engage in therapy. 
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The data from Elaine indicate that ( 1 ) with the exception of confident collaboration (specifically confidence in the therapeutic process rather than the actual therapist) and idealization of the relationship, alliance does change in response to the introduction of therapy; (2) alliance was not stable over time in only two alliance factors : goal and task agreement and patient dedication ; and (3) anxiety and therapeutic bond co-vary simultaneously so that as anxiety decreases, the sense of bond increases ; as social functioning improves Elaine 's active participation in therapy increases, and as anxiety decreases Elaine becomes less engaged in the therapeutic process. 
Fiona Fiona presented at the clinic seeking alleviation of anxiety and a reduction in the frequency and intensity of her panic attacks. She was also seeking help with interpersonal issues, and wished to better understand a past abusive relationship. Her therapist noted an obsessive-compulsive character style that may have served to bind her anxiety. In addition to focusing on her anxiety and interpersonal concerns, the therapist also aimed to alleviate depressive symptoms and improve Fiona's self-image. Data was collected over 3½ weeks prior to therapy and 20 weeks of treatment. All of Fiona's symptoms indicated the absence of clinically significant distress. All of her scores on the OQ-45 were in the sub-clinical range, with only one scale approaching clinical significance. That scale was social functioning, which had a baseline mean of 
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10.43 (SD = 1.50) and one point in the baseline phase (at time two) above the clinical cut-off point of 12. Her depression as assessed by the BDI was in the minimal range (her mean score was 8) and her anxiety, despite being a presenting concern, was also in the minimal range with a mean baseline score of 2. Results of the initial Simulation Method analysis indicated significant improvement during treatment in social functioning and depression only. Visual analysis of three of Fiona's alliance factors (CCOL, CCOL2 & BOND) indicated zero variance after the first or second time-point and so these variables were excluded from further statistical analysis. The Jack of variance in these factors clearly indicate that the null hypotheses, of no change in alliance with the introduction of therapy and the continuing stability of alliance across time, should be retained for these three factors. Inspection of Table 26 indicates a lack of significant change in goal and task agreement (GOAL) with the introduction of treatment; however there was a significant decrease in patient dedication and a significant increase in idealization of the relationship. However, further analysis indicated no significant parameters for baseline slope, treatment mean or treatment slope. Therefore, in Fiona's case, both null hypotheses of no change in alliance in response to the introduction of therapy and of stability in alliance across time, are unequivocally retained. However, several significant cross-correlational statistics were associated with the three varying alliance factors. The alliance factor Goal and Task Agreement (GOAL) and the measure of social functioning (OQSR) simultaneously co-varied at lag zero, as did 
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Idealized Relationship with both symptom distress (OQSD) and total score (OQ-Total) as assessed by the OQ-45. However, while the relationship between GOAL and OQSR was positive, indicating that improvements in social functioning matched simultaneous decreases in goal and task agreement, the relationship between IDRX and both OQSD OQ-Total was negative. Thus, improvements in symptom distress and overall functioning simultaneously matched Fiona's increasing sense of helpful collaboration and lack of disagreement with the therapist. The alliance factor, Idealized Relationship, was also predictive of social functioning 
(OQSR) at a lag value of 1. This relationship was positive, so that as Fiona's sense of collaboration in the therapy decreased and her sense of disagreement with the therapist increased, her social functioning improved 3-4 days later. Perhaps an increasing sense of self-assertion and diminishing dependency in the therapy promoted similar changes in her social environment. Patient dedication (DEDP) also predicted interpersonal functioning (OQIR) at a lag value of 2. This relationship was negative, so that as Fiona became more actively engaged and open in the therapy, her interpersonal functioning improved one week later. Fiona's data indicated (1) a retention of the null hypothesis, for all alliance factors, that the introduction of therapy has no effect on perceptions of alliance; (2) a retention of the null hypothesis, for al1 alliance factors, of stability in alliance across time; and (3) simultaneous covariance between goal and task agreement and social functioning, simultaneous covariance between idealization of the relationship and both symptom 
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distress and genera] functioning (OQ-Total), decreasing idealization of the relationship predicting later improvement in social functioning, and increased engagement in the therapeutic process predicting later improvement in interpersonal functioning. 
Gerald Gerald sought therapy for help with a long history of social anxiety and depression. He also had a history of impaired social functioning, in terms of an inability to sustain long­term employment. He possessed considerable intelligence but his thinking could become disorganized when he felt himself to be stressed . Due to Gerald's over-reliance on intellectualization and avoidance as defenses against engagement with others and the expression of emotion, his therapist predicted that the development of a strong, stable alliance would be difficult. Data was co1 1ected for 5 weeks prior to therapy and 21  weeks of treatment. The mean scores of all of Gerald's symptom measures on the OQ-45, were clinically elevated for both the baseline and treatment phase, suggesting relative]y intractable and serious dysfunction. A mean score of 15.75 on the BDI, indicated mild depression and a mean score of 5.9 on the BAI indicated minimal anxiety. Table 31 indicates significant improvement in interpersonal functioning (OQIR) and anxiety (BAI) in the treatment phase, but neither change was clinically significant: OQ-IR dropped from 19.7 to 19. 15, still remaining in the clinically elevated range ; and BAI dropped from 5.9 to 3.79, remaining in the minimal range of anxiety. 
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Table 31 also indicates a significant decrease in goal and task agreement (GOAL) and an increase in patient dedication (DEDP) and idealization of the relationship (IDRX), suggesting a rejection of the null hypothesis of no change in alliance with the introduction of therapy for these three alliance variables. However, further analysis of the parameters associated with the models that were fit to these variables produced significant statistics for treatment parameters for all alliance factors, except patient dedication (DEDP). Thus the null hypothesis was rejected for five of six alliance variables. The second null hypothesis of stability in alliance across time was also rejected for the same five alliance factors, and retained only for patient dedication on the basis of no significant slope parameters in the model. Cross-correlational analyses produced three significant relationships between alliance and symptom change. Confident Collaboration 2 (COL2), or Gerald's confidence in the therapist, positively related to social functioning (OQSR) at lag zero. This indicated that as his confidence in the therapist waned, his social functioning was simultaneously improving. An example of why this might occur is if Gerald self-confidence increased (perhaps a friend was encouraging him) to the point that he felt less need for therapy, sensing that he could help himself more, and simultaneously felt encouraged by his new found confidence to seek out work. This example is purely speculative, of course, but serves to explicate how simultaneous covariance, i.e. , lag zero relationships, can be understood clinically. 
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Social functioning (OQSR) was predictive of goal and task agreement (GOAL) at lag 1 and the relationship was positive. This indicated that improvement in social functioning was associated with decreased goal and task agreement 3-4 days later. This pattern is similar to that between OQSR and COL2 except for the lag value, which indicates a time­contingent relationship, whereby changes in social functioning clearly precede changes in goal and task agreement Gerald 's perception of the therapeutic bond (BOND) was also predictive of changes in anxiety as assessed by the BAI at lag two. This relationship was negative, whereby an increase in the sense of bond or attachment to the therapist entailed a decrease in anxiety one week later. One way to understand this is that the development of a more secure attachment to the therapist created a greater sense of security for the client that may have served as the equivalent of a "secure base,, outside of therapy (see Ainsworth, 1982 for a discussion of the concept of secure base and its relation to anxiety in human behavior). Gerald 's data indicated that: ( 1 )  the null hypothesis of no change in alliance in response to the introduction of therapy was retained for only one alliance factor, patient dedication; (2) the null hypothesis of stability in alliance scores across time was also retained for the one alliance factor, patient dedication; and (3) there was simultaneous covariance between confidence in the therapist and social functioning; improved social functioning predicted a later decrease in goal and task agreement; and an increased therapeutic bond predicted a later reduction in anxiety. 
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Hilda 
Hilda presented to the clinic with depressive symptoms that appeared to have developed 
in response to the end of a 3½-year relationship with her boyfriend. Despite being of 
average intelligence, her therapist noted a tendency towards disorganized thought. Hilda 
also appeared to have an underdeveloped sense of self and a reduced capacity for 
independence, although it is unclear whether this was reflective of a long-standing 
personality style or a transient reaction to the break-up with her boyfriend. Soon after 
therapy began, she reconciled with her boyfriend and her depressive symptoms began to 
decrease. The therapist felt the alliance to be insecure and under-developed and the 
patient abruptly terminated treatment. 
Hilda's mean symptom scores for the baseline period indicated marked distress. All her 
scores on the OQ-45 were significantly above the clinical cut-off point. Her BDI mean 
score of 2 1 .29 placed in the range of moderate depression, and her mean BAI score of 
23 .79 placed her in the moderate range of anxiety. During treatment, all of her scores on 
the OQ-45, with the exception of social functioning, dropped beyond the clinical cut-off 
point. Symptom distress and total score on the OQ-45 both dropped by more than 1 5  
points, indicating significant clinical improvement. 
Also social functioning dropped to 12.27 (SD = 3.22), which is close to the clinical cut­
off of 1 2. Her mean BDI score in treatment dropped to 7.04, indicating a change to 
minimal depression . Her mean BAI score dropped to 10. 1 5, indicating a change to mild 
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anxiety. Table 36 indicates _that all of these changes were statistically significant , although inspection of the component responsible for change indicate that the improvement in symptom distress (OQSD) and interpersonal functioning (OQIR) were independent of the effects of treatment. The results of the Simulation Method analysis, presented on Table 36, indicated that there was a significant increase in the alliance factors COL2, GOAL and BOND and a significant decrease in IDRX. However, results from fitting models to the data indicate significant treatment parameters for CCOL, GOALS, DEDP and IDRX. Thus, for the four alliance factors CCOL, GOAL, DEDP and IDRX, the null hypothesis of no change in alliance with the introduction of therapy was rejected. Four variables, CCOL, GOAL, DEDP and IDRX contained significant slope parameters in either the baseline or treatment phase and the null hypothesis of stability in alliance across time was rejected for these variables. Six significant time-contingent relationships were detected between alliance and symptom measures. All the cross-correlational values were negative, indicating that decreases in symptoms were associated with improved alliance. Symptom Distress (OQSD) significantly predicted Confident Collaboration (CCOL) at lag 2. As symptom distress lessened (improved), then one week later Hilda's confidence in the therapeutic process increased. Changes in social functioning (OQSD) significantly predicted Goal and Task Agreement at lag 3. Thus, as social functioning improved, Hilda was more 193 
likely to perceive a greater degree of agreement with her therapist over the goals of 
treatment 11/2 weeks later. 
Changes in anxiety as assessed by the BAI predicted changes in therapeutic bond 
(BOND) at lag 5 ,  indicating that as anxiety decreased, the sense of attachment and liking 
for the therapist increased 2½ weeks later. It is possible that less anxiety enabled more 
trust on Hilda' s behalf; however, it is puzzling as to why the change in alliance occurred 
2½ weeks later rather than in the next session. A similar lag of 5 was seen in the 
significant relationship between anxiety on the BAI and patient dedication (DEDP). In 
this relationship, as anxiety decreased, Hilda' s active participation in the therapeutic 
process increased 2½ weeks later. Two symptom measures predicted idealization of the 
relationship (IDRX) at lag 1 .  As symptom distress (OQSD) decreased, and also as total 
distress (OQ-Total) decreased, Hilda experienced a greater sense of collaboration and 
diminished disagreement with the therapist 3½ days later. 
Hilda' s data indicate ( 1 )  rejection of the null hypothesis of no change in alliance with the 
introduction of therapy for the four alliance factors CCOL, GOAL, DEDP and IDRX; (2) 
rejection of the null hypothesis of stability in alliance across time for the four variables 
CCOL, GOAL, DEDP and IDRX; and (3) decreases in OQSD predicted increases in 
CCOL, GOAL and IDRX; decreases in BAI predicted increases in BOND and DEDP; 
and a decrease in OQ-Total predicted an increase in IDRX. 
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General Findings Consideration of the data on a subject-by-subject basis is a fruitful exercise if one wishes to elaborate the clinical understanding of the patient. The results discussed above touched on some possible interactions between alliance and outcome, but moving from subject to subject it is difficult to develop a clear picture of consistent patterns of interaction. Across the eight subjects, the three central hypotheses were retained and rejected for different variables with little apparent consistency. No single parameter was consistently associated with change in any one alliance factor across all subjects. Furthermore, across all subjects, in only one predicted lead-lag relationship, BAI-+DEDP, was a significant relationship detected in more than one subject at the exact same lag. In this case both Elaine and Hilda had a lag 5 significant relationship with BAI predicting DEDP 2Y2 weeks later. Ironica11y, the r-value of this relationship for Elaine was +.448, while for Hilda it was -.485 ! The r-value mismatch inherent in this single replicated result is representative of the lack of any clear pattern of results across the subjects . Certainly, one's respect for the use of single-subject designs in clinical setting settings increases when one sees how much idiographic detail would be lost if the data were simply summed across multiple subjects. However, the disadvantage to a single-subject design is that it can be difficult to discern if a singular result is idiosyncratic to that subject, if it is a statistical artifact or if it can be generalized to other subjects with, for example, the same coping style or a similar profile 195 
on a personality test. It becomes important to know such things when one desires to wed science to practice and apply what was learnt with one patient to future work with others. For that reason, this study also attempted to collate the results of the individual subjects so as to better convey a sense of how well the three various hypotheses fared across all subjects. The first null hypothesis was stated as an expectation of no significant change in the mean or slope of the six alliance factors as a result of the introduction of therapy. Early psychoanalytic literature focused on the distinction between transferential aspects and positive, reality base� aspects of a patient 's attachment to the therapist and Zetzel ( 1956) was the first to use the term therapeutic a1liance as something distinct from transference . However, this conceptual distinction has yet to be empirically confirmed. Based on an analysis of the model parameters that accounted for significant change, in the case of single subjects, this null hypothesis was rejected for a particular alliance factor if at least one of the treatment parameters (X or XT) were significant, i.e., indicating a change in mean (X) or slope (XT) with the introduction of therapy. The results of these parameter significance tests across all subjects were presented together in Tables 4 1  to 46 for each alliance subscale. A binomial test was performed on the ratio of significant combinations of treatment parameters (pertinent to this hypothesis) to non­significant combinations. The results of the six binomial tests indicated that there were more significant treatment parameters for Confident Collaboration, Confident Collaboration 2, and Goal and Task 
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Agreement across an subjects than would be expected by chance alone. This result entailed rejection of the null hypothesis that alliance does not change in relation to the introduction of therapy. However, there were less significant treatment parameters for Bond, Patient Dedication and Idealization of the Relationship across all subjects than would be expected by chance alone, indicating retention of the null hypothesis for these three alliance factors. One interesting implication of this result is that alliance is not a singular construct. Half of the factors that contribute to the construct of alliance appear to be reality-based responses to the therapeutic process, while the other half appear to be less responsive to actual therapy, and potentially more transference-based. However, due to the low number of subjects in the study this result is equivocal because of the reduced sensitivity of the binomial test - the significant results were accounted for by ratios of 5 and 6 out of 8 while all the non-significant results were accounted for a ratios of 4 out of 8 - a difference of only I or 2 significant results. A similar problem regarding the low number of subjects is encountered in assessing the generalizability of results related to the second null hypothesis that alliance is stable over time. This hypothesis was also tested through analysis of slope parameters (T and XT) from the models fitted to each of the six alliance variables. If either slope parameter was significant, indicating an increasing or decreasing slope beginning in either the baseline or treatment phase, the null hypothesis was rejected as the alliance measure was changing continuously over time. The slope parameter significance tests from all subjects were 
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presented together in Tables 41 to 46 for each alliance subscale. Again a binomial test 
was performed on the ratio of significant combinations of treatment parameters (pertinent 
to this hypothesis) to non-significant combinations. 
For all alliance factors, there were never more than four significant results across all eight 
subjects ,  resulting in consistently non-significant p-values for each variable. Thus, for all 
alliance measures the null hypothesis of stability in alliance across time was retained. The 
consistency of low ratios of significant results across all alliance factors increases the 
confidence that indeed alliance is relatively stable over time. Therefore, at pivotal times 
in therapy, such as in the initial session, it may be critically important for the therapist to 
work on impacting the alliance when such an immediate change in mean may be 
produced. The importance of focusing on sudden drops or jumps in alliance is inherent in 
the notion that it is the repair of ruptures in alliance that accounts for impact on outcome 
rather than steady constant work to bring about a continuously improving alliance . 
Indeed, as cited in the introduction, Safran et al . ( 1990) found that positive outcome was 
associated with successful repairs of alliance rather than a linearly-increasing 
development of alliance throughout therapy. 
The central hypothesis of this dissertation, however, has been whether or not there is a 
time-contingent relationship between alliance and symptom change, and whether changes 
in alliance precede changes in symptoms or vice versa. As noted at the beginning of this 
section, no consistent pattern of lead-lag relationship emerged from the pooled results of 
the eight subjects. Of the predicted 26 lead-lag relationships expected to hold between 
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alliance and symptom measures, only 12 of them were found to result in a significant correlation. With a-levels set at . 10 for this portion of the analysis (due to the difficulty of detecting a significant result after pre-whitening a series) one would expect to detect 3 significant relationships by chance alone - however, in this case the probability of obtaining 12 significant results is less than .001 when the proportion of expected non­significant result is .90. Within these twelve relationships there were 5 significant and distinct negative-lag correlations, 5 significant and distinct zero-lag correlations and 13 significant and distinct positive-lag correlations. Negative lags indicated that changes in alliance preceded changes in symptomatology, while positive lags indicated that changes in symptomatology preceded changes in alliance . Zero-lags indicated simultaneous co­variation. These 23 significant relationships were tested for generalizability across all eight subjects. Effects sizes for all 23 relationships were calculated for each individual subject and then a mean effect-size was calculated (although in a few cases a subject 's effect size for a particular relationship was omitted because of clear lack of variance in the alliance measure). Nine of the 23 relationships thus tested were found to have small effect sizes when summed across all subjects. These nine relationships, which consisted of 3 zero-lag, 1 negative-lag and 5 positive-lag relationships, are presented in Table 47 . There was often large variance in both the significance level and direction of the correlation, so that the presence of even a small effect size is indicative of a meaningful result. Certainly , this 199 
meta-analytic approach to evaluating time-contingent relationships could be much improved by a priori categorization of subjects, and then pooling effect sizes for hypothesized relationships within specific categories but such considerations will be discussed further on. The three significant zero-lag relationships, indicating simultaneous covariance, were OQSD�IDRX (r = -.11), OQSR�GOAL (r = 0.1 1) and OQTOT�IDRX (r = -0.14). Thus it appears that as symptom distress and total distress as assessed by the OQ-45 decrease (i.e., improve), a patient' s tendency to idealize the relationship and avoid disagreements with the therapist simultaneously increases. As a patient's social functioning improves, goal and task agreement with the therapist simultaneously decreases. It is possible that these simultaneous relationships are mediated by time­contingent relationships to other symptom or alliance measures, but it is beyond the scope of this study to assess that possibility. The one negative-lag relationship, indicating that change in alliance preceded change in symptoms, was OQSR+-IDRX (lag 1, r = 0. 1 1). Thus, as a patient becomes more able to disagree with the therapist, their social functioning improves 3-4 days later. Hatcher & Barends ( 1996) suggested a similar relationship between IDRX and outcome in general, and noted that improvement was generally more likely if a patient could express some disagreement with the therapist. It is certainly plausible that self-assertion in therapy could promote confidence in a patient's ability to assert herself in other settings with a lessened fear of negative consequences. 
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The five positive�lag relationships, indicating that change in symptoms preceded change in alliance, were OQIR�DEDP (lag 4, r = -0. 13), OQSR�COL2 (lag 2, r = -0.14), OQSR�DEDP (lag 1, r = -0. 11), OQTOT�IDRX (Jag 1, r = -0. 16) and BAI�DEDP (lag 1, r = -0.14). Three symptom measures were found to be associated with later changes in patient dedication. Thus, as interpersonal, social functioning and anxiety levels improve, patient dedication (engagement and openness in the therapy) increases 3-4 days later, 2 weeks later, and 3-4 days later (respectively). Improvement in social functioning also predicts increased confidence in the therapist one week later. Understanding of the zero-lag relationship OQTOT+-+IDRX discussed above is complicated by the finding of a positive lag 1 relationship OQTOT�IDRX, which indicates that decreases in total distress also predicts increased idealization of the relationship 3-4 days later. Figure 97 below graphically displays these relationships and it can easily be seen how several variables affect patient dedication. OQTOT/OQSDt 
t 
(1) OQTOTt � IDRX!� 
(2) OQIR! � GOAL! t OQSR! 
(3) BAI! � COL2t DEDPt DEDPt DEDPt Figure 97: Graphical display of time-contingent and simultaneous relationships 
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There are three separate influences on patient dedication. The clearest ones are seen in 
paths (2) and (3); whereby a decrease (improvement) in the measure of interpersona] 
functioning (OQIR!) is associated with increased patient dedication (DEDPt) 2 weeks 
later (each "-." symbol represents one lag value). Decreased anxiety (BAI!) is also 
associated with increased patient dedication (DEDPt) 3-4 days later. A more intriguing 
relationship is shown in path (1)  beginning with a hypothetical worsening of total distress 
(OQTOTj) leading to more disagreements and decreased idealization of the therapist 
(IDRX!) 3-4 days later, which in turns leads to an improvement in social functioning 
(OQSRt). This improvement in social functioning in tum leads to increased patient 
dedication (DEDPj) 3-4 days later and increased confidence in the therapist (COL2j) a 
week later. 
Although this is a hypothetical model, it is worth considering the possibility that a 
therapist in such a situation might, for example, be focused on repairing a supposed 
rupture in goal and task agreement and then later interpret improved patient dedication 3-
4 days later as a sign of his/her effectiveness at "repairing" the rupture . It is humbling to 
realize that such a theoretically sound clinical observation would be misguided - the 
eventual result of increased patient dedication had nothing to do with a so-called repair 
of alliance - the momentum for change in the alliance began with the worsening of 
overall distress . This clearly illustrates some of the pitfalls of constructing theoretical 
models on the basis of anecdotal case studies , and serves as a strong argument for the 
necessity of the scientific method when studying clinical phenomena. 
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Limitations of the Current Study 
It is striking that in only one relationship does alliance predict symptom change - this 
contrasts with existing literature that stresses the importance of alliance in producing 
positive outcome in therapy. Of course, this one study with its small sample of subjects 
and narrow range of presenting problems by no means overturns the common assumption 
that alliance causes change in symptomatology. Specific limitations of this study were, of 
course, its small pool of subjects, which limit the study's generalizability. There was very 
little ethnic diversity in the subjects and only one male subject. There was also limited 
pre-screening of subjects and their diagnosis was not confirmed by use of a standardized 
interview. Furthermore, the majority of subjects presented with symptoms in the sub­
clinical range - a potential problem with a design such as this is that more clinically 
distressed patients may be unwilling to delay treatment unti I after a suitable baseline 
period. However, the sub-clinical scores may also reflect a problem with the validity of 
the measures used to assess outcome. 
The therapists involved in this study had limited clinical experience , ranging from two to 
eleven months of clinical experience. Half of the therapists had less than six months of 
experience. Furthermore, although all the treatment plans indicated an insight-oriented 
approach, it is unclear how that differed from therapist to therapist - indeed, within the 
experienced psychoanalytic community there is a wide diversity in how "insight­
oriented" therapy is practiced . No attempt was made to assess the level of competence of 
the therapist, level of activity in sessions, or the suitability of their match with the patient. 
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There was also no measure of their sense of the alliance - indeed given that one aspect of 
this study concerned itself with assessing transferential components of the alliance, it 
would be helpful to have an assessment of the alliance from someone other than the 
patient. 
A further limitation of this study is its quasi-experimental design - without experimental 
controls it is impossible to determine if some unmeasured third variable may be causing 
changes in alliance and symptomatology in such a manner that it appears that changes in 
symptoms are "causing" changes in alliance. For example, one such unmeasured variable 
might be the structure of therapy itself - a person needs to be organized to make 
appointments and pay for sessions and simply setting one hour aside each week can 
require assertion with family members or employers . In this regard, consider a significant 
negative lag 3 relationship between social functioning and goal and task agreement (as 
was the case with Hilda) so that as social functioning improves so does agreement on the 
goals of therapy 1 ½ weeks later. 
In such a case, one might assume that, as the patient notices improvement in her social 
environment, her willingness to go along with the therapist's treatment plan increases . 
However, what if the change occurs in both variables because of the effects of being in a 
structured therapy? Perhaps the initial impact from the structured therapy is seen in her 
social environment because she has had to make immediate changes to her work 
schedule. Over a slightly longer period {11/2 weeks longer) the structured nature of the 
therapy may begin helping her organize her thoughts, settle her feelings and calm down 
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enough so as to better understand how therapy works and to appreciate the importance of setting clear goals and mutual collaboration. In this example, one might mistakenly assume that changes in social functioning cause changes in goal and task agreement, when in fact it would be the experience of being in a structured therapy that would account for changes in both the outcome and alliance measures . Certainly the use of time-dependent cross-correlational analyses can provide the initial step in exploring causal relationships, but they need to be extended and improved upon by the addition of controlled studies. Finally, there are also some difficulties with the statistical methodologies used to analyze the results . The limitations of the Haugh-Box procedure were already discussed in the introduction, including underestimation of causal parameters , difficulties in fitting an appropriate model to the data and an increased proportion of error measurement in the residuals . Use of the procedure was also quite time-consuming and unlikely to become a popular tool for clinicians . Data management was difficult even for such a small number of subjects, due to the amount of data generated by continuous measurement - these concerns would make such a study difficult to implement in a busy practice . Also, the intuitively simpler Simulation Method for detecting significant treatment effects is unfortunately limited by its inability to differentiate slope effects from changes in the mean (due to is reliance on a Speannan Rho statistic), and it was not always in agreement with the results derived from the fitted models. 
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Future Directions 
This study can be considered exploratory in nature, and in several ways it has laid down a 
foundation for future naturalistic studies regarding questions of clinical concern. There is 
a clear need for continued study of therapeutic alliance: the equivocal and also 
unexpected results of this study cry out for replication as they raise some important 
questions about the nature of the therapeutic alliance and its relationship to outcome. Is it 
reality-based? For all factors and for all patients? If alliance truly is stable then what 
phenomena best account for sudden changes in it? Is outcome more commonly a 
predictor of alliance than vice versa? How do alliance factors inter-relate and is their 
relationship time-contingent? Can we fit causal path mode]s to time-series data? 
I do not know the answer to these questions but in making suggestions as to how they 
might be answered, I would like to focus on the use of improved methodologies, more 
specific hypotheses, clinical uses of time-series designs, and group analyses. Regarding 
the statistical approach that I used in this study, I would argue for a combination of what 
is best in both the Simulation Method and the Durbin-Watson approach to assessing time­
series designs. The Simulation Method's greatest advantage is its use of simulated 
streams to determine probability-values and to adjust for auto-correlation. Its downfall is 
its reliance on Spearman' s Rho, a rank-ordered test that is insensitive to slope parameters. 
Without a component analysis of slopes and means it is not possible to confidently 
ascribe symptom change to treatment effects . Use of simulated streams with a Pearson r­
statistic and a regression model would certainly make it more useful. 
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Other methodology issues concern improved experimental designs and use of appropriate measures. Use of pre-screening questionnaires to assess patient characteristics relevant to treatment such as personality style, characteristic defenses and coping style could allow for a more efficient grouping of subjects when analyzing results. Evaluation of therapist variables, including competency and experience, could better elucidate how alliance develops between particular individuals . Regarding the use of appropriate measures, one obvious suggestion for improvement is to use fewer and shorter measures. Over-reliance on self-report measures that ask subjects to assess their inner state is likely to increase the degree of error measurement - which is already a problem with the Haugh-Box procedure. I would recommend that the client and intake-evaluator devise a short 5 to 7 item scale that assesses objective measures of distress, e.g. that ask a client "how many times did you wake up during the night?" rather than "How well did you sleep?" Shorter forms, although possibly compromising reliability, would also allow for an increase in the frequency of data collection. For example, I have used a seven item check-list in my own clinical work that allowed data to be collected four times a day, resulting in a rapid accumulation of data across a short time span. I also hope that future researchers will re-visit the specific relationships that appeared to be significant in this study and well as those that reached near-significance. One of the most serious limits of cross-correlational analyses is the practical difficulty of specifying what lag values to investigate a priori, and the increased possibility of type I errors when 
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running a multitude of correlations. Hopefully, this study has offered fruitful possibilities 
for future researchers to pursue. I also think it is important to emphasize that power in 
time-series comes from the number of data-points , not the number of subjects (unless one 
is specifically concerned with creating generalizable results). With a pro-longed 
treatment, it would be possible to split a series into sections and confirm if certain 
patterns of interaction are maintained. Better yet, one could devise a more controlled 
study, whereby different variables are manipulated during different stages of therapy and 
assess the effect of the effect of these variables on mean levels and slopes . 
I believe that time-series methodologies could also be of practical value in a clinical 
setting. For example, data could be collected during the initial phases of therapy and 
analyzed for particular relationships. On the basis of the initial results, the therapist could 
decide where to focus his/her efforts, and after an adequate time-period has passed then 
he/she could test the effectiveness of the intervention . Thus, both the planning of an 
intervention and the assessment of its effectiveness can be improved with this 
methodology. 
Finally, it is important to be able to produce general findings that can be of practical 
benefit to one's colleagues, and not just to one specific patient . More effective grouping 
of the results of several time-series studies is an important step in the evolution and 
widening utility of time-series designs. One attractive possibility is the use of 
Hierarchical Linear Models (HLM) that could be used as an exploratory method to 
analyze the aggregated single-case data. HLM' s enable the researcher to model the 208 
response profile of each subject in a study as a function of specific variables and so retain the level of detail provided by a pure single-subject design through consideration of individual response curves while also enabling the application of group methodology to assess for systematic variation in individual response patterns. (Nugent, 1996). A HLM analysis allows the researcher to identify variables that function to moderate the effects of treatment and produce different response paths. For example, a possible variable for consideration in this study could be level of therapist experience. 
Conclusion Conducting this study provided me with much insight into the intricacies of time series design and analysis, but less assurance as to the exact nature of the relationship of alliance to outcome. No clear unequivocal pattern emerged, and until elements of this study are further replicated, I can offer no firm conclusions. Alliance appears to be predominantly reality-based when it refers to a patient 's  confidence in the therapeutic process, confidence in the therapist and agreement on goals and tasks. However, when alliance refers to bond, patient dedication and idealization of the relationship, it is more transference-based. Alliance also appears to be relatively stable across time. When considering the final hypothesis of this study it is difficult to determine with certainty if the relationship between alliance and outcome is predominantly time-contingent or simultaneous. However, based on the meta-analysis of cross-correlational statistics, it 209 
appears that two-thirds of the significant associations between alliance and outcome were 
time-contingent. 
Two results were most striking, however: ( 1) the clear predominance of time-contingent 
relationships in which symptom change was predictive of later alliance change, rather 
than vice versa and (2) the absence of an effect size above r = 0. 16. How are we to 
understand this? I could refer to limitations of the methodology or the limited power, but 
I would prefer to end with some insight from a patient. After several years of a difficult 
yet ultimately successful once-weekly therapy for debilitating depression, the patient, 
when asked what was most helpful about therapy, replied that is it was like a hand that 
gently guided her, without judging her harshly . It had provided assurance that , however 
bad things were, her story would always be told and, once told, things would feel just a 
little bit better. Over time, however, the story shifted from tales of the painful past to tales 
of the present and future. That shift marked a move into health and contentment. 
She emphasized, however, that it was time that healed and that even the addition of daily 
sessions would not have hastened the process - the value of the therapy was that it 
provided a reassuring witness to the passing of time and the process of natural change. 
Considering this explanation in conjunction with the result of this study - namely that 
symptom change predominantly predicted alliance - I am inclined to believe that 
therapeutic alliance is simply the ticket that allows us the privilege of traveling with our 
patients and weathering the passage of time together , and when symptoms change, as 
they are wont to do with the passing of days, that ticket is renewed, re-issued or re­
routed. 
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APPENDIX 2 19 
Table Al  presents the Z-scores corresponding to each subject's r-statistic for certain lag­valued cross-correlations between alliance and symptom scales that were found to be significant at that particular lag for at least one subject in the initial analysis. Relationships in bold in the first column indicate those relationships whose mean Z-score across all subjects was found to be significant (E.S. > . 10). These significant relationships were presented earlier in the main text in Table 47. This table is included here so that the reader may further evaluate the heterogeneity of the results, and also to allow for further analysis of the results for possible patterns that might explain the varying effect-sizes. Table Al:  Effect-sizes (summed across all subjects) for relationships found to be significant at specific lags for at least one subject 
RelationshiJ! Lag A B C D E F G H 
O{l_SD-+CCOL +2 . 1 84 -0152 .277 .288 . 14 1  .078 -.460 
OQSD+-+IDRX 0 .245 -.026 .033 -.576 -.053 -.299 
O{l_SD-+IDRX +l .094 -.019 . 122 -.068 -.025 -.648 
OQIR+-DEDP -2 .32 1 -.074 .066 . 14 1  . 13 1  -.400 -. 162 -.266 
OQIR+-DEDP - 1  . 101  . 163 -.041 -.436 . 192 -.207 -. 175 -.023 
O(l_lR-+DEDP +4 -.472 -.224 -.224 -.018  -.095 . 161  .004 -.203 
OQSR+-COL2 -2 .556 .028 .090 . 177 -.424 -. 1 17 . 16 1  
OQSR+-+COL2 0 -.058 -. 173 .036 . 1 1 3 .039 .424 . 103 
O(l_SR-+COL2 +2 -.424 -.006 -.388 .032 -.234 -.026 .025 
OQSR+-+GOAL 0 .008 -.074 .066 . 16 1  -. 173 .529 . 1 1 8 .270 
OQSR-+GOAL +l  -.067 -.073 -.087 .069 .056 . 103 .424 . 177 
O�SR-+GOAL +3 -.255 .085 . 144 -.245 .059 .266 .009 -.5 17  
O�SR-+BOND +l -.093 . 192 -.0134 -.424 .008 -. 13 1  -.304 .030 
O(l_SR-+DEDP +l -.218 -. 128 .041  -.095 -.563 . 154 :-.224 . 157 
O(l_SR+-IDRX -1 -.029 -.015  .053 .424 . 1 1 6 . 104 
OQTOT+-+IDRX 0 .075 .008 .053 -.58 1 -.012 -.388 
O�TOT-+IDRX +l -.039 -. 161  . 124 -.093 -. 148 -.633 
BDI+-IDRX +4 .203 -.058 .388 -.032 -.001 -.321 
BAI+-BOND -2 -. 199 . 1 10 .035 -.027 .209 -.377 -. 182 
BAI+-+BOND 0 -.255 .046 -.007 . 103 -.563 .332 -.092 
BAI-+BOND +5 .055 .02 1 -. 167 -. 157 .282 .047 -.563 
BAl-+DEDP +1 -.476 -. 157 . 13 1  -. 121  -.354 -.055 -. 1 1 1  .038 
BAI-+DEDP +5 -.026 .343 -. 161  .083 .523 . 126 -.064 . -.529 
Note: Cross-correlational r-statistics for relationships involving the alliance subscale IDRX were not included in 
calculating l:Z for subject 4, Deirdre. and subject 5, Elaine, because of lack of variability. Also cross-
correlational r-statistics for relationships involving the alliance subscales CCOL, COL2 & BOND were not 
included in calculating l2 for subject 6, Fiona, because of lack of variability. 220 
VITA 
Mark Moore was born in Dublin, Ireland on September 26th, 1972, the eldest of two sons. 
He received a Bachelor of Arts in Psycho1ogy form Trinity College Dublin in 1995. He 
spent three years as a high-school teacher in Japan. In 1 998 he moved to the United 
States, where he began graduate studies in Clinical Psychology at the University of 
Tennessee, Knoxville. His research interests have focused on hypnosis, imagery, 
Jinguistics, therapeutic alliance, psychotherapy outcome, and the integration of science 
and practice. He currently resides in Phi ladelphia, where he is developing his clinical 
interest in psychoanalytic psychotherapy, in addition to pursuing clinical and research 
interests in conducting psychotherapy with cancer patients. He is also a founding member 
of Concision LLC, a consultancy group that aids practitioners in the deve1opment of 
process and outcome research. 
22 1 
